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 The purpose of this research was to measure the serum 25-hydroxyvitamin D 
[25(OH)D] response to daily supplementation with 800 IU vitamin D3 during winter in 
premenopausal women living in Maine, and to examine the effects of body composition 
and hormonal contraceptive use on baseline serum 25(OH)D levels and the response to 
supplementation.   
 One hundred twelve women (22.2±3.7 years old) received placebo from March 
2005 until September 2005 when they were randomized to receive either placebo or 800 
IU vitamin D3 through February 2006.  Eighty-six women completed the study.  Body 
composition was measured by dual-energy x-ray absorptiometry.  Actual vitamin D3 
content of the supplements averaged 885 IU per capsule. 
 In February 2005 the mean±SD serum 25(OH)D was 62.0±23.4 nmol/L in all 
subjects.  Twenty-nine percent of subjects had optimal serum 25(OH)D levels (≥75 
nmol/L).  Serum 25(OH)D levels were significantly higher (p < 0.0005) in the 58 
 
 hormonal contraceptive users (68.6±24.0 nmol/L) than in the 28 non-users (48.3±14.8 
nmol/L).  The 25(OH)D concentration increased with estrogen dose.  Subjects in the 
highest tertile body fat (>33%) had significantly lower serum 25(OH)D levels (47.8±17.3 
nmol/L) than subjects in the middle and lowest tertiles (69.4±23.8 and 69.0±22.2 
nmol/L).  Estrogen dose, percent body fat, and alcohol consumption were significant 
predictors of February 2005 serum 25(OH)D levels. 
 Serum 25(OH)D levels increased by 35.3±23.2 nmol/L from February 2005 to 
February 2006 in the treatment group, compared to 10.9±16.9 nmol/L in the placebo 
group.  Treatment group, magnitude of summer increase in 25(OH)D, estrogen dose, and 
baseline serum 25(OH)D levels, but not body fat, were significant predictors of the one-
year change in 25(OH)D levels. 
 Daily supplementation with 800 IU vitamin D3 during winter achieved optimal 
25(OH)D levels (≥75 nmol/L) in 80% of subjects, indicating that this dose is too low to 
optimize vitamin D status in the population as a whole.   Body fat does not appear to 
influence the serum 25(OH)D response to supplementation with vitamin D3, except 
through its influence on the baseline serum 25(OH)D level.  Further research is needed to 
determine whether there is a health benefit to the higher serum 25(OH)D levels in oral 
contraceptive users. 
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 Chapter 1 
INTRODUCTION 
Serum 25-hydroxyvitamin D [25(OH)D] levels are used to measure the adequacy 
of vitamin D status.  The consensus among researchers is that 25(OH)D concentrations of 
at least 75 nmol/L are optimal.1,2  Serum 25(OH)D levels reflect both dietary intake of 
vitamin D and cutaneous synthesis of vitamin D after exposure to solar ultraviolet-B 
radiation.3  An individual’s serum 25(OH)D concentration is usually less than optimal 
after winter in Maine (44o53’N)4 due to insufficient sunlight from November through 
February.5  Vitamin D insufficiency is widespread at northern latitudes such as Maine, 
even in populations with dietary vitamin D intake equal to, or greater than, the current 
Dietary Reference Intake of 200 IU daily for 19 to 50 year olds.4,6-8   
Insufficient vitamin D levels are of concern because vitamin D insufficiency is 
associated with suboptimal calcium absorption9,10 and increased parathyroid hormone 
levels,11-15 which lead to increased bone resorption, accelerated corticol bone loss, and 
increased risk of fracture.1  Currently, an estimated 10 million Americans have 
osteoporosis, 8 million of whom are women.16  In addition to the effect on bone, 
inadequate vitamin D may play a role in the development of type 1 diabetes,17 multiple 
sclerosis,18 hypertension,19 and in the outcome of certain cancers.20  Since vitamin D 
insufficiency is widespread, even in populations that meet the Dietary Reference Intake, 
further research is needed to determine the intake required to achieve optimal serum 
25(OH)D concentrations, and, once this is determined, strategies must be developed to 
raise the population to optimal levels.  
 1
 Research is needed to determine how much vitamin D3 intake is needed to 
optimize serum 25(OH)D levels for different age groups.  The purpose of this research 
project was to evaluate the serum 25(OH)D response to supplementation with 800 IU 
vitamin D3 during winter.  The primary objective was to achieve optimal serum 25-
hydroxyvitamin D levels in premenopausal women living in Maine.  The secondary 
objective was to examine the effects of body mass index (BMI), body composition, and 
oral contraceptive use on baseline serum 25-hydroxyvitamin D levels and the response to 
oral vitamin D supplementation. 
 2
 Chapter 2 
LITERATURE REVIEW 
Metabolism of Vitamin D 
 Vitamin D can be synthesized in the skin upon exposure to ultraviolet-B radiation 
and is, therefore, not technically a vitamin, but rather a steroid hormone.  There are two 
forms of vitamin D: vitamin D2, ergocalciferol, which is found in plants, and vitamin D3, 
cholecalciferol, which is synthesized in the skin of animals and humans upon exposure to 
sunlight.  Vitamin D written without a subscript may refer to either vitamin D2 or vitamin 
D3.21 
 Skin synthesis is the primary source of vitamin D3 and provides 90 to 100% of the 
vitamin D requirement for most people.3  In the skin of humans, 7-dehydrocholesterol 
(provitamin D3), which is produced in relatively large quantities, absorbs ultraviolet-B 
radiation (290-315 nm wavelengths) upon exposure to sunlight.  Absorption of the 
radiation causes transformation of 7-dehydrocholesterol to previtamin D3.  Previtamin D3 
is thermodynamically unstable and is isomerized to form the more stable vitamin D3 in 
one to three days.  Vitamin D3 diffuses from the skin into the extracellular space and is 
picked up by vitamin D-binding protein (DBP) in the dermal capillary bed.  DBP carries 
vitamin D3 primarily to the liver.  However, some (approximately 12%) vitamin D is 
deposited in adipose tissue for storage along the way.22-24 
 Vitamin D-binding protein is the primary transport protein for 25(OH)D, 
1,25(OH)2D, and vitamin D3.  Less than 5% of the binding sites on DBP are occupied by 
vitamin D sterols.25,26  DBP is produced in the liver and has a high affinity for 25(OH)D; 
88% of 25(OH)D is bound to DBP; 12% is bound to albumin, and less than 1% is in the 
 3
 free (unbound) form.25  Other vitamin D metabolites are bound to DBP with less affinity.  
The regulation of DBP is unclear.  Lower levels are found in nephrotic syndrome (due to 
urinary losses) and severe liver disease (due to poor production),25 but this does not seem 
to affect the binding capacity of DBP because binding sites are largely unoccupied under 
normal conditions.27  Estrogen increases hepatic production of DBP, resulting in higher 
concentrations during pregnancy and oral contraceptive use.25  The concentration of DBP 
is not affected by vitamin D deficiency or excess.27   
 When individuals are exposed to higher doses of ultraviolet radiation, the serum 
25(OH)D response does not increase proportionately resulting in vitamin D 
intoxication.28  Instead, previtamin D3 and vitamin D3 absorb sunlight and are converted 
to other photoproducts, including lumisterol, tachysterol, suprasterols, and toxisterols, 
which are sloughed off with the skin rather than continuing on the pathway to 25(OH)D 
production.3,29  Therefore, the skin cannot generate excessive quantities of vitamin D3 to 
cause vitamin D intoxication upon exposure to sunlight.29   
 Vitamin D is slowly released from adipose tissue during times of vitamin D 
deprivation.3,22,29,30  The mechanism for the release of vitamin D from adipose tissue is 
unknown. 
 About 50% of the vitamin D consumed from the diet is incorporated into micelles 
and absorbed by passive diffusion into intestinal cells.23  Within the intestinal cell, 
vitamin D is incorporated into chylomicrons and excreted into the lymphatic system for 
transport to the blood.  In the blood, some vitamin D is transferred from the chylomicrons 
to DBP for delivery to extrahepatic tissues for storage.31  After chylomicrons enter the 
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 blood, they undergo conversion to chylomicron remnants that contain the vitamin D and 
are taken up by the liver via hepatic receptors.23  
 Vitamin D3 synthesized in the skin after exposure to ultraviolet-B (UVB) 
radiation is transported mainly via DBP, whereas vitamin D ingested from the diet is 
transported primarily by chylomicrons in the bloodstream.23,25,32  Upon reaching the liver, 
delivered either by chylomicron remnants or DBP, vitamin D is hydroxylated by a 25-
hydroxylase enzyme, forming 25(OH)D, the major circulating form of vitamin D.  
Although 25-hydroxylase is less efficient when vitamin D is in abundance, 25-
hydroxylase is poorly regulated.  Therefore, the serum 25(OH)D concentration reflects 
overall vitamin D status.23  A membrane receptor on the hepatocyte quickly picks up 
chylomicron remnants, resulting in a quicker increase in serum 25(OH)D concentration 
after oral vitamin D consumption compared to cutaneous production.31,32  In contrast, 
vitamin D from the skin diffuses into the blood more slowly and enters the liver more 
gradually, allowing for prolonged production of 25(OH)D.32  Serum 25(OH)D levels 
have been found to be sustained for a longer period following cutaneous vitamin D 
synthesis than after oral consumption of vitamin D.32,33  
 From the liver, 25(OH)D is released back into the bloodstream where it is 
transported bound to DBP to the kidney and other tissues.  In the kidney and other 
tissues, 25(OH)D is further hydroxylated by a 1-α-hydroxylase enzyme, producing the 
active form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D], which interacts with 
nuclear vitamin D receptors (VDR) in the cells to influence gene transcription.23   
 The primary function of 1,25(OH)2D is to maintain serum calcium levels within a 
normal range so as to support cellular activities and neuromuscular function.29  A 
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 decrease in serum calcium concentration stimulates the parathyroid gland to secrete 
parathyroid hormone (PTH), which goes to the kidney to stimulate production of 
1,25(OH)2D from 25(OH)D.  DBP carries 1,25(OH)2D to the intestines where it acts via 
the vitamin D receptor in the intestines to increase active calcium absorption.  If there is 
inadequate dietary calcium to maintain serum calcium concentrations, 1,25(OH)2D and 
PTH work together to stimulate reabsorption of calcium from the renal tubules and 
mobilize calcium from the skeleton to maintain normal serum calcium levels.29,34  The 
steroid hormone, 1,25(OH)2D, is only made in the kidneys as needed, and production is 
tightly regulated by PTH and calcium.20   
 High concentrations of 1,25(OH)2D inhibit 1-α-hydroxylase activity, and increase 
24-hydroxylase enzyme activity, which acts to degrade 1,25(OH)2D to calcitroic acid for 
excretion.35  The 24-hydroxylase enzyme produces 24,25-dihydroxyvitamin D and 
1,24,25-trihydroxyvitamin D, intermediates in the degradation of 1,25(OH)2D to 
calcitroic acid.36  Calcitroic acid is excreted via bile in feces.37  Twenty-five-
hydroxyvitamin D is also broken down via this pathway.36  High serum 1,25(OH)2D 
levels decrease the half-life of 25(OH)D,38 most likely by increasing metabolic clearance 
as noted by increased fecal, urinary, and biliary excretion of catabolic products.39-41  An 
increase in 1,25(OH)2D due to inadequate serum calcium and vitamin D can accelerate 
the depletion of 25(OH)D stores.42   
 Serum concentrations of 1,25(OH)2D are only about 1/100 of serum 
concentrations of 25(OH)D and the half-life of 1,25(OH)2D is only four to six hours, 
compared to three to four weeks for 25(OH)D.42     
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  Recently, vitamin D receptors and 1-α-hydroxylase were found in many tissues 
outside the kidney; these tissues produce 1,25(OH)2D, which acts locally to regulate cell 
growth.  This 1,25(OH)2D does not enter circulation and is therefore not measured as part 
of the serum concentration.  Extrarenal production of 1,25(OH)2D is dependent on an 
adequate supply of 25(OH)D reaching the tissues.20 
 In summary, vitamin D, whether consumed orally or synthesized cutaneously 
upon exposure to UVB radiation, is transported to the liver where it is hydroxylated to 
25(OH)D.  Then, 25(OH)D is carried by DBP from the liver to the kidney and extrarenal 
tissues where it is further hydroxylated to the biologically active 1,25(OH)2D. 
Functions of Vitamin D 
 The primary function of vitamin D is to maintain serum calcium levels within a 
normal range so as to support cellular activities and neuromuscular function.29  Vitamin 
D is necessary for calcium absorption, for bone mineralization, and in the prevention of 
rickets, osteomalacia, and osteoporosis.  In addition to the calcemic roles, vitamin D also 
appears to have important non-calcemic, non-skeletal-related functions including: 
reducing the risk of developing autoimmune diseases such as type 1 diabetes, rheumatoid 
arthritis, and multiple sclerosis; improving immune function; and improving the outcome 
of certain cancers.  
 The functions of vitamin D are carried out through the actions of the active form, 
1,25(OH)2D, which interacts with nuclear vitamin D receptors (VDRs).  VDRs act 
through vitamin D-responsive elements (VDREs) to either initiate or suppress gene 
transcription.34,43 
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 Calcemic Functions 
Calcium Absorption 
 Vitamin D is necessary for active transport of calcium across the intestinal cell 
mucosa.  When serum calcium levels start to decrease, the parathyroid gland is stimulated 
to secrete PTH, which then increases renal 1,25(OH)2D production.  The 1,25(OH)2D 
interacts with nuclear vitamin D receptors (VDRs) in the intestinal cells activating genes 
for calcium binding protein (calbindin) and other proteins involved in calcium and 
phosphorus transport across the cell membranes, through the cells, and into circulation to 
maintain serum calcium levels.43   
 If there is inadequate dietary calcium to maintain serum calcium concentrations, 
1,25(OH)2D and PTH work together to stimulate reabsorption of calcium from the renal 
tubules and mobilize calcium from the skeleton to maintain normal serum calcium 
levels.29,34  
 Without vitamin D the intestine only absorbs 10% to 15% of dietary calcium via 
passive diffusion.  Calcium absorption increases to 30% with adequate vitamin D and up 
to 80% during growth, lactation, and pregnancy.44  Postmenopausal women with mean 
serum 25(OH)D levels of 86.5 nmol/L absorbed 45% to 65% more calcium than did 
women with mean serum 25(OH)D levels of 50.1 nmol/L.9  In another study, after 
adjusting for age, calcium intake, and 1,25-dihydroxyvitamin D concentration, serum 
25(OH)D level was the most significant determinant of calcium absorption in elderly 
women.45     
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 Bone Mineralization and Fracture Risk 
 Vitamin D is essential for the prevention of rickets (poor mineralization resulting 
in softening of the bones) in children and osteomalacia (defective bone mineralization) 
and osteoporosis (porous, thinned bones) in adults.  Rickets causes deformity and 
increased risk of fracture in children.  Osteomalacia results in pain, weakness, and 
fragility of bones in adults.  Rickets, osteomalacia, and osteoporosis increase fracture 
risk.20 
 When there is inadequate 25(OH)D, calcium absorption decreases and serum 
calcium drops, which stimulates secretion of PTH by the parathyroid gland, resulting in 
secondary hyperparathyroidism.  Parathyroid hormone alone, and in cooperation with 
1,25(OH)2D, induces maturation of osteoclasts in the bone, which release hydrochloric 
acid and enzymes to destroy the bone matrix, releasing calcium and other minerals into 
the circulation.34,44  Over time, the withdrawal of mineral from the bone and destruction 
of the matrix results in osteoporosis.29  Secondary hyperparathyroidism also increases 
renal tubular absorption of calcium and loss of phosphorus in the urine resulting in an 
inadequate calcium-phosphate product to promote mineralization of the bone, which 
leads to osteomalacia and rickets.44 
 Accumulation of peak bone mass during childhood and adolescence and the rate 
of bone loss during aging are two of the main factors contributing to osteoporosis.46,47  
Although accumulation of bone mass is most rapid during late childhood and early 
adolescence, bone mass can continue to accumulate until women are in their late 
twenties47 and bone loss typically begins after age 30.  Vitamin D intake is positively 
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 correlated with bone mineral density (BMD) in young adult women.47,48  Similarly, serum 
25(OH)D levels and BMD are positively correlated in adolescent girls.46,49 
 In the elderly, men and women receiving 700 IU vitamin D3 and 500 mg calcium 
daily over three years experienced a significant reduction in bone loss and a 54% 
reduction in non-vertebral fractures.50  Researchers have found that supplementation with 
vitamin D significantly reduces bone loss in elderly subjects50-52 and fracture risk.50-56  
The decrease in fracture risk is likely due to both the improvements in bone density and 
in muscle strength.57 
Skeletalmuscular Comfort 
 In osteomalacia, it is believed that the osteoblasts deposit collagen matrix on the 
endosteal and periosteal surfaces of the skeleton, but without adequate calcium phosphate 
product, the matrix is rubbery and is not strong enough to support the weight of the 
skeleton.  Instead, the rubbery matrix expands under the periosteal covering, putting 
pressure on the covering, which is innervated with sensory pain fibers, resulting in the 
deep bone aching and pain associated with osteomalacia.58  Muscle pain and weakness 
probably precede bone disease and can occur in patients without signs of osteomalacia.59  
However, the mechanism for this muscle pain is not yet known.   
 Osteomalacia, which causes generalized aching in the bones, and muscle pain and 
weakness, is common in vitamin D deficiency60,61 and can be misdiagnosed as 
fibromyalgia.58,59,62  But, unlike in fibromyalgia, correction of the vitamin D deficiency 
can provide nearly complete pain relief.59,63  In Minnesota, more than 90% of hospital 
inpatients with nonspecific muscle aches and bone pain had severe vitamin D 
deficiency.62  In Denmark, 88% of Arab women with muscle weakness and bone pain 
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 were severely vitamin D deficient.60  In the Arab women, treatment with vitamin D, 
which increased serum 25(OH)D levels by over 400% (from 6.7 ± 0.6 to 34.4 ± 2.0 
nmol/L) significantly reduced subjective complaints of muscle and bone discomfort, in 
most cases within one and a half months.  Vitamin D supplementation also significantly 
improved objective measures of muscle power (maximal voluntary quadricep contraction, 
single twitch stimulation, maximal production rate, and maximal relaxation rate) in the 
same women.59  Middle-aged men and women experienced a 24.8 ± 8.0% improvement 
in overall muscle power when mean serum 25(OH)D levels increased from 7.0 ± 0.7 to 
48.3 ± 8.3 nmol/L.59 
 In the elderly, low serum 25(OH)D levels are associated with decreased muscle 
strength and increased risk of falling.64-66  Improvement in the function of type-II muscle 
fibers after supplementation with vitamin D may explain the reduced risk of falling seen 
in some supplementation studies.64 
Non-Skeletal Functions 
 In the United States and worldwide, people who live at higher latitudes, and 
therefore have limited access to sunlight, have increased risk of prostate, colon, breast, 
ovarian, and esophageal cancers and non-Hodgkins lymphoma,67-70 multiple sclerosis,71 
type 1 diabetes,72 rheumatoid arthritis,73 and hypertension.74,75 
 Adequate amounts of the active form of vitamin D, 1,25(OH)2D, are necessary in 
cancer prevention and other diseases.  In the kidneys, low calcium levels promote the 
production of 1,25-dihydroxyvitamin D; however, this is not the case in the extra-renal 
tissues where adequate supply of the substrate, 25(OH)D, is necessary for 1,25(OH)2D 
production.20 
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  Most of the studies relating vitamin D status to disease rates are based on 
associations and are, therefore, not necessarily causal.  Thus, the role of vitamin D in 
cancer and autoimmune disease is still somewhat controversial.   
Cancer 
 The active form of vitamin D, 1,25(OH)2D, plays an important role in the 
proliferation and differentiation of cells.  Normal tissue and some cancer cells (including 
prostate, colon, breast, and lung cancer cells) have 1-α-hydroxylase and are able to 
convert 25(OH)D into 1,25(OH)2D, which interacts with the vitamin D receptor (VDR) in 
these cells, decreasing their differentiation and promoting their maturation, to regulate 
cell growth and possibly prevent malignancy.20,29      
 Studies show that serum 25(OH)D levels of at least 50 nmol/L decrease the risk of 
developing and dying of colon, prostate, and breast cancer by 30% to 50%.30,67,68,70  In a 
review of 18 observational studies looking at 25(OH)D levels or oral vitamin D intake 
and colon cancer, Gorham et al76 found that colorectal cancer risk can be decreased by 
50% with serum 25(OH)D levels above 80 nmol/L compared with 29 nmol/L or with oral 
intake of at least 1000 IU vitamin D3 daily compared with 100 IU daily. 
 In a study designed to look at fracture risk, women in rural Nebraska receiving 
1400 to 1500 mg calcium and 1100 IU vitamin D3 daily for four years had a 0.402 
relative risk (RR) for all cancers compared to women receiving placebo.77  The RR 
dropped to 0.232 when only cancers diagnosed after the first year were included (cancers 
diagnosed during the first year might have been present, but undiagnosed, at the start of 
the study).  Subjects receiving 1400 to 1500 mg calcium, but no vitamin D, daily for four 
years had a RR of 0.532 for all cancers compared to placebo.  Their RR did not change 
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 when only cancers diagnosed after the first year were included.  Over the four-year 
period, out of 1180 women, there were 50 non-skin cancer diagnoses occurring in the 
breast (19), colon (3), lung (7), lymph/leukemia/myeloma (10), uterus (3), and other (8).  
Baseline serum 25(OH)D levels and treatment were significant predictors of cancer risk 
using linear regression analysis.  The RR for the calcium-only group suggests a protective 
effect of calcium, or, the researchers suggest, it could be a chance occurrence since, with 
the exception of colon cancer, no other studies have ever shown an association between 
calcium and cancer.  High calcium intake may reduce 1,25(OH)2D concentration, which 
would result in slower consumption and degradation of 25(OH)D.42  This would act like a 
higher dose of vitamin D and could explain the protective effect of calcium. 
Autoimmune Diseases 
 Development of type 1 diabetes, multiple sclerosis, and rheumatoid arthritis has 
been prevented in mice prone to these diseases after treatment with 1,25(OH)2D at an 
early age.73,78-82  The likely mechanism of action is that 1,25(OH)2D interacts with T-
helper lymphocytes, which suppresses the inflammatory responses of T-helper type 1 
lymphocytes.34 
 The risk of developing type 1 diabetes was reduced by 80% in non-obese diabetic 
mice, prone to type 1 diabetes, who received 1,25(OH)2D throughout their lives.78,81    
 In humans, children in Finland who received the recommended dose of 2000 IU 
vitamin D daily during their first year of life in 1966 were 80% less likely to develop type 
1 diabetes over the next 30 years.17  Additionally, children who had been diagnosed with 
rickets during childhood were three times more likely to develop type 1 diabetes.17 
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  Experimental autoimmune encephalomyelitis (EAE) is the animal model for 
multiple sclerosis (MS).  Administration of adequate 1,25(OH)2D to animals can 
eliminate or suppress EAE at any stage of development.79  However, this therapy caused 
hypercalcemia in the animals. 
 Munger and colleagues,18 analyzing serum samples of white military personnel, 
found an inverse relationship between serum 25(OH)D levels before age 20 and risk of 
developing multiple sclerosis.  For the Hispanics and African Americans no significant 
relationship was seen, probably due to the smaller sample size and, in blacks, lower 
serum 25(OH)D levels.  Among whites, the odds ratio of developing MS was 0.38 in the 
highest quintile of serum 25(OH)D (>99.1 nmol/L) compared to the lowest quintile of 
25(OH)D (<63.3 nmol/L).  Having serum 25(OH)D concentrations above 100 nmol/L 
reduced the risk of multiple sclerosis by 51% compared with serum concentrations less 
than 75 nmol/L.18 
 In mice, supplementation with 1,25(OH)2D decreased symptoms and arrested the 
progression of arthritis in animals inflicted with an animal version of rheumatoid arthritis 
(RA).  Supplementation with 1,25(OH)2D prevented the development of arthritis in 
mice.73   
Immunity 
 Researchers believe that 1,25(OH)2D stimulates the innate immune response.  
Vitamin D prevents macrophages from releasing too many cytokines and chemokines83 
and enhances macrophage ability to function.84,85  The active form of vitamin D, 
1,25(OH)2D, activates the gene for production of the antimicrobial peptide (AMP), 
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 cathelicidin.86-88  Antimicrobial peptides act like antibiotics to destroy invading 
microorganisms, and accelerate wound healing.87 
 In human studies, there is evidence that adequate vitamin D status benefits 
immunity.  When serum from African Americans with low 25(OH)D levels was 
inoculated with Mycobacterium tuberculosis, macrophages produced 63% less 
cathelicidin than did macrophages in serum from white Americans with higher 25(OH)D 
levels.88  Addition of 25(OH)2D to the African American serum increased cathelicidin 
production to that seen in the white serum.  
 When Wayse and colleagues89 compared 80 children with lower respiratory 
infections to healthy controls, 80% of the ill children had serum 25(OH)D levels less than 
25 nmol/L, compared to only 31% of the controls.  Some researchers suggest adequate 
vitamin D levels may protect against influenza.90  In a psychiatric hospital in California, 
none of the men receiving high doses of vitamin D for treatment of deficiency became ill 
during an influenza outbreak that affected over 100 men at the facility.91  In 756 young 
Finnish men serving in the military, Laaksi and colleagues92 found that men who had 
serum 25(OH)D levels less than 40 nmol/L in July missed significantly more days of 
military duty due to respiratory infection over the following six months.  The men with 
vitamin D deficiency missed a median of four days compared to two days missed by the 
control group.92 
Hypertension   
 Adequate vitamin D may help prevent hypertension by preventing 
overstimulation of the renin angiotensin system (RAS).  The proposed mechanism for the 
effect of vitamin D on hypertension, as demonstrated in mice, is that 1,25(OH)2D down-
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 regulates renin gene transcription through a mechanism involving the VDR.93  VDR 
knock-out mice had increased renin expression and increased angiotensin II production 
resulting in hypertension, which was corrected with an angiotensin converting enzyme 
(ACE) inhibitor.93  Further research is needed to examine the molecular mechanism for 
vitamin D regulation of renin expression. 
 Hypertensive patients exposed to UVB radiation for three months experienced a 
162% mean increase in serum 25(OH)D levels and a 6 mmHg mean drop in diastolic and 
systolic blood pressure; there was no change in a group exposed to UVA radiation.19  
This change in blood pressure upon exposure to UVB is similar to that obtained from 
medications.19  Data from the Health Professionals’ Follow Up Study and the Nurses’ 
Health Study revealed the pooled relative risk of incident hypertension was 3.18 for men 
and women with serum 25(OH)D levels less than 37.5 nmol/L compared with those with 
levels greater than 75 nmol/L.75 
Inflammation 
 Likely through its role in enhancing the immune system, decreasing cytokine 
production83 and enhancing macrophage function,84,85 vitamin D also plays a role in 
decreasing inflammation.94  Studies have reported an inverse relationship between C-
reactive protein and serum 25(OH)D levels.94,95  Van den Berghe and colleagues94 saw a 
decrease in C-reactive protein and interleukin-6 (IL-6) concentrations in critically ill 
patients receiving 500 IU vitamin D3 in parenteral nutrition daily.  Timms and 
colleagues95 gave 47 vitamin D deficient adults (25(OH)D levels less than 27 nmol/L) 
either 500 or 50,000 IU vitamin D3 intramuscularly every three months for one year.  
Serum 25(OH)D levels increased to 37.5 nmol/L in the high dose group, and 32.9 nmol/L 
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 in the low dose group.  The researchers reported difficulty in accurately measuring 500 
IU vitamin D3 to be given intramuscularly and speculated that subjects received 
injections containing more than 500 IU which might explain the lack of a difference in 
final serum 25(OH)D levels between the two dosage groups.  Overall, C-reactive protein 
levels decreased by 23% in the subjects receiving vitamin D3; there was no placebo 
group.95   
 In men and women over 50 years old participating in NHANES III, serum 
25(OH)D concentrations were inversely associated with periodontal attachment loss.96  
Periodontal attachment loss is the loss of periodontal ligament and alveolar bone, which 
is characteristic of periodontal disease.96  Men in the lowest quintile lost 0.39 mm more 
attachment than those in the highest quintile of serum 25(OH)D concentration; women in 
the lowest quintile of serum 25(OH)D lost 0.26 mm more periodontal attachment.  BMD 
and attachment loss were not significantly associated.  The researchers credit the anti-
inflammatory effects of vitamin D for the inverse association with periodontal disease.96  
Possibly, vitamin D inhibits the release of proinflammatory cytokines in response to 
bacteria in the dental plaque.  Without sufficient vitamin D, the cytokines stimulate bone 
resorption in the affected teeth.96  The same researchers looked at the association between 
gingivitis and serum 25(OH)D levels in NHANES III participants.97  Gingivitis is a better 
tool for examining the effect of vitamin D on inflammation because, unlike periodontal 
disease, its development is completely unrelated to bone.  The highest quintile of serum 
25(OH)D (median 99.6 nmol/L) had 20% lower odds of bleeding than the lowest quintile 
(median 32.4 nmol/L).  There was a significant inverse association between serum 
25(OH)D levels and bleeding of the gums on probing (a measure of gingivitis).  This 
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 association did not reach a threshold at a point where gingival inflammation leveled off, 
suggesting that serum 25(OH)D concentrations higher than 90-100 nmol/L may be 
needed to reduce inflammation. 
Summary  
 Vitamin D is essential for maintaining skeletal strength throughout the lifecycle98 
and may also play important roles in the prevention and treatment of several cancers, 
hypertension, and autoimmune diseases.20,30  
 The actions of vitamin D are carried out by the active hormonal form, 
1,25(OH)2D, interacting with a vitamin D receptor in the cell nucleus to enhance or 
suppress gene transcription.  Adequate serum 25(OH)D is critical to provide adequate 
substrate for hydroxylation to 1,25(OH)2D.  Because 1,25(OH)2D produced outside the 
kidneys does not enter into circulation, measurement of the active form of vitamin D does 
not reflect adequacy of vitamin D status.  Instead, assessment of serum 25(OH)D 
concentration is the appropriate indicator of vitamin D status. 
Optimal Levels of Serum 25(OH)D 
 Serum 25-hydroxyvitamin D concentration is the best measure of vitamin D status 
because it reflects both cutaneous synthesis of vitamin D and absorption of vitamin D 
from the diet.  The enzyme that converts vitamin D into 25(OH)D, 25-hydroxylase, is 
poorly regulated.  Therefore, 25(OH)D concentration reflects overall vitamin D status.  In 
the past, optimal levels of 25(OH)D were the levels that prevented osteomalacia and 
rickets.2 
 Most laboratories use 37.5 to 50 nmol/L (15 to 20 ng/mL) as the lower limit of 
normal for 25(OH)D.  To obtain the normal range, a diverse population of asymptomatic 
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 subjects was sampled.  However, this “normal” population could include individuals with 
inadequate sun exposure and suboptimal serum 25(OH)D levels.9  Hollis and colleagues99 
suggest the “normal” population should be redefined as sun-replete individuals such as 
lifeguards, surfers, and farmers from locations where vitamin D is synthesized year-
round.  In 93 surfers and skateboarders in Honolulu, Hawaii (21oN) with self-reported 
sun exposure of three or more hours on five or more days per week for the previous three 
months, serum 25(OH)D levels ranged from 28 to 178 nmol/L.99  Similarly, the median 
serum 25(OH)D levels of 30 sun-replete healthy men who spent long hours outdoors 
during the summer in Nebraska (landscaping, construction, farming, or recreation) was 
122 nmol/L (interquartile range: 100 to 154 nmol/L) in late summer.10 
 The optimal level of 25(OH)D is the concentration associated with the maximum 
suppression of PTH, maximum calcium absorption, maximum bone mineral density and 
reduced rate of bone loss, reduced rate of falling and improved muscle strength, and 
reduced risk of fractures.1  During a round table discussion at the 5th International 
Symposium on the Nutritional Aspects of Osteoporosis, held in Lausanne, Switzerland in 
May 2003, five of the six leading vitamin D researchers agreed that, based on the 
evidence available, the optimal concentration of serum 25(OH)D is at least 70 to 80 
nmol/L.1  Further research is needed to determine the optimal concentration of serum 
25(OH)D required for the non-calcemic functions of vitamin D; however, preliminary 
evidence suggests levels of at least 75 nmol/L are desirable.2,100 
Maximum Suppression of PTH 
 Many studies have found an inverse relationship between serum 25(OH)D levels 
and PTH levels.8,11-15,101  Researchers have found that serum PTH levels increase when 
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 serum 25(OH)D levels drop below 37 nmol/L,11,15 50 nmol/L,12 78 nmol/L,13 95 
nmol/L,101 and 110 nmol/L.14  Possible explanations for the wide range of estimated 
threshold levels include variations in ethnicity, age, and calcium intake of the subjects, 
renal insufficiency, and the use of unstandardized assays for serum 25(OH)D levels.102,103 
Maximum Calcium Absorption 
 In a study of postmenopausal women, calcium absorption increased with serum 
25(OH)D levels up to 80 nmol/L, at which point fractional calcium absorption plateaued.  
Women with mean serum 25(OH)D levels of 86.5 nmol/L absorbed 45% to 65% more 
calcium than did women with mean serum 25(OH)D levels of 50.1 nmol/L.9  In healthy 
men, calcium absorption did not change significantly when serum 25(OH)D levels 
dropped from 122 nmol/L at the end of summer to 74 nmol/L at the end of winter.10  
These studies suggest that the threshold for maximum calcium absorption is at serum 
25(OH)D levels of at least 75 nmol/L. 
Reduced Rate of Falling / Improved Muscle Strength 
 Low serum 25(OH)D levels are associated with decreased muscle strength and 
increased risk of falling in the elderly.  Increasing serum 25(OH)D levels from 30 to 65 
nmol/L significantly increased muscle strength (measured by the “timed up&go” test, 
knee flexor strength, knee extensor strength, and grip strength) and reduced the number 
of falls in older men and women.64  In another study, elderly men and women with serum 
25(OH)D levels between 50 and 74 nmol/L were twice as likely to experience loss of grip 
strength (an indicator of muscle strength that is positively correlated with both lower- and 
upper-extremity strength) compared to subjects with serum 25(OH)D levels above 75 
nmol/L.65  
 20
 Reduced Risk of Fractures 
 A meta-analysis of vitamin D supplementation and fracture risk revealed that 
fractures were prevented at serum 25(OH)D levels of at least 74 nmol/L, and optimal 
fracture prevention was achieved when serum 25(OH)D levels reached at least 100 
nmol/L.57  In one study, overall fracture risk was decreased by 22% in community-
dwelling men and women with a mean serum 25(OH)D level of 74.3 nmol/L, compared 
to those with a mean of 53.4 nmol/L.55  Other vitamin D supplementation studies that 
failed to achieve serum 25(OH)D levels greater than 75 nmol/L did not find a significant 
reduction in fracture risk.104-106  
Maximum Bone Mineral Density and Reduced Rate of Bone Loss 
 In an analysis of NHANES III data, Bischoff-Ferrari and colleagues107 found a 
positive correlation between serum 25(OH)D levels and BMD, which continued as serum 
25(OH)D levels increased above 100 nmol/L. 
 In another study, when serum 25(OH)D levels were maintained above 90 nmol/L 
in 100 postmenopausal women, wintertime bone loss was decreased compared to the 
control group, resulting in a slight gain in BMD of the spine over one year.108  Similarly, 
postmenopausal women with a mean serum 25(OH)D level of 100 nmol/L experienced 
significantly less femoral bone loss over one year than subjects with a mean serum 
25(OH)D level of 66.3 nmol/L.109  These studies suggest that levels even greater than 75 
nmol/L may be optimal to prevent bone loss in postmenopausal women. 
Conclusion 
 The above evidence suggests that optimal serum 25(OH)D levels are at least 75 
nmol/L, and possibly higher.  Based on the recent editorial by Dawson-Hughes and 
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 colleagues,1 which reports an informal consensus among prominent vitamin D 
researchers to establish 75 nmol/L as the lower end of the optimal serum 25(OH)D range, 
this level was selected as the cut-off for determining optimal concentrations of serum 
25(OH)D in this research study.  Increasing serum 25(OH)D levels in the US to at least 
75 nmol/L would result in an expected 4% to 5% increase in BMD; a 4% to 6% increase 
in lower extremity function in older adults; and a 25% reduction in hip or non-vertebral 
fractures.103 
Factors Influencing Serum 25(OH)D Levels 
Dietary Vitamin D Intake 
Recommended Dietary Intake Levels of Vitamin D 
 The recommended Adequate Intake set by the Food and Nutrition Board of the 
Institute of Medicine for Vitamin D, in the absence of sunlight, is 200 IU for children and 
adults up to 50 years old; 400 IU for adults 51 through 70 years old; and 600 IU for 
adults over 70 years old.21  However, the data used to set this intake recommendation in 
1997 are now obsolete and most researchers agree that at least 800 to 1000 IU daily is 
needed for optimal vitamin D status in the absence of sunlight.1 
Sources of Vitamin D 
 Most people rely on food to meet their vitamin D requirement during times of 
inadequate sunlight.  Few foods, primarily oily fish such as salmon, mackerel, and 
sardines; cod liver oil; and organ meats, are natural sources of vitamin D.  Oily fish is not 
consumed daily by most individuals in the United States; therefore, the US population 
must rely on fortified foods for vitamin D.110  In fact, 65 to 87% of dietary vitamin D 
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 intake comes from fortified foods in the US.111  A list of foods that contain vitamin D can 
be found in Appendix A. 
 In the early 1930’s the United States began fortifying milk with 100 IU vitamin 
D2 or D3 per eight ounce cup in an effort to prevent rickets in children.112  However, the 
actual amount of vitamin D in milk has been found to vary considerably.112,113  In 
addition to milk, some orange juice, some cereals and breads, some yogurts, and some 
margarines are fortified with vitamin D in the US (see Appendix A).  Despite fortified 
food, women 19 to 50 years old only consumed an average of 168 IU vitamin D daily 
from fortified and naturally occurring food sources111 leading some researchers to argue 
for higher levels of fortification in a larger variety of foods.110,114  However, even with 
more fortification, supplemental vitamin D may still be necessary for individuals with 
inadequate sun exposure,114 including those living at high latitudes. 
 Sunlight, in the form of ultraviolet-B (UVB) radiation, is the primary source of 
vitamin D, providing 90 to 100% of the requirement for most people who are exposed to 
adequate sunlight.3  The amount of vitamin D3 produced by whole-body exposure to one 
minimal erythemal dose (MED) of sunlight (the amount needed to cause a light pinkness 
to the skin) is equivalent to the consumption of 10,000 to 25,000 IU oral vitamin D2.115  
However, the exact amount of vitamin D produced in response to sunlight will vary by 
age and skin type,116 and is highly variable between individuals, with some individuals 
having low serum 25(OH)D levels despite abundant sun exposure.117 
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 Factors that Influence Cutaneous Synthesis of Vitamin D 
 Anything that reduces the number of UVB photons absorbed by the skin or 
decreases the amount of 7-dehydrocholesterol in the skin will decrease or eliminate 
vitamin D synthesis. 
Latitude, Time of Day, and Season 
 The position of the sun in the sky varies daily and seasonally.  When the sun is 
low on the horizon, UV radiation must travel farther, is more easily scattered, and is more 
absorbed by ozone than when the sun is directly overhead, resulting in fewer UVB 
photons reaching the earth’s surface.5  Because of the tilt of the earth on its axis, UV 
radiation must travel farther to reach areas closer to the north or south poles than to reach 
areas nearer the equator.  Therefore, the ability of the skin to synthesize vitamin D is 
affected by latitude, season, and time of day.5 
 Above 35oN latitude, no previtamin D3 is produced in the skin for four to six 
months during winter.20  In Boston (42oN) human skin samples synthesized the greatest 
amount of previtamin D3 in June and July and did not synthesize any previtamin D3 on 
cloudless days from November through February.5  In Edmonton, Canada (52oN), no 
previtamin D3 was synthesized from October through March.5  In Orono, Maine (44oN), 
no vitamin D3 synthesis occurred in human skin samples on a sunny day at the end of 
February.118  Below 35o latitude (Los Angeles and Puerto Rico), however, previtamin D3 
was formed year-round.5  Similar results were found in the southern hemisphere; in 
Argentina previtamin D3 synthesis was negligible in Ushuaia (55oS), but adequate in 
Buenos Aires (34oS) during winter.119  The period when there is insufficient UVB for 
vitamin D synthesis is known as “Vitamin D Winter”.120  
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  In North America (30oN to 43oN), serum 25(OH)D levels are reported to be at 
their lowest point at the end of the Vitamin D Winter in February, rapidly increase after 
March, reach their peak in August, and then slowly decline after September.6,121,122 
 Time of day also affects the zenith angle of the UVB rays, and, therefore, affects 
vitamin D synthesis.  In Boston in July, vitamin D synthesis can occur as early as 0700 
EST and continue as late as 1700 EST, with peak synthesis between 1000 and 1400.123  In 
August in Orono, Maine, significant vitamin D3 synthesis only occurred between 1000 
and 1600.118  During spring and autumn in Boston, vitamin D synthesis only occurs 
between 1000 EST and 1500 EST.115 
 In summary, season, latitude, and time of day affect the amount of UVB radiation 
reaching the earth’s surface and, therefore, affect cutaneous vitamin D synthesis.  
Maximum vitamin D synthesis occurs at the equator at midday during summer.  No 
vitamin D is synthesized during winter at high latitudes at any time of day. 
  Pollution 
 Aerosols in the atmosphere deflect UVB photons, thus decreasing the amount of 
UVB radiation reaching the earth’s surface.120  High ozone levels in the troposphere 
absorb UVB photons and reduce cutaneous synthesis of vitamin D.115  Extremely high 
atmospheric ozone levels can extend the duration of “Vitamin D Winter” by two months 
and increase the latitude for “Vitamin D Winter” by approximately ten degrees.120  
Individuals living in locations with high levels of pollutants in the air may have lower 
serum 25(OH)D levels than in areas with low pollution rates. 
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 Cloud Cover 
 Ultraviolet-B radiation at the earth’s surface can be reduced by as much as 45% 
on a cloudy day.124  Sullivan and colleagues118 compared in vitro previtamin D3 
production on a cloudy summer day with a sunny summer day in Maine and found 
previtamin D3 production was reduced by 50% when cloudy. 
Sunscreen 
 Sunscreens, although beneficial in the prevention of skin cancer, prevent vitamin 
D synthesis in the skin.  Sunscreen with a sun protection factor (SPF) of eight or greater 
reduces vitamin D production by more than 95% if applied and reapplied according to 
package instructions.125  In fact, twenty white individuals who used sunscreen on sun-
exposed areas for more than one year had serum 25(OH)D levels 55% lower than 
matched controls (40.2 versus 91.3 nmol/L) during summer.126  Two (10%) of the 
sunscreen users had vitamin D deficiency (serum 25(OH)D levels less than 20 
nmol/L).126 
 On the other hand, Wolpowitz and Gilchrest127 argue that most individuals do not 
apply sufficient amounts of sunscreen, reapply it as directed, or cover all sun-exposed 
body surfaces and, therefore, are not receiving enough sun protection to prevent vitamin 
D synthesis.  They also argue that, even if properly applied, sunscreens with SPF-15 
permit 1/15 (6%) of UVB photons to penetrate the skin and, therefore, vitamin D 
deficiency due to sunscreen use is highly unlikely.127 
 In Australia, Marks and colleagues128 gave 113 people either sunscreen with SPF-
17 or a placebo cream.  All subjects were instructed to apply the cream daily, and to 
reapply if they were likely to have sweated, washed, or rubbed it off during the day.  All 
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 subjects were advised to avoid sun exposure at midday, and to wear hats and clothing for 
sun protection since they could be in the placebo group and getting no other sun 
protection.  The researchers found no significant difference in serum 25(OH)D levels 
between the sunscreen users and the control group.  However, there were some 
weaknesses in this study, which may explain why Marks and colleagues failed to find any 
difference in serum 25(OH)D levels.  Subjects were only instructed to apply cream to 
their head, neck, forearms and dorsum of each hand, which left their legs, and upper arms 
exposed to sunlight and could explain why sunscreen users synthesized vitamin D.  All 
subjects were encouraged to protect themselves from sun by avoiding midday sun and 
wearing protective hats and clothing; therefore, subjects in the placebo group likely had 
decreased vitamin D synthesis.  Overall, serum 25(OH)D levels increased only 12.3 
nmol/L, which was less than the seasonal differences of 20.1 nmol/L4 and 31 nmol/L129  
seen in other studies between winter and summer. 
 Thus, sunscreen, if applied to all exposed skin, and reapplied frequently, can 
prevent vitamin D synthesis.  In reality, however, most individuals do not apply and 
reapply sunscreen to all sun-exposed areas regularly enough to cause vitamin D 
deficiency. 
Clothing 
 Clothing absorbs UVB radiation, preventing vitamin D synthesis.  When subjects 
wearing black or white clothes made from cotton, polyester, or wool fabric were exposed 
to six MEDs of ultraviolet radiation, they did not produce any vitamin D.130  Vitamin D 
deficiency is common in sunny countries such as Saudi Arabia, Jordan, and the United 
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 Arab Emirates, where, due to cultural clothing customs, women rarely expose their skin 
to sunlight.131-133 
Aging 
 In general, compared to younger people, older people are more likely to stay 
inside during the peak period for vitamin D production, wear more clothing, and use 
more sunscreen than younger people, putting them at risk for lower serum 25(OH)D 
levels.134  In addition, the amount of 7-dehydrocholesterol in the skin may decrease by 
more than 50% by age 70,135 possibly due to decreased skin thickness and skin mass.136  
Despite the decrease in 7-dehydrocholesterol, the elderly are still able to make vitamin 
D3, it just takes longer to make the same amount as a younger person.137  Elderly stroke 
patients in Japan who were exposed to 15 minutes of sunlight on their hands and faces 
every pleasant weather day for one year increased their mean serum 25(OH)D levels 
from 18 to 52 nmol/L.  In contrast, in a similar group of patients who were not regularly 
exposed to sunlight, mean serum 25(OH)D levels dropped from 17 to 13 nmol/L.137  
Older individuals may have lower baseline serum 25(OH)D levels than younger people 
due to decreased sun exposure and a decreased ability to synthesize vitamin D in the skin. 
Melanin 
 The skin pigment melanin acts as natural sunscreen.115  People with dark skin do 
not make vitamin D3 as efficiently as people with white skin.5,138,139  Dark-skinned 
individuals with Fitzpatrick skin types V or VI (dark brown or black) require ten to fifty 
times more sun exposure to produce the same amount of vitamin D3 as lighter skinned 
individuals with skin types II or III (fair or slightly beige skin).138  In fact, in Boston in 
June, a black skin sample (type V) had negligible conversion of 7-dehydrocholesterol to 
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 vitamin D3 after 20 to 30 minutes of UVB exposure, whereas a white skin sample (type 
II) exhibited significant vitamin D3 production after just five to ten minutes.140 
 Analysis of data from NHANES III found that mean serum 25(OH)D levels in 
non-Hispanic whites were 1.2 to 1.7 times higher than levels in Mexican Americans or 
non-Hispanic blacks.121  In Boston, 20 to 40 year old white women had serum 25(OH)D 
levels more than twice those of black women in summer and in winter.141 
Tanning Beds 
 Tanning beds that provide an artificial source of UVB radiation promote vitamin 
D3 synthesis.  At the end of winter in Boston, the serum 25(OH)D levels of adults who 
had used a tanning bed in the previous six months were 90% higher than adults who did 
not use a tanning bed.142  The tanners, who had tanned an average of 6.2 years, had 
significantly lower PTH levels and higher total hip BMD than non-tanners. 
 Skin pigmentation also affects vitamin D production from artificial UVB 
radiation.  After 12 weeks of artificial UVB radiation with 0.75 MED in each tanning 
session, serum 25(OH)D levels increased 210% in subjects with skin type II (fair), 187% 
in subjects with skin type III (medium), 125% in subjects with skin type IV (olive or light 
brown), and 40% in subjects with skin type V (brown).140 
Other Factors that Influence Serum 25(OH)D Levels  
Obesity 
 There is an inverse relationship between serum 25(OH)D levels and body mass 
index (BMI) or body fat14,129,139,143-149  As DBP transports vitamin D to the liver for 
hydroxylation, some vitamin D is deposited in the adipose tissue for storage.22,23,24,146  
Obese individuals with large amounts of adipose tissue pick up and store more vitamin D, 
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 resulting in lower serum 25(OH)D levels.146  It is believed that once the adipose tissue 
has been saturated, the vitamin D remains in the serum and is delivered to the liver for 
hydroxylation, but there are no long term data on vitamin D supplementation in obese 
adults.34 
 Wortsman and colleagues146 found that obese individuals had a 57% lower serum 
25(OH)D response to UV radiation compared to normal weight peers.  However, the 
amount of 7-dehydrocholesterol converted to vitamin D3 was not different between the 
two groups.  Therefore, the researchers concluded that obesity does not affect the ability 
of the skin to make vitamin D3, but affects the release from skin into the circulation.146  
 Arunabh and colleagues129 found a significant difference in serum 25(OH)D 
levels between women with the lowest and highest quartiles of total body fat (<31% body 
fat and 56.6 nmol/L compared with >42% body fat and 44.2 nmol/L).  There was a 
significant inverse correlation between fat quartile and the likelihood of achieving serum 
25(OH)D levels of at least 80 nmol/L.  Because total body fat correlated with serum 
25(OH)D levels more strongly than either BMI or weight, researchers concluded that 
adiposity, rather than body mass, impacts serum 25(OH)D levels.129,148  Similarly, 
Bolland and colleagues150 found lower serum 25(OH)D levels at the end of summer in 
post-menopausal women and older men in the highest quartile of fat mass compared to 
those in the lowest quartile; however, they did not find a significant difference in serum 
25(OH)D levels at the end of winter. 
 NHANES III data demonstrated that white women with a healthy BMI (18.5 to 
25) had higher 25(OH)D levels than white obese women (BMI ≥30).139  No relationship 
was seen in African American women possibly due to the higher proportion of lean body 
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 mass or to the lower serum 25(OH)D levels in African Americans.139  Eighty-nine 
percent of morbidly obese adults undergoing gastric bypass surgery in Bangor, Maine 
had serum 25(OH)D levels less than 80 nmol/L before surgery.151 
 Vitamin D stored in adipose tissue is slowly released during times of vitamin D 
deprivation.3,22,29,30  However, in the obese, vitamin D is presumed to be sequestered deep 
in the body fat, so it is less bioavailable than in normal weight individuals.43  
 Bell and colleagues143 suggested an alternative hypothesis to explain the lower 
serum 25(OH)D levels associated with obesity.  They suggested that the elevated 
1,25(OH)2D levels seen in obese individuals exert negative feedback on 25(OH)D 
production in the liver.143  However, the findings of Wortsman and colleagues146 
contradict this theory as they found no difference in 25(OH)D production in obese 
subjects receiving oral vitamin D. 
 In research, BMI or, preferably, body fat, should be accounted for when 
evaluating vitamin D status.  Clinically, obese individuals should be assessed for vitamin 
D deficiency. 
Estrogen 
 Oral contraceptives are prescribed most often for preventing pregnancy, but are 
sometimes used to control acne, or moderate menses.  Oral contraceptive pills must be 
taken daily and may contain either progestin only, or a combination of estrogen (ethinyl 
estradiol) and progestin.  Depending on the prescription, the active pills may provide 15, 
20, 25, 30, or more than 35 μg estrogen per day.  The active pills may be monophasic, 
biphasic, or triphasic and are taken for the first 21 days of the menstrual cycle followed 
by 7 days of inactive pills (placebo) or no pill.  Monophasic oral contraceptives provide 
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 the same amount of estrogen and progestin every day for the first 21 days.  Biphasic pills 
provide the same amount of estrogen for the first 21 days, but the progestin dose is lower 
in the second half of the cycle.  Triphasic pills have the same or varying doses of 
estrogen, and varying doses of progestin throughout the cycle.  In addition to the oral 
contraceptive pill, hormonal contraception is available as a skin patch, vaginal ring, 
injection, or implant.  The vaginal ring and skin patch provide a steady low dose of 
estrogen equivalent to less than 15 μg per day.  
 Serum 25(OH)D levels are 15 to 25 nmol/L higher in oral contraceptive users 
than in non-users.139,152,153  In rural Iowa during summer, mean serum 25(OH)D levels 
were 25% (15 nmol/L) higher in 20-34 year old white women on oral contraceptives 
compared to those not on oral contraceptives.152  In Boston during winter, Harris and 
Dawson-Hughes153 found that oral contraceptive users had serum 25(OH)D levels 41% 
(24.1 nmol/L) higher than non-users.  Analysis of NHANES III data collected in summer 
and winter found mean serum 25(OH)D levels 24.3% (24.8 nmol/L) higher in white oral 
contraceptive users compared to non-users.139 
 The mechanism for the increased serum 25(OH)D levels in oral contraceptive 
users is uncertain.  In male rats, estrogen administration increases mitochondrial 25-
hydroxylase activity in the liver, which increases serum 25(OH)D levels.154  In rabbits 
and cattle, vitamin D-binding protein stimulates 25-hydroxylase activity .155  Since 
estrogen stimulates hepatic production of DBP in humans, DBP levels are increased in 
oral contraceptive users.25  However, in humans, there is no evidence that the increase in 
serum 25(OH)D levels in oral contraceptive users is due to increased 25-hydroxylation in 
the liver. 
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  Oral contraceptives are believed to increase serum 25(OH)D levels due to the 
increase in DBP causing increased circulating concentrations of serum vitamin D 
sterols.25  Estrogen delivered transcutaneously or via skin patch does not increase serum 
DBP concentrations.156  Approximately one month following pregnancy, or after oral 
contraceptives are discontinued, DBP concentrations return to normal.25 
 Although the DBP and total 25(OH)D concentrations are increased, the 
percentage of sterol in the free form is decreased, and the concentration of free 25(OH)D 
remains unchanged.25,157  Likewise, studies have shown an increase in DBP and total 
1,25(OH)2D concentrations after three months of oral estrogen use, but there was no 
increase in the concentration of free 1,25(OH)2D.156,158   
 According to the free hormone hypothesis, the biologic activity of a hormone is 
affected by its free (unbound) concentration, not by its bound concentration.159  
Therefore, since total serum 25(OH)D levels are increased in oral contraceptive users due 
to increased DBP concentration, but the concentration of free 25(OH)D remains similar 
to those not using oral contraceptives, one could presume there should not be a 
physiologic advantage to oral contraceptive use in terms of serum 25(OH)D status.  
However, evidence of the effect of elevated serum 25(OH)D in oral contraceptive users 
on health is lacking. 
 The change in endogenous estrogen levels during the menstrual cycle is not 
associated with any detectable change in 25(OH)D levels.160,161  The phases of change in 
estrogen levels may be too short to detect changes in 25(OH)D levels.161  Hormone 
replacement therapy with one to two mg estradiol daily in postmenopausal women 
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 increased plasma levels of vitamin D-binding protein,162 but did not affect serum 
25(OH)D levels.162,163 
Gender 
 Serum 25(OH)D concentrations were generally 20% higher in elderly men than in 
elderly women living in Boston in summer and fall, but not from February to May.14  The 
difference in serum 25(OH)D levels may have been due to a difference in sun exposure 
as the men reported spending more time outdoors.14  Dietary intake of vitamin D was 
similar between the men and women.14  Elderly women have decreased estrogen levels, 
which may also lower their serum 25(OH)D levels.14 
 NHANES III data showed the rate of vitamin D insufficiency was two times 
higher in females than males of the same age.121  Another study of older women and men 
in the Netherlands found that women had lower 25(OH)D levels than men, but this 
difference disappeared after adjustment for body fat.149 
 The differences in serum 25(OH)D concentration seen between men and women 
may be explained by differences in sun exposure and body fat.  Therefore, it is not clear 
whether there is a gender difference in serum 25(OH)D levels. 
Calcium Intake  
 In healthy men fed their normal diets (estimated to contain 800 mg calcium) plus 
2000 mg calcium for six to seven weeks during winter, serum 25(OH)D levels increased 
significantly more than in a control group.164  Serum 1,25(OH)2D levels decreased 
significantly in the group receiving calcium.  The authors hypothesized the increase in 
serum 25(OH)D and decrease in serum 1,25(OH)2D could be due to one of the following: 
a) increased calcium intake decreases PTH secretion, which decreases 1,25(OH)2D and 
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 causes an increase in 25(OH)D due to a released negative feedback inhibition of 25-
hydroxylase enzyme; or b) increased calcium intake stimulates 25-hydroxylation of 
vitamin D; or c) increased calcium intake, or the resulting decrease in 1,25(OH)2D, may 
decrease the metabolism of 25(OH)D.164 
 The findings of Bell and colleagues,165 that 1,25(OH)2D may inhibit the formation 
of 25(OH)D from vitamin D3 support the first hypothesis.  In addition, in hypocalcemic, 
vitamin D-deficient rats, Haddad and colleagues166 found that dietary calcium stimulated 
hepatic microsomal 25-hydroxylase activity.  In support of the second hypothesis, 
researchers found decreased 25-hydroxylase activity166 and decreased 25(OH)D 
production40 in calcium deficient rats.   
 There is also much research supporting the third hypothesis that increased 
calcium, or the resulting decrease in 1,25(OH)2D, may decrease 25(OH)D catabolism.  
High serum 1,25(OH)2D levels decrease the half-life of 25(OH)D,38 most likely by 
increasing metabolic clearance.39-41  In rats fed a calcium free diet, the resulting 
secondary hyperparathyroidism caused an increase in 1,25(OH)2D, which increased the 
metabolic clearance rate of 25(OH)D.39,40  Bolt and colleagues40 found the clearance rate 
of 25(OH)D was similar to the increased production rate of 1,25(OH)2D found in other 
studies of rats deprived of calcium, leading the researchers to conclude that the increased 
turnover of 25(OH)D was due to increased production of 1,25(OH)2D.   
 Therefore, the decreased 25(OH)D levels in calcium deficient rats are likely due 
to both increased metabolic clearance of 25(OH)D for the production of 1,25(OH)2D, and 
decreased production of 25(OH)D from vitamin D.40  Similarly, in humans, infusion with 
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 1,25(OH)2D stimulated the excretion of 25(OH)D catabolic products, resulting in a 
shorter half-life of 25(OH)D.42   
 Calcium intake may affect baseline serum 25(OH)D levels in individuals with 
very low calcium intakes by stimulating serum 1,25(OH)2D production thereby lowering 
serum 25(OH)D levels, and decreasing 25-hydroxylation of vitamin D. 
Alcohol Consumption 
 Moderate alcohol consumption increases estrogen levels in postmenopausal 
women,167 which may reduce bone loss168 and increase serum 25(OH)D levels.  In elderly 
women, some researchers have found a positive association between moderate alcohol 
consumption and serum 25(OH)D levels,169,170 while others have found no association 
with serum 25(OH)D levels.168  Lamberg-Allardt and colleagues171 found a positive 
association between alcohol and serum 25(OH)D levels in healthy adult men and women 
(30 to 42 years).  Moderate alcohol consumption may influence serum 25(OH)D levels 
and, therefore, should be considered when evaluating vitamin D status. 
Smoking 
 Some studies have shown a negative association between smoking and serum 
25(OH)D levels in healthy adult men and/or women,92,171-173 elderly women,147,170 and 
adult patients with Crohn’s Disease.174  Other studies, however, have failed to find any 
relationship between smoking and vitamin D status.129,149,169  Another study found a 
relationship between smoking and 25(OH)D levels in adult women, but not in men.173  
Some of the studies129,169,175 may have failed to find a relationship between smoking and 
serum 25(OH)D levels due to a low percentage of participants who were smokers. 
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  The mechanism for the relationship between smoking and serum 25(OH)D levels 
is uncertain, but may be due to changes in sex hormones.172,175,176  Some researchers have 
found that, in postmenopausal women receiving hormone replacement therapy, estrogen 
levels are lower in smokers than in non-smokers177,178 presumably due to increased 
hepatic clearance of estrogen.177  Lower estrogen levels could result in lower serum 
25(OH)D levels.  However, Ortego-Centeno and colleagues179 found higher levels of 
serum estradiol and serum hormone binding globulin (SHBG) in premenopausal smokers 
than in non-smokers.  SHBG increases with estrogen and thyroid hormones.176  Other 
researchers found that SHBG levels were significantly reduced after smoking cessation in 
postmenopausal women176 and in men and women with a mean age of 32.2 years.175  
Thus, serum 25(OH)D levels may be lower in smokers, but the mechanism for this 
possible decrease is uncertain. 
Assay Methods 
 Because serum 25(OH)D is highly hydrophobic and exists in two forms, 
25(OH)D2 and 25(OH)D3, it is very difficult to assay.180  Furthermore, assay results vary 
by 33% or more between labs.181,182  Therefore, it is difficult to compare results between 
supplementation studies. 
 High performance liquid chromatography (HPLC), DiaSorin Radioimmunoassay 
(RIA), Nichols Advantage Competitive Binding Protein Assay, and Immunodiagnostic 
Systems (IDS) RIA are the assays that have been most commonly used for determining 
25(OH)D levels in research over the past few years.180  Recently, however, it was 
discovered that the very popular Nichols Advantage assay and the IDS RIA did not detect 
25(OH)D2 well and are, therefore, no longer used.180  The DiaSorin RIA, when used by 
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 experienced personnel, was able to accurately measure both 25(OH)D2 and 25(OH)D3.180  
Measuring 25(OH)D by HPLC is considered the gold standard.  However, this slow and 
expensive method is only accurate if it is performed by a highly experienced 
individual.180  Until a method to standardize assays is developed, caution must be used 
when comparing results from different research studies.183 
Diseases and Medications 
 Diseases characterized by intestinal malabsorption, liver disease, and kidney 
disease as well as some medications such as corticosteroids, anticonvulsants, some 
weight loss medications, and medications for treatment of high cholesterol affect serum 
25(OH)D levels.  Higher rates of vitamin D insufficiency have been documented in 
patients with malabsorptive diseases such as cystic fibrosis,184-186 celiac disease,187 and 
inflammatory bowel disease (Crohn’s disease and ulcerative colitis)174 than in healthy 
controls, often despite oral vitamin D supplementation.  Vitamin D insufficiency is 
common in liver disease due to fat malabsorption and also due to poor hydroxylation.188 
 Patients with nephrotic syndrome have low serum 25(OH)D levels due to a 
combination of urinary excretion of vitamin D-binding protein, and long-term 
glucocorticoid use.189  Weng and colleagues189 found 90% of children with nephrotic 
syndrome had serum 25(OH)D levels less than 75 nmol/L. 
 Corticosteroids decrease calcium absorption,190 which increases PTH, stimulating 
renal 1,25(OH)2D, and leading to a decrease in serum 25(OH)D levels.42  Orlistat, a 
pancreas lipase inhibitor prescribed for weight loss, may cause malabsorption of vitamin 
D and/or calcium.191   
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  The impact of the hypolipidemic drug cholestyramine on serum 25(OH)D levels 
was mixed.  Knodel and colleagues192 reported impairment of vitamin D absorption in 
people taking large doses of cholestyramine (more than 32 grams daily).  Two other 
studies, however, showed no deleterious effects of cholestyramine therapy (24 gm daily) 
on serum 25(OH)D levels.193,194 
 Serum 25(OH)D levels are lower in individuals taking anticonvulsant 
medications, including, but not limited to, phenobarbitol, phenytoin, carbamazapine, 
oxycarbazepine and valproate.195,196  Although research results are mixed, anticonvulsant 
medications are believed to induce 24-hydroxylase enzymes which promotes the 
degradation of 25(OH)D. 195,196  
Factors that Influence Response to Supplementation 
Baseline Serum 25(OH)D Levels 
 Studies have shown that subjects with lower serum 25(OH)D levels have a larger 
increase in serum 25(OH)D levels due to supplementation (hereafter referred to as 
response to supplementation) than individuals with higher serum 25(OH)D 
levels.28,145,197-199  Barger-Lux and colleagues145 believe that this difference in response to 
supplementation depending on baseline levels suggests that hepatic 25-hydroxylation is a 
saturable process.  
 When Trang and colleagues197 gave adults 4000 IU vitamin D3 daily for 14 days, 
the serum 25(OH)D levels of subjects in the lowest tertile of baseline serum levels (10 to 
34 nmol/L) increased 30.6  ± 16.2 nmol/L, compared to a 13.3 ± 13.9 nmol/L increase in 
the highest tertile (50 to 86 nmol/L).197  In another study of young and old men living in 
the Boston area, there was a significant inverse correlation between baseline serum 
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 25(OH)D levels and response to supplementation with 800 IU vitamin D3 daily during 
winter.198  Baseline serum 25(OH)D levels (but not BMI or vitamin D intake) were 
predictive of response to supplementation in the young men, but not in the old men.198 
 In Ireland, DeLappe and colleagues199 supplemented elderly women with 800 IU 
vitamin D3 and 1000 mg calcium for three months.  The 36 women who had baseline 
serum 25(OH)D levels less than 50 nmol/L increased mean serum 25(OH)D 
concentrations significantly from 28.9 to 52.5 nmol/L; the 15 women who had baseline 
levels greater than 50 nmol/L increased their serum levels from 73.9 nmol/L to 76.1 
nmol/L, an insignificant change.  In nursing home residents in Brazil, serum response to 
7000 IU vitamin D3 per week was significantly influenced by baseline serum 25(OH)D 
levels, but not body fat.200  Residents with baseline levels less than 50 nmol/L increased 
serum levels by 25 nmol/L compared to a 13 nmol/L increase in residents with baseline 
serum 25(OH)D levels greater than 50 nmol/L.  On the other hand, Orwoll and 
colleagues201 did not see any effect of baseline serum 25(OH)D levels on response to 
supplementation with 1000 IU vitamin D3 in 30 to 82 year old men.  However, with a 
mean of 60 nmol/L, there may not have been enough low serum 25(OH)D levels to see 
an effect. 
 One study also observed a stronger response to ultraviolet radiation in subjects 
with low baseline serum 25(OH)D levels.  In 13 German men and women, 20 to 57 years 
old, when exposed to a high dose of ultraviolet radiation over 21 days (total of 36 J/cm2), 
serum 25(OH)D levels increased twice as much in subjects with baseline serum 25(OH)D 
levels less than 25 nmol/L compared to those with baseline serum levels greater than 50 
nmol/L.28 
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 Obesity 
 The effect of body fat on response to supplementation is uncertain.  Wortsman 
and colleagues146 found no difference between obese and normal weight subjects in their 
response to oral supplementation with a one-time dose of 50,000 IU vitamin D2.  
Likewise, elderly subjects in Brazil, given 7000 IU vitamin D3 weekly, had a similar 
25(OH)D response to supplementation, regardless of tertile of body fat.200  In another 
study, however, when given three different doses of vitamin D3, heavier men had less of a 
response to supplementation.145  The researchers calculated that men weighing 85 kg had 
approximately 65% of the response to supplementation as did 55 kg men.145 
Calcium Intake  
 A high calcium diet may increase the serum 25(OH)D response to oral vitamin D 
supplementation by increasing serum calcium levels slightly, which will decrease PTH 
secretion, thereby decreasing production of 1,25(OH)2D.  Decreasing 1,25(OH)2D will 
slow the depletion of 25(OH)D stores42 because less 25(OH)D will be used as substrate 
for 1,25(OH)2D production.  In one study, serum 25(OH)D levels increased significantly 
less in eight normal subjects taking 100,000 IU vitamin D2 with 2000 mg calcium for 
four days than when taking the same amount of vitamin D2 alone.202  In another study 
however, Goussous and colleagues,203 using intakes of calcium and vitamin D within the 
range that are usually recommended, found that daily calcium intakes of 500 or 1500 mg 
did not affect the serum 25(OH)D response to supplementation with 800 IU vitamin D3 
for three months during winter.  
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 Cholecalciferol (Vitamin D3) versus Ergocalciferol (Vitamin D2 
 Until recently, vitamin D2 and vitamin D3 were believed to be equally effective at 
increasing serum 25(OH)D levels.  However, recent studies show that D3 is the more 
effective form of supplemental vitamin D.197,204,205 
 Tjellesen and colleagues204 gave 19 premenopausal women either 4000 IU 
vitamin D2 or vitamin D3 for eight weeks.  In the vitamin D2 group, 25(OH)D2 increased 
68 nmol/L, but 25(OH)D3 decreased by 51.5 nmol/L (more than would be expected due 
to season), so the total 25(OH)D remained unchanged.  In the vitamin D3 group, 
25(OH)D3 and total 25(OH)D increased 32 nmol/L.  The researchers suggested the 
decrease in vitamin D3 in the vitamin D2 group may have been due to either competition 
for hydroxylase or up-regulated catabolism.204 
 A few years later, Trang and colleagues197 gave volunteers either 4000 IU vitamin 
D2 or vitamin D3 or nothing for 14 days.  Total 25(OH)D increased 23.3 nmol/L in the 
vitamin D3 group versus only 13.7 nmol/L in the vitamin D2 group, and 3.0 nmol/L in the 
untreated group.197  The researchers attributed this difference to the findings of Holmberg 
and colleagues206 that, in hepatic mitochondria, the hydroxylation rate of vitamin D3 is 
five times that of vitamin D2.  In the same study, no hydroxylation of vitamin D2 and very 
little hydroxylation of vitamin D3 was detected in the microsomes. 
 Armas and colleagues205 gave 30 men either 50,000 IU vitamin D2 or vitamin D3 
or nothing daily for 28 days.  Serum 25(OH)D2 and 25(OH)D3 increased the same 
amount in the first three days, suggesting they were absorbed and hydroxylated the same.  
However, by the end of the study, total 25(OH)D was 22 nmol/L higher in the vitamin D3 
group than in the vitamin D2 group.205  Since DBP has a higher affinity for D3 than D225 
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 the researchers concluded that vitamin D3 is metabolized more slowly and vitamin D2 is 
cleared more quickly, resulting in a lower response to supplementation.205  In work by 
Guo and colleagues,207 it appears that vitamin D2 is preferentially 24-hydroxylated and is 
therefore degraded more quickly.  Vitamin D3, however, is preferentially 25-
hydroxylated. 
Dose of Vitamin D3 
 Higher doses of vitamin D3 increased serum 25(OH)D levels less per unit of 
vitamin D consumed than did lower doses of vitamin D3.208,209  When Vieth and 
colleagues210 gave subjects either 1000 or 4000 IU vitamin D3 for three months during 
late winter, the increases in serum 25(OH)D levels per microgram of vitamin D3 input 
were 1.02 and 0.59 nmol/L, respectively.  In another study, subjects were given either 
5000 or 10,000 IU vitamin D3 daily and serum 25(OH)D levels increased 0.736 and 
0.636 nmol/L per microgram of vitamin D3 intake, respectively.209 
Aging 
 Aging does not appear to affect response to supplementation with oral vitamin 
D3.198,211  Harris and colleagues198 found no significant difference between 18 to 35 year 
old men and 62 to 79 year old men in their response to supplementation with 800 IU 
vitamin D3.  Vieth and colleagues211 found that adults less than 50 years old and adults 
more than 70 years old consuming similar amounts of vitamin D had no difference in 
serum 25(OH)D levels.  However, the researchers did find that older adults needed a 
higher 25(OH)D concentration to maximally suppress PTH and, therefore, may need a 
higher recommended intake than younger adults.211 
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 Absorption 
 Diseases characterized by intestinal malabsorption can affect serum response to 
oral supplementation with vitamin D3.  Some medications, such as some weight loss 
medications, and some medications for the treatment of high cholesterol induce fat 
malabsorption and may, therefore, also affect serum 25(OH)D levels. 
 Despite vitamin D supplementation, higher rates of vitamin D insufficiency have 
been documented in patients with malabsorptive diseases such as cystic fibrosis,184-186  
celiac disease,187 and inflammatory bowel disease (Crohn’s disease and ulcerative 
colitis)174 than in healthy controls, suggesting a reduced response to supplementation in 
these disorders.   
 Orlistat, a pancreas lipase inhibitor prescribed for weight loss, may cause 
malabsorption of vitamin D and/or calcium191 and would, therefore, reduce response to 
supplementation.  Large doses of cholestyramine induce fat malabsorption and 
impairment of vitamin D absorption.192  Two other studies, however, showed no 
deleterious effect of cholestyramine therapy on serum 25(OH)D levels.193,194 
Gender 
 In Brazilian nursing home patients, Canto-Costa and colleagues200 saw no 
difference in response to supplementation between men and women given 7000 IU 
vitamin D3 weekly for twelve weeks. 
Other 
 Estrogen, alcohol consumption, and smoking influence baseline serum 25(OH)D 
levels, but their impact on the response to supplementation has yet to be determined.   
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 Summary 
 The typical American diet provides little vitamin D and, therefore, has a minimal 
effect on serum 25(OH)D levels.  The majority of vitamin D for most people comes from 
cutaneous synthesis upon exposure to sunlight.  Winter at high latitudes, pollution, and 
cloudy skies scatter UVB photons reducing cutaneous synthesis of vitamin D and 
lowering serum 25(OH)D levels.  Sunscreen, clothing, and dark skin pigmentation block 
UVB rays from reaching the skin, thereby decreasing synthesis of vitamin D and serum 
25(OH)D levels.  Increased body fat, elevated 1,25(OH)2D levels, smoking, and some 
medical conditions and medications cause decreased serum 25(OH)D levels.  On the 
other hand, hormonal contraceptives and moderate alcohol consumption result in 
increased serum 25(OH)D levels.  These factors must be considered when assessing 
serum 25(OH)D levels in individuals and populations.  In addition, 25(OH)D assays are 
not standardized, which makes comparisons between studies difficult. 
 Baseline serum 25(OH)D levels are known to be inversely associated with 
response to oral vitamin D supplementation.  Medical conditions characterized by 
malabsorption and medications inducing fat malabsorption are believed to hinder 
response to supplementation.  However, the effects of obesity, calcium intake, estrogen, 
gender, alcohol, and smoking on serum 25(OH)D response to supplementation are 
uncertain at this time. 
Prevalence of Vitamin D Insufficiency 
 Many studies have documented high rates of vitamin D deficiency in 
premenopausal women in North America, particularly at the end of winter and in 
northern latitudes (Table 1).  When comparing these studies, it is important to remember 
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the many factors that influence serum 25(OH)D levels, including the type of assay used, 
the latitude and season in which serum 25(OH)D levels were drawn, and the age and race 
of the subjects.  The cut-off values for 25(OH)D indicating insufficiency vary among the 
studies; they are all higher than the 27.5 nmol/L used to set the DRI in 1997,21 but most 
are lower than the optimal level of 75 nmol/L.   
Analysis of NHANES III data for non-Hispanic white, non-Hispanic black, and 
Mexican American women between the ages of 20 and 39 years, living in the US at lower 
latitudes (median latitude 32ºN) in winter, found 40% of subjects with serum 25(OH)D 
levels less than 50 nmol/L and 55% with levels less than 62.5 nmol/L.121  Because of the 
unpredictable weather at higher latitudes during winter, the NHANES III data was 
collected at 25oN to 47oN (median 39oN) during summer.  Eighteen percent of 20 to 39 
year old non-Hispanic white, non-Hispanic black, and Mexican American women living 
in the north were found to have serum 25(OH)D levels less than 50 nmol/L and 30% had 
levels less than 62.5 nmol/L during summer.121 
In Omaha (41oN), Kinyamu and colleagues212 found a much lower incidence of 
vitamin D insufficiency than other researchers.  They compared institutionalized and 
free-living elderly women with younger women and found only 6% of 25 to 35 year old 
women had serum 25(OH)D levels less than 30 nmol/L between November and May.  
Eight percent of the institutionalized women, and 1.6% of the free- living elderly women 
had serum 25(OH)D levels below 30 nmol/L.212  More recently in Omaha,  Armas and 
colleagues116 found a much higher incidence of vitamin D deficiency with 58% of young 
men and women (19 to 49 years old) having levels below 80 nmol/L at the end of 
summer and 96% at the end of winter.  The same researchers observed that although 
 Table 1.  Prevalence of vitamin D insufficiency in North America. 
Study Assay Used* Latitude Season Gender Age Race 
Mean 
25(OH)D 
(nmol/L) 
% Below 50 
nmol/L 
% Below 75 
nmol/L 
median 
32oN 
Southern 
US 
Winter 62.7 40% 
Looker et al. 
2002121 
 
RIA 
median 
39oN 
Northern 
US 
Summer
F 20 – 39 
White, Black, 
Mexican 
American 
81.6 18% 
- 
Kinyamu et al. 
1997212 CPB 
41oN 
Omaha Winter F 25 – 35 n/a 70.6 ± 26.3 
6%  
(30 nmol/L) - 
Rucker et al. 
20027 RIA 
51oN 
Calgary Winter M, F 27 – 89 98% White 57.3 ± 21.3 39% 
86%  
(80 nmol/L) 
Sullivan et al. 
20054 CPB 
44oN 
Bangor Winter F 9 – 11 White 55.9 ± 16.5 48% - 
Tangpricha et 
al. 20028 CPB 
42oN 
Boston March M, F 18 – 29 60% White 70 ± 25 36% - 
Vieth et al. 
20016 RIA 
43oN 
Toronto Winter F 18 – 35 White 58 ± 24 
21%  
(40 nmol/L) - 
White ~75 - 51% Weng et al. 
2007213 RIA 
40oN 
Philadelphia Winter M, F 6 – 21 Black ~ 45 - 94% 
*RIA = Radioimmunoassay, CPB = Competitive Protein Binding 
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 subjects who reported just casual summer sun exposure (i.e. walking to and from the car) 
had a seasonal fluctuation in serum 25(OH)D levels, their summer sun exposure was not 
sufficient to increase serum 25(OH)D levels above 80 nmol/L.116  In a study of healthy 
young men and women (18 to 29 years) in Boston (42ºN), Tangpricha and colleagues8 
found that 36% had serum 25(OH)D levels less than 50 nmol/L in March.   
In 18 to 35 year old women living in Canada (43ºN), where milk is fortified with 
vitamin D at the same level as in the US, 21% of white women, some of whom were 
taking multivitamin supplements, had 25(OH)D levels less than 40 nmol/L in winter.6  In 
Calgary, Canada (51oN), 20% of 27 to 89 year old men and women had serum 25(OH)D 
levels less than 40 nmol/L; 39% had levels less than 50 nmol/L; and 86% had levels less 
than 80 nmol/L during winter.7 
Similar rates of vitamin D insufficiency were seen in children and adolescents in 
the US.  In Bangor, Maine (44oN), over a three-year period, 48% of healthy white 
adolescent girls (9 to 11 years) were found to have at least one serum 25(OH)D level less 
than 50 nmol/L at the end of winter4 and all subjects were found to have at least one 
serum 25(OH)D level less than 75 nmol/L at the end of winter.214  Likewise, 51% of 
white 6 to 21 year olds in the Philadelphia area (40oN) had serum 25(OH)D levels less 
than 75 nmol/L during winter.213  The researchers found a much higher prevalence of 
vitamin D insufficiency in black children with 94% presenting with serum levels less 
than 75 nmol/L during winter.213     
As mentioned previously, serum 25(OH)D levels fluctuate seasonally.  Sullivan 
and colleagues4 saw a 28% (20.1 nmol/L) drop in mean serum 25(OH)D levels from 
summer to winter in adolescent girls.  Arunabh and colleagues129 found a 37% drop (from 
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 84 to 53 nmol/L) in mean serum 25(OH)D levels from summer to winter in white 
women.  In 24 to 70 year old women, serum 25(OH)D levels increased 18.0 nmol/L 
(36%) from winter to summer in London.215  In white women in Toronto, Canada, serum 
25(OH)D levels measured in summer were 31% higher than those measured in winter.6   
Although serum 25(OH)D levels are higher in summer than in winter, there are 
still cases of vitamin D deficiency at the end of summer.  Seventeen percent of adolescent 
girls in Bangor, Maine had serum 25(OH)D levels less than 50 nmol/L at the end of 
summer.4  Nationally, NHANES III data revealed 18% of women living between 25 and 
47oN latitude had serum 25(OH)D levels less than 50 nmol/L at the end of summer.121  
NHANES III data also showed that the rate of vitamin D insufficiency was two times 
higher in females than males of the same age.121   
Although less common, vitamin D deficiency is present at the end of summer in 
some individuals, and vitamin D deficiency rates are much higher at the end of winter, 
affecting up to 94% of some populations.  It is not known whether there is a cumulative 
negative effect of repeated cycles of insufficient wintertime serum 25(OH)D levels 
during adolescence and young adulthood on the ability to achieve peak bone mass.121  
However, given the many important functions of vitamin D, optimizing levels of serum 
25(OH)D year-round is a logical goal. 
Supplementation Studies 
Previous Supplementation Trials 
 The general consensus among vitamin D researchers is that the optimal 
concentration for serum 25(OH)D is at least 75nmol/L.1  Many people do not reach these 
levels in winter.  The amount of vitamin D needed to optimize levels for various groups 
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 needs to be determined.  Once this amount is ascertained, strategies must be developed to 
raise the entire population to optimal levels.  A number of vitamin D supplementation 
trials have been completed.  When comparing these studies, one must consider the many 
factors that may affect response to supplementation, including season and exposure to 
UVB radiation (whether through natural or artificial means), body fat, baseline serum 
25(OH)D levels, the form of vitamin D used (vitamin D2 or vitamin D3), the type of assay 
used, and, in women, exogenous estrogen use.  In addition, it is important to consider 
whether the supplementation period was long enough for the serum 25(OH)D to reach an 
equilibrium concentration.  The half-life of serum 25(OH)D levels is approximately three 
to four weeks42 and the concentration equilibrium is reached approximately four weeks 
after supplementation begins.216  When comparing studies, one must also keep in mind 
that many studies do not measure the actual vitamin D content of the supplement.  Some 
manufacturers may put more vitamin D in the supplement than the label states in order to 
compensate for storage losses,216 so the response to supplementation may be exaggerated 
in some studies if the actual vitamin D content is not measured. 
 In the US, no supplementation studies have focused on the vitamin D needs of 
premenopausal women.  In the few studies worldwide that have supplemented 
premenopausal women with vitamin D3, they have either failed to consider hormonal 
contraceptive use, had a small sample size, included men in the sample, or did not 
account for changing serum 25(OH)D levels due to season.  Rarely were the supplements 
evaluated for actual vitamin D3 content.   
 Van der Klis and colleagues217 gave 800 IU vitamin D3 to six Dutch 
premenopausal women, five of whom were on oral contraceptives, for four weeks during 
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 March.  Serum 25(OH)D levels increased from 46.2 nmol/L to approximately 82 nmol/L, 
a 1.8 nmol/L increase per microgram of vitamin D3.  There was no placebo group to 
control for the decreasing serum 25(OH)D levels that would be expected during March in 
the Netherlands (52oN).217   
 Barnes and colleagues218 administered a chewable supplement containing either 
600 IU vitamin D3 and 1500 mg calcium or just 1500 mg calcium daily to 27 men and 
women aged 18 to 27 years for eight weeks, from January to March, in Northern Ireland 
(55oN).   Use of oral contraceptives was not mentioned.  Serum 25(OH)D levels 
increased 38.6 nmol/L from a baseline level of 47.9 nmol/L in the group receiving 
vitamin D, and decreased 7.2 nmol/L in the control group.  After adjusting for the change 
in the control group, serum 25(OH)D levels increased 2.1 nmol/L per microgram of 
vitamin D3 in the treatment group.218  
 In another study, 14 men and women, aged 22 to 60 years, drank one cup of 
orange juice fortified with 1000 IU vitamin D3 and 350 mg calcium daily; another 12 
subjects drank one cup of orange juice fortified with calcium only every day for 12 
weeks, from March until May, in Boston (42oN).219  Serum 25(OH)D levels increased 
from 37.0 to 94.0 nmol/L in the group receiving vitamin D fortified orange juice.  In the 
control group, serum 25(OH)D levels increased from 50.0 to 73.0 nmol/L due to the 
spring season.  After accounting for the change in the control group, serum 25(OH)D 
levels increased 1.4 nmol/L per microgram of vitamin D3.  Information on oral 
contraceptive use and menopausal stage was not provided. 
 In Denmark (56oN), 19 healthy premenopausal women, 5 of whom were taking 
oral contraceptives, were given either 4000 IU vitamin D2 or vitamin D3 and 500 mg 
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 calcium for eight weeks from September to November.204  The capsules were analyzed 
for actual vitamin D content and were found to contain 4400 IU vitamin D3.  There was 
no placebo group to describe the seasonal decrease in serum 25(OH)D levels that would 
be expected between September and November.  In the vitamin D3 group, serum 
25(OH)D levels increased from 77.5 nmol/L to 113.4 nmol/L, a change of 0.33 nmol/L 
per microgram of vitamin D3.  After adjusting for a 51.5 nmol/L drop in the serum 
25(OH)D concentration in the group supplemented with vitamin D2, the change per 
microgram of vitamin D3 increased to 0.79 nmol/L.  The researchers suggested the drop 
in serum 25(OH)D levels in the vitamin D2 group was too large to be due to the seasonal 
change in vitamin D3 production alone and suggested competition between vitamin D2 
and vitamin D3 for hydroxylation as the cause.204   
 Vieth and colleagues210 gave 61 men, and pre-and postmenopausal women either 
1000 or 4000 IU vitamin D3 for three months, starting in January and February in 
Toronto, Canada (43oN).  In the group receiving 1000 IU, serum 25(OH)D levels 
increased from 43.3 nmol/L to 68.7 nmol/L, a 1.02 nmol/L increase per microgram of 
vitamin D3.  In the group receiving 4000 IU, serum 25(OH)D levels increased from 37.9 
to 96.4 nmol/L, an increase of 0.59 nmol/L per microgram of vitamin D3.210 
 In a frequently cited attempt to help determine the dose-response relationship for 
vitamin D3 and serum 25(OH)D levels, Heaney and colleagues209 studied 67 healthy 
young men (age 38.7 ± 11.2 years, BMI 26.2 ± 2.4) with daily dietary vitamin D intakes 
less than 200 IU during winter in Omaha, Nebraska (41oN).  Subjects consumed either 
placebo or 1000, 5000, or 10,000 IU vitamin D3 tablets daily for five months.  Serum 
25(OH)D levels decreased 11 nmol/L in the placebo group, and increased 12, 92, 159 
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 nmol/L in the 1000, 5000, 10,000 IU groups, respectively.  Using the dose-response 
curves from this data, the researchers determined that serum 25(OH)D levels increase by 
0.7 nmol/L for every microgram (40 IU) of vitamin D3 input.209 
 In the supplementation studies involving young women described above, the 
increase in serum 25(OH)D levels per microgram of vitamin D3 intake ranged from 0.59 
to 2.1 nmol/L, which bracket the value obtained by Heaney and colleagues.209  In the 
studies in which baseline serum 25(OH)D levels were lowest, the change in serum 
25(OH)D levels in response to supplementation was the greatest.210,219  
Theoretical Dose Required 
 Previous studies of 18 to 35 year old men and women in North American (41o to 
43oN) have found serum 25(OH)D levels at the end of winter in the range of 
approximately 58 nmol/L6 to 70 nmol/L.8,212  Using the 0.7 nmol/L increase in 25(OH)D 
levels per microgram of vitamin D3 intake suggested by Heaney and colleagues,209 a dose 
of 285 to 970 IU vitamin D3 would be required to optimize the mean vitamin D status of 
these populations.  Furthermore, in a recent editorial by Dawson-Hughes and colleagues,1  
researchers suggested at least 800 to 1000 IU vitamin D3 would be necessary to achieve a 
mean serum 25(OH)D concentration of 75 nmol/L. 
Risk and Safety Monitoring 
 Vitamin D toxicity is not subtle.  It causes soft tissue calcification, hypercalcemia, 
and dehydration.  Hypercalcemia is characterized by fatigue, muscle weakness, nausea 
and vomiting, thirst, and loss of appetite.  Development of hypercalciuria (increased ratio 
of urinary calcium to urinary creatinine) precedes hypercalcemia in vitamin D 
intoxication220 and is, therefore, a useful and convenient monitor of vitamin D tolerance.  
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 However, hypercalciuria can be caused by many factors unrelated to hypercalcemia and 
vitamin D intoxication, and should not be considered an adverse effect of vitamin D 
supplementation if serum calcium levels remain normal.216   
 Based on a serum 25(OH)D response to supplementation of approximately 1.0 
nmol/L per microgram of vitamin D3 intake, the current Adequate Intakes for vitamin D, 
200 IU for 1 to 50 year olds; 400 IU for 51 to 70 year olds; and 600 IU for those older 
than 70, would only increase serum 25(OH)D levels by 4, 8, and 12 nmol/L, respectively.  
The current tolerable upper limit (2000 IU) would increase serum 25(OH)D levels by 35 
nmol/L.  Vitamin D intoxication occurs when serum 25(OH)D levels exceed 220 
nmol/L221 to 375 nmol/L,216,222,223 or more.224  Using NHANES data, Nesby-O’Dell and 
colleagues139 found the mean serum 25(OH)D levels of white women in the US to be 
82.5 ± 1.5 nmol/L.  In summer in Toronto (43oN), 95% of white women had serum 
25(OH)D levels no higher than 90 nmol/L.6  The highest serum 25(OH)D levels of sun-
replete individuals in the US were 154 to 178 nmol/L.10,99  The current tolerable upper 
limit, if consumed daily, would be unlikely to cause vitamin D intoxication, even in sun-
replete individuals in the US. 
 Vitamin D toxicity has only occurred in individuals taking more than 10,000 IU 
daily.  Mawer and colleagues221 reported vitamin D intoxication in eight patients who had 
been taking 50,000 to 200,000 IU vitamin D2 daily for six or more years.  Koutkia and 
colleagues223 reported a patient who presented to the hospital with hypercalcemia after 
taking an over-the-counter vitamin D3 supplement for two years.  When analyzed, the 
supplement contained 26 to 430 times the labeled amount of vitamin D3.  The patient had 
been taking 156,000 to 2,604,000 IU vitamin D3 for an unknown length of time.223  
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 Serum calcium levels usually normalize within one to four months of discontinuing 
vitamin D supplements,220 but it may take years for serum 25(OH)D levels to drop below 
115 nmol/L after reaching toxic levels, even without exposure to UVB radiation.223 
 Although the body protects itself from vitamin D intoxication upon exposure to 
excessive sunlight, in theory, adults receiving profuse amounts of sunshine may be more 
susceptible to vitamin D toxicity when taking supplements because of the cumulative 
effect of sun and supplements.225  In addition, patients with granulomatous diseases such 
as sarcoidosis and tuberculosis should avoid vitamin D supplements and sunshine 
because granulomas cause hypercalcemia due to unregulated production of calcitriol.226 
Summary 
 The documented cases of vitamin D intoxication have occurred at intake levels far 
exceeding the upper limit of 2000 IU.  Although vitamin D intoxication is rare, and is 
highly unlikely to occur in individuals supplemented with 800 IU vitamin D3, safety 
monitoring of serum calcium and urinary calcium to creatinine ratio may detect changes 
in calcium excretion related to vitamin D intoxication.  At “safe” supplementation levels, 
the existing literature on supplementation in adult men and women indicates a response 
to supplementation of approximately 1.0 nmol/L per microgram of vitamin D3 intake.  
However, most studies have included men in the sample, and failed to consider the effect 
of exogenous hormones, body composition, and season on the response to 
supplementation.  A supplementation study of premenopausal women in the United 
States, that takes into consideration oral contraceptive use, seasonal fluctuations in serum 
25(OH)D levels, and body composition, is needed to help determine how much vitamin 
D3 is needed to optimize serum 25(OH)D levels in this population.   
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 Rationale for Research Project 
 Vitamin D has many skeletal and non-skeletal purposes.  There is a high 
prevalence of vitamin D insufficiency in Maine and other areas above 35oN latitude due 
to inadequate UVB radiation for synthesis of vitamin D during winter.  Many factors 
influence an individual’s vitamin D status, including sun exposure, skin color, body 
composition, and oral contraceptive use.  Researchers speculate that approximately 800 
to 1000 IU vitamin D3 is required to raise serum 25(OH)D levels to at least 75 nmol/L in 
the absence of sunlight.  Further research is needed to determine how much vitamin D3 is 
required to optimize serum 25(OH)D levels for different age groups, while taking into 
consideration sun exposure, skin color, body composition, and hormonal status.  There 
have been no studies looking at the serum 25(OH)D response to supplementation with 
800 IU vitamin D3 in premenopausal women in the United States that takes into 
consideration the use of hormonal contraceptives and body composition. 
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Chapter 3 
METHODS AND MATERIALS 
Study Design 
 In February 2005, 112 women aged 19 to 35 years enrolled in the study to receive 
six months of placebo daily followed by five months of either an 800 IU oral vitamin D3 
supplement or a matching placebo daily.  The goal was to achieve a serum 25(OH)D 
level of at least 75 nmol/L in the treatment group during winter. 
 The project took place over 16 months (Figure 1):   
• November 2004 – February 2005:  Four-month recruitment period 
• February 2005: Measurement of baseline serum 25(OH)D levels 
• March – September 2005: Six-month run-in period 
• September 2005 – February 2006: Five-month placebo-controlled, double-
blind vitamin D supplementation period 
 Blood samples were drawn in February 2005, September 2005, and February 
2006 for analysis of serum 25(OH)D, PTH, and calcium levels.  Urine samples were 
obtained in February 2005, September 2005, and February 2006 for analysis of urinary 
calcium and creatinine levels.   
 Each participant had a total body scan using dual energy x-ray absorptiometry 
(DXA) in March 2005 and again in March 2006 for determination of percent body fat and 
bone mineral density.  Height was measured in March 2005 and March 2006; weight in 
light clothing without shoes was measured in March 2005, September 2005, and March 
2006.
 THE VITAMIN D STUDY TIMELINE           
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Figure 1.  The Vitamin D Study timeline. 
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  Upon enrollment, subjects completed a Health History Questionnaire (Appendix 
B), which was then reviewed with them to determine eligibility for the study.  Every 
three months thereafter, participants completed a brief lifestyle questionnaire (Appendix 
B) to update their health history and provide information about sun exposure, oral 
contraceptive use, and so on.  In addition, three-day food records were collected upon 
enrollment and during the following winter.    
Subjects and Recruitment 
 One hundred twelve women, aged 19 to 35 years, living in the Bangor, ME area, 
were recruited from a pool of roughly 6000 female students at the University of Maine 
and 15,000 women in this age range in Penobscot County, Maine.  Enrollment was open 
to any ethnic or racial group.  Premenopausal women were chosen as a homogeneous 
group in which to assess vitamin D intake requirements.   
 During the fall semester of 2004, students were recruited at the University of 
Maine through mailings to all female freshman, sophomores, and juniors (see Appendix 
C), and through e-mail folders and bulletin boards.  Women within the community were 
recruited through fliers on public bulletin boards (see Appendix D) and through a local 
television station. 
 To be eligible for participation in the study, subjects were required to have a body 
mass index between 18.5 and 40 kg/m2, and be free of any disease or condition that 
influences calcium, or vitamin D metabolism, such as hyper- and hypothyroidism, 
primary hyperparathyroidism, diabetes, celiac disease, cystic fibrosis, liver disease, 
kidney disease, or inflammatory bowel disease.  Women who were pregnant or planned 
to become pregnant during the study period were excluded, as were those taking any 
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 medications that affect calcium or vitamin D metabolism, including corticosteroids and 
anti-convulsant medications.  Subjects were asked not to travel to a southern latitude 
between September and March, and to refrain from using tanning booths.  Subjects had 
not regularly consumed any calcium or vitamin D-containing supplement within the 
previous four months and agreed not to take any calcium, vitamin D, or multivitamin 
supplements other than those provided during the study period.  Subjects with baseline 
serum 25(OH)D levels less than 22.5 or greater than 175 nmol/L were excluded.   
 Subjects were recruited in November and December 2004.  In January 2005 
informational meetings were held for women interested in participating in the study.  
Interested individuals completed a brief, confidential Health History Questionnaire (see 
Appendix B), which was then reviewed with them to screen for eligibility. 
 Written informed consent was obtained from each subject.  This study was 
approved by the University of Maine Human Subjects Committee and St. Joseph 
Hospital’s Institutional Review Board.  The consent form is found in Appendix E.  
January 2005 
 Interested individuals attended informational meetings to learn more about the 
study and to be screened for eligibility.  At this time, written informed consent was 
obtained from each subject.  Appointments were scheduled to have blood drawn at the 
University of Maine Cutler Health Center in February and to have dual energy x-ray 
absorptiometry (DXA) scans for assessment of body composition at the Maine Center for 
Osteoporosis Research and Education (MECORE) in March.  Subjects were given 
instructions for completing a three-day food record to include two weekdays and one 
weekend day. 
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 Baseline - February / March 2005 
 In February 2005, prior to the University of Maine spring break, participants 
reported to Cutler Health Center to have their blood drawn for measurement of baseline 
serum 25(OH)D, PTH, and calcium levels.  A random urine sample was obtained from 
each subject for measurement of urinary calcium and creatinine.  Participants answered a 
brief lifestyle questionnaire to update their health history and provide information about 
nutritional supplement use, contraceptives, and sun exposure, including winter vacation 
locations and use of tanning booths.  In March 2005, participants reported to the Maine 
Center for Osteoporosis Research and Education (MECORE) for DXA scan and 
measurement of height and weight. 
 At MECORE, subjects received their first three-month supply of placebo 
capsules, which were manufactured by Tishcon, Corporation (Westbury, NY).  During 
the run-in period from March to September 2005, all subjects took a placebo for six 
months.  Subjects with less than 75 percent compliance with placebo, as determined by 
pill counts every three months, were to be dismissed from the trial.  
June 2005 
 In June 2005, subjects who were in the Bangor area for the summer reported to 
the Vitamin D Research Room (123 Hitchner Hall, University of Maine) to return unused 
capsules for assessment of compliance and to pick-up a new supply of placebo.  At this 
time, subjects completed a lifestyle questionnaire to update their health history (see 
Appendix B).  Because estrogen-containing medications affect serum 25(OH)D levels, 
the lifestyle questionnaire given every three months included questions to detect changes 
in use or non-use of prescription contraceptives.   
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  A new supply of placebo was mailed to subjects who were not in the Bangor area 
during the summer.  Subjects were instructed to finish the pills in their current pill bottle 
before starting the new bottle.  All unused capsules were to be returned for counting in 
September.  The lifestyle questionnaire was mailed to these subjects along with an 
addressed and stamped envelope for ease of return. 
September 2005 
 Subjects were contacted via email in late August 2005 to schedule appointments 
for phlebotomy at Cutler Health Center in September.  In September, subjects reported to 
Cutler Health Center again to provide blood and urine samples, and to have their weights 
measured.  Participants returned unused placebo capsules.   
 In August, individuals were randomly assigned to either the treatment group or 
the control group using Research Randomizer (version 3.0) software.  The random 
number generator assigned subjects to either the treatment group or the placebo group.  
One-third of the subjects (36/103) were randomized to the placebo group; two-thirds 
(67/103) to the treatment group.  At the time of randomization, t-tests were conducted 
and no significant differences were seen between the two groups regarding baseline 
serum 25(OH)D levels, percent body fat, or age.  An investigator not directly involved 
with the subjects transmitted the list of subjects in the treatment group and the placebo 
group to the pharmacist at Cutler Health Center to be packaged in child-resistant vials 
labeled with each subject’s name and identification number.  The researchers and 
subjects remained blinded to the content of the capsule taken by the subjects.  In 
September, subjects picked up a three-month supply of either placebo or 800 IU vitamin 
D3 and completed another lifestyle questionnaire (see Appendix B), which included a 
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 skin type questionnaire that was used to categorize them according to Fitzpatrick skin 
type (I-VI).227 
December 2005 
 In December 2005 subjects reported to the Vitamin D Research Room to return 
unused capsules for assessment of compliance and to pick-up a new supply of capsules.  
Returned capsules were counted to measure percent compliance.  Subjects completed 
another lifestyle questionnaire to update their health histories (see Appendix B).  
Instructions for recording three-day food records were reviewed with subjects and they 
were asked to again record intake on two weekdays and one weekend day. 
February / March 2006 
 In February 2006, prior to the University of Maine spring break, participants 
reported to Cutler Health Center to provide blood and urine samples.  Participants 
answered a final brief lifestyle questionnaire to update their health history (see Appendix 
B) and returned unused capsules, which were counted to measure percent compliance.  
The compliance rates were calculated for September to December and December to 
February, and the mean percent compliance was used in data analysis.  In March 2006, 
participants reported to the Maine Center for Osteoporosis Research and Education 
(MECORE) for the final DXA scan and measurement of height and weight. 
Vitamin D3 Supplements 
 The supplements and matching placebo were manufactured by Tishcon 
Corporation (Westbury, NY). The capsules were analyzed for actual vitamin D3 content 
using high performance liquid chromatography (HPLC) on three separate occasions.  At 
the time of manufacture (February 2005), Tishcon Corporation measured 869 IU vitamin 
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 D3 per capsule.  At the beginning and end of the supplementation period, an independent 
laboratory (Analytical Laboratories of Anaheim, Inc) measured 956 IU vitamin D3 
(September 2005) and 832 IU vitamin D3 (April 2006).  The average vitamin D3 content 
of the capsules was 885 IU vitamin D3.  No vitamin D3 was detected in the placebo 
capsules by either the manufacturer or the independent laboratory. 
 Qualified medical personnel at Cutler Health Center packaged the capsules in 
child-resistant vials labeled with each subject’s name and identification number.  The 
placebo capsules contained maltrin and magnesium stearate; the vitamin D capsules 
contained maltrin, magnesium stearate, and vitamin D3.  
Analysis of Serum and Urine Samples 
 Non-fasting serum samples were obtained by skilled phlebotomists from Cutler 
Health Center in February 2005, September 2005, and February 2006.  Samples from all 
subjects were drawn within a two-week time period.  Ten milliliter blood specimens were 
centrifuged within two hours of being drawn, and the serum was removed and frozen in 
one milliliter aliquots at -70oC until analysis.  Serum samples were shipped on dry ice to 
the Medical University of South Carolina, Charleston for analysis of 25(OH)D and PTH 
by Dr. Bruce Hollis.  Serum 25(OH)D was measured by radioimmunoassay.228  The 
intraassay and interassay coefficients of variation were less than 10%.  Intact PTH was 
measured by radioimmunoassay (DiaSorin Inc., Corp., Stillwater, MN).  The intraassay 
and interassay coefficients of variation were less than 10%.  Serum samples were assayed 
for baseline 25(OH)D levels in March 2005 to determine eligibility for the study and to 
assure that mean baseline 25(OH)D levels were not significantly different between 
groups at randomization.  Serum samples from all three points in time were batch-
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 analyzed at the conclusion of the study to avoid inter-assay variation.  Serum samples 
were protected from ultraviolet light during processing.   
 Serum 25(OH)D levels were measured in September and February when levels 
are at their highest and lowest points of the year, respectively.122  Five months elapsed 
from the start of vitamin D3 supplementation to the next measurement of serum 25(OH)D 
to allow ample time for equilibration at the new level of intake before levels were 
reassessed. 
 Serum calcium was measured by a colorimetric assay using the clinical analyzer 
(Beckman-Coulter CX-4 PRO) in the Clinical Nutrition Laboratory at the University of 
Maine.  A random urine sample was collected from each subject in February 2005, 
September 2005, and February 2006 for measurement of calcium and creatinine content.  
Urinary calcium and creatinine were measured by a colorimetric assay using the clinical 
analyzer (Beckman-Coulter CX-4 PRO) in the Clinical Nutrition Laboratory at the 
University of Maine, and the urinary calcium to creatinine ratio was calculated.  The 
calcium to creatinine ratio was used to monitor tolerance to the supplementation.   
Anthropometric Measurements 
 Height was measured in March 2005 and March 2006 using a calibrated 
stadiometer.  Weight in light clothing, without shoes, was measured using an electronic 
standing scale in March and September 2005 and March 2006. 
 Body fat content was measured using dual energy x-ray absorptiometry (DXA) on 
a Hologic QDR 2000 (Hologic Inc., Waltham, MA, USA) by a single DXA technician in 
March 2005 and March 2006 at the Maine Center for Osteoporosis Research and 
Education.  DXA is a valid measure of body composition and body fat.229  The DXA 
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 machine was calibrated against a phantom daily.  The coefficient of variation (CV) was 
0.6%.  Urine pregnancy tests were confirmed negative prior to DXA scans. 
Questionnaires 
 Every three months between February 2005 and February 2006, participants 
answered a brief lifestyle questionnaire to update their health history and provide 
information about nutritional supplement use, intake of alcoholic beverages, hormonal 
contraceptive use, and sun exposure, including winter vacation locations and use of 
tanning booths.  Specific brand names of hormonal contraceptives were obtained and a 
daily average intake of estradiol was calculated.  Subjects also completed a skin type 
questionnaire to categorize them according to Fitzpatrick skin type (I-VI).  
Dietary Intake Assessment 
 Subjects completed three-day food records in February 2005 and again in 
February 2006.230  Instructions for recording three-day food records (two weekdays and 
one weekend day) were reviewed with subjects prior to keeping each food record.  
Subjects were instructed to record intake immediately after consumption and to include 
as much information as possible including brand names, package sizes, and recipes when 
possible.  Serving sizes were either measured with measuring cups when possible, or 
estimated using common household items (i.e. ¼ cup is approximately the size of a golf 
ball).  Food records were analyzed using Nutritionist Pro software, version 2.5 (Axxya 
Systems, Stafford, TX) for calories, protein, calcium, sodium, and vitamin D intake.  
Sun Exposure Questionnaire 
 The February 2005 and September 2005 Lifestyle Questionnaires (see Appendix 
B) included a series of questions used for calculating sun exposure.118  Subjects were 
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 asked the approximate number of days worked per week, the number of days off per 
week, and the number of days spent on vacation.  In addition, they were asked how many 
hours they spent outside between 1000 EST and 1500 EST while at work, on their days 
off, or on vacation.  Based on a 16-week summer (May through August), the average 
number of hours spent outside per week was calculated.  An example showing the 
calculation of the average weekly number of hours of sun exposure can be found in 
Appendix F. 
Statistical Analysis 
 All data from subject records were entered into a Microsoft Excel spreadsheet.  
The statistical analysis was performed using SPSS, Student Version 13.0.   
 Vitamin D intake, sun exposure, body fat, BMI, and oral contraceptive use are 
known to affect serum 25(OH)D levels.  Both multiple and logistic regression were used 
to measure the effects of these variables on serum 25(OH)D levels, the serum 25(OH)D 
response to supplementation with 800 IU vitamin D3, and the seasonal increase in serum 
25(OH)D levels.  Additionally, age, years of oral contraceptive use, tanning during 
winter, BMI, sun exposure during the previous summer, skin type, the summer increase 
in serum 25(OH)D levels, smoking, day of the menstrual cycle on which blood was 
drawn, and dietary calcium and vitamin D intake were included as independent variables 
in the logistic regression analysis of baseline serum 25(OH)D levels.  The cut-off for 
baseline serum 25(OH)D levels in the binary logistic regression was 75 nmol/L (the 
optimal serum 25(OH)D level).  In the analysis of the one-year change in serum 
25(OH)D levels, estrogen dose, the magnitude of the summer increase in serum 25(OH)D 
levels, baseline 25(OH)D levels, the randomization group, mean body fat, change in 
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 serum calcium levels, smoking, one-year change in calcium and vitamin D intake, 
alcohol consumption, the one-year change in calcium to creatinine ratio, one-year change 
in sun exposure, tanning bed use during winter, and the number of days with a cold were 
included as independent variables.  The cut-off for one-year change in serum 25(OH)D 
levels in the binary logistic regression was 40 nmol/L (0.25 standard deviation above the 
mean). 
 In the logistic regression analyses, the Wald statistic was used to test the 
significance of the regression coefficients for each independent variable.231  Nagelkerke’s 
R2 was used to approximate the percent of variance explained by the model.232  The 
Hosmer and Lemeshow test, a chi-square test of goodness of fit, was used to determine 
whether the regression model fit the data at an acceptable level.233 
 Student’s t-test was used to compare means between two variables, and one-way 
analysis of variance was used to compare means between multiple variables.  
Assumptions were tested by examining normal probability plots of residuals and scatter 
diagrams of residuals versus predicted residuals.  No violations of normality, linearity, or 
homogeneity of variance were detected.   
 Statistical significance was set at 0.05. 
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 Chapter 4 
 
RESULTS 
 
Subject Characteristics 
 
 In February 2005, 112 subjects enrolled in the study, 98 of whom completed the 
study in February 2006 (a retention rate of 88%).  Ten subjects chose to withdraw from 
the study and four subjects were excluded from the study because their baseline 
(February 2005) serum 25(OH)D levels were outside the range (22.5 to 175 nmol/L) 
established for inclusion criteria (two were above and two were below the acceptable 
range).  Reasons cited for withdrawing from the study included moving out of the area 
(5/10), desiring to take a multivitamin (2/10), and personal reasons (3/10).  Twelve 
subjects who either started or quit using hormonal contraceptives during the study were 
excluded from analysis, leaving a total of 86 participants (Figure 2, flowchart).   
 The baseline (February 2005) characteristics are summarized in Tables 2a and 2b 
for the 103 subjects who were randomized to receive either placebo or 800 IU vitamin 
D3.  Independent samples t-tests revealed no significant differences between the groups.   
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 Table 2a.  Comparison of baseline characteristics between the treatment and 
placebo groups in the 103 subjects who were randomized. 
Treatment Group Placebo Group   
n Mean ± SD n Mean ± SD 
 
p 
Age (y) 67 22.0 ± 2.9 36 22.3 ± 4.3 NS 
BMI  (kg/m2) 67 25.8 ± 4.9 36 26.4 ± 5.4 NS 
Total body fat (%) 67 30.0 ± 7.4 36 30.7 ± 7.6 NS 
Height (cm) 67 164.8 ± 6.2 36 163.3 ± 7.3 NS 
Weight (kg) 67 70.1 ± 14.6 36 70.0  ± 13.3 NS 
2004 Summer sun exposure 
(h/wk) 
67 16.0 ± 9.4 36 18.1 ± 8.6 NS 
Serum 25(OH)D (nmol/L) 67 61.9 ± 25.1 36 60.3 ± 22.1 NS 
Serum PTH (pg/mL) 67 30.7 ± 9.7 36 34.0 ± 14.0 0.21 
Serum calcium (mg/dL) 67 9.7 ± 0.27 36 9.7 ± 0.24 NS 
Urine calcium:creatinine 67 0.14 ± 0.08 36 0.13 ± 0.08 NS 
Years of contraceptive use* 43 2.67 ± 2.1 25 3.2 ± 3.8 NS 
*Only includes subjects using hormonal contraceptives 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 2b.  Comparison of the daily nutrient intake at baseline (February 2005) 
between the treatment and placebo groups in the 103 subjects who were 
randomized. 
Treatment Group Placebo Group  
n Mean ± SD n Mean ± SD 
 
p 
Calories (kcal/d) 67 1759 ± 455 36 1749 ± 418 NS 
Protein (g/d) 67 67.4 ± 19.8 36 67.1 ± 18.6 NS 
Sodium (mg/d) 67 2980 ± 1007 36 2905 ± 996 NS 
Calcium (mg/d) 67 890 ± 403 36 903 ± 357 NS 
Vitamin D (IU/d) 67 143 ± 120 36 139 ± 101 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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Recruited 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
__________RANDOMIZATION__________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
June – Sept 2005 
5 moved away 
(n = 98)
12 excluded for 
changing oral 
contraceptive use 
(n = 86)
Placebo Group 
31 Subjects 
March – June 2005 
4 excluded for baseline 25(OH)D 
levels outside range 
3 w/d for personal reasons 
2 w/d to take vitamins 
(n = 103) 
February 2005 
4 No-shows for blood draw 
(n = 112)
Vitamin D 
Group 
55 
Subjects 
Figure 2.  Flowchart of participation. 
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 Characteristics of Subjects Who Did Not Complete the Study 
 
 Serum PTH levels were significantly higher in the 26 individuals who did not 
complete the study compared to the 86 subjects who completed the study, but there were 
no other significant differences at baseline (Table 3). 
Table 3.  Comparison of baseline characteristics of subjects who completed the 
study and those who did not. 
Did Not Complete 
the Study 
Completed the 
Study 
 
n Mean ± SD n Mean ± SD 
 
 
p 
Age (y) 26 21.7 ± 2.1 86 22.2 ± 3.7 NS 
BMI  (kg/m2) 26 25.9 ± 4.9 86 25.9 ± 5.1 NS 
Serum 25(OH)D 
(nmol/L) 
26 58.2 ± 32.6 86 62.0 ± 23.4 NS 
Serum PTH (pg/mL) 26 36.6 ± 13.5 86 30.9 ± 11.3 0.034 
2004 Summer sun 
exposure (h/wk) 
26 17.0 ± 8.6 86 16.3 ± 9.2 NS 
Calorie intake (kcal/d) 25 1745 ± 426 86 1747 ± 444 NS 
Protein intake (g/d) 25 69.5 ± 24.3 86 67.4 ± 19.1 NS 
Sodium intake (mg/d) 25 3089 ± 1039 86 2924 ± 975 NS 
Calcium intake (mg/d) 25 847 ± 453 86 908 ± 375 NS 
Vitamin D intake (IU/d) 25 149 ± 86 86 139 ± 117 NS 
Subject groups were compared with use of independent samples t-tests. 
 
Baseline Characteristics of Subjects Who Completed the Study 
 The baseline (February 2005) characteristics are summarized in Tables 4a and 4b 
for the 86 subjects who completed the study.  Independent samples t-tests revealed no 
significant differences between the treatment and placebo groups.   
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 Table 4a.  Comparison of treatment and placebo groups at baseline (February 2005) 
in the 86 subjects who completed the study.  
Treatment Group Placebo Group  
n Mean ± SD n Mean ± SD 
 
p 
Age (y) 55 22.3 ± 3.1 31 23.2 ± 4.6 NS 
BMI  (kg/m2) 55 25.5 ± 4.8 31 26.5 ± 5.7 NS 
Total body fat (%) 55 29.8 ± 7.3 31 30.6 ± 7.9 NS 
Height (cm)  55 164.7 ± 6.2 31 163.3 ± 7.7 NS 
Weight (kg)  55 69.3 ± 14.1 31 70.4 ± 13.8 NS 
2004 Summer sun exposure 
(h/wk) 
55 15.4 ± 9.3 31 18.1 ± 8.9 NS 
Serum 25(OH)D (nmol/L) 55 62.1 ± 24.0 31 61.9 ± 22.6 NS 
Serum PTH (pg/mL) 55 29.7 ± 9.1 31 32.9 ± 14.4 NS 
Serum calcium (mg/dL) 55 9.8 ± 0.27 31 9.7 ± 0.25 NS 
Urine calcium:creatinine 55 0.149 ± .0.80 31 0.127 ± 0.086 NS 
Oral contraceptive use (y) 55 1.8 ± 2.0 31 2.5 ± 3.7 NS 
Compliance (%) 55 97.5 ± 11.4 31 96.1 ± 13.6 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 4b.  Comparison of the daily intake from food at baseline (February 2005) 
between the treatment and placebo groups in the 86 subjects who completed the 
study. 
Treatment Group Placebo Group  
n Mean ± SD n Mean ± SD 
 
p 
Calories (kcal/d) 55 1729 ± 451 31 1778 ± 438 NS 
Protein (g/d) 55 67.0 ± 19.2 31 68.1 ± 19.3 NS 
Sodium (mg/d) 55 2899 ± 941 31 2970 ± 1048 NS 
Calcium (mg/d) 55 892 ± 385 31 937 ± 360 NS 
Vitamin D (IU/d) 55 138 ± 125 31 140 ± 104 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Baseline Serum 25(OH)D Levels 
 
 Thirty-eight percent of the subjects were vitamin D deficient (serum 25(OH)D 
levels less than 50 nmol/L), 33% were vitamin D insufficient (serum 25(OH)D 50 to 74 
nmol/L), and 29% had optimal vitamin D levels (serum 25(OH)D levels at least 75 
nmol/L).  Pearson’s chi-square revealed no significant differences in the percent of 
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 subjects in the treatment and placebo groups with optimal, insufficient, or deficient serum 
25(OH)D levels at baseline (Figure 3).  Independent samples t-tests showed no 
significant differences in mean serum 25(OH)D levels between the groups (Table 5). 
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Figure 3.  Frequency of vitamin D sufficiency, insufficiency, and deficiency at 
baseline (February 2005) in the 86 subjects who completed the study. 
 
Table 5.  Comparison of mean serum 25(OH)D levels in the placebo and treatment 
groups by level of baseline serum 25(OH)D levels. 
Placebo Group Treatment Group 
Baseline Serum 25(OH)D 
Category 
 
 
n 
Mean Serum 
25(OH)D ± SD 
(nmol/L) 
 
 
n 
Mean Serum 
25(OH)D ± SD 
(nmol/L) 
<50 nmol/L 14 40.8 ± 5.0 19 37.7 ± 8.6 
50 – 74 nmol/L 7 65.1 ± 7.1 21 62.3 ± 8.1 
≥75 nmol/L 10 89.0 ± 11.0 15 92.7 ± 14.9 
Mean 25(OH)D levels were compared with use of independent sample t-tests. 
Percent of subjects in treatment versus placebo groups were compared using Pearson’s 
chi-square test, with no significant differences. 
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 Hormonal Contraceptives 
 Thirty-four subjects (62%) in the treatment group and 24 (77%) in the placebo 
group used hormonal contraceptives.  Pearson chi-square analysis indicated there was no 
significant difference in the percent of subjects using hormonal contraceptives in the 
treatment group compared to the placebo group.  Baseline serum 25(OH)D levels were 
not significantly different between the placebo and treatment groups for the subjects not 
on hormonal contraceptives, on the low or high estrogen doses, or for the hormonal 
contraceptive users overall (Table 6a).  However, serum 25(OH)D levels were 
significantly higher in the subjects in the medium estrogen dose group who were in the 
treatment group compared to the placebo group (Table 6a).  Serum 25(OH)D levels were 
significantly higher in hormonal contraceptive users than in non-users, and analysis of 
variance showed that serum 25(OH)D levels increased as exogenous estrogen dose 
increased (Table 6b).  Serum 25(OH)D levels and exogenous estrogen dose were 
positively correlated (r = 0.463, p < 0.0005).  Ninety-seven percent of non-hormonal 
contraceptive users compared to 51% of hormonal contraceptive users had serum 
25(OH)D levels less than 75 nmol/L at baseline (February 2005). 
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 Table 6a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among levels of exogenous estrogen exposure in 
the 86 subjects who completed the study. 
Treatment Group Placebo Group  
 
n 
Mean 25(OH)D ± SD
(nmol/L) 
 
n 
Mean 25(OH)D ± SD
(nmol/L) 
 
 
p 
Non-hormonal 
contraceptive users 21 49.0 ± 16.0 7 46.1 ± 11.1 NS 
Hormonal 
contraceptive users 34 70.2 ± 24.8 24 66.5 ± 23.2 NS 
      
Non-hormonal 
contraceptive users 21 49.0 ± 16.0 7 46.1 ± 11.1 NS 
Low exogenous 
estrogen (15 μg/d) 6 46.5 ± 7.6 3 55.6 ± 17.7 NS 
Medium exogenous 
estrogen (20-25 μg/d) 9 80.2 ± 22.6 6 52.0 ± 16.0 0.021
High exogenous 
estrogen (>25 μg/d) 19 72.9 ± 25.2 15 74.4 ± 23.7 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 6b.  Baseline (February 2005) serum 25(OH)D levels among levels of 
exogenous estrogen exposure in the 86 subjects who completed the study. 
   
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
 Non-hormonal contraceptive users 28 48.3 ± 14.8 
 Hormonal contraceptive users 58 68.6 ± 24.0 
<0.0005
     
A Non-hormonal contraceptive users 28 48.3 ± 14.8 
B Low exogenous estrogen (15 μg/d) 9 49.5 ± 11.6 
C Medium exogenous estrogen (20-25 μg/d) 15 68.9 ± 24.2 
D High exogenous estrogen (>25 μg/d) 34 73.6 ± 24.2 
<0.0005
Mean 25(OH)D levels were compared among estrogen doses with use of ANOVA. 
Tukey’s post-hoc analysis: A,C (p = 0.012); A,D (p < 0.0005); B,D (p = 0.013); B,C (p = 
0.121) 
 
Body Mass Index 
 Pearson chi-square analysis shows no significant differences in the percent of 
subjects in the treatment group compared to the placebo group who were of healthy 
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 weight, overweight, or obese according to their BMI (Figure 4).  Serum 25(OH)D levels 
did not differ between treatment and control groups among the three BMI categories 
(Table 7a).  There was a significant inverse correlation between baseline serum 25(OH)D 
levels and BMI (r = -0.383, p < 0.0005), and serum 25(OH)D levels are significantly 
lower in the obese subjects compared to the healthy-weight subjects (Table 7b). 
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Figure 4.  Percent of subjects of healthy weight, overweight, and obese at baseline 
(February 2005) in the 86 subjects who completed the study. 
  
Table 7a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among BMI categories in the 86 subjects who 
completed the study. 
Treatment Group Placebo Group  
 
BMI 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
<25 kg/m2 29 68.8 ± 24.6 17 70.0 ± 21.3 NS 
25 – 30 kg/m2 18 61.6 ± 21.2 7 54.7 ± 25.4 NS 
>30 kg/m2 8 39.1 ± 11.9 7 49.1 ± 16.3 0.191
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 7b.  Baseline (February 2005) serum 25(OH)D levels among BMI categories in 
the 86 subjects who completed the study. 
  
BMI 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
A <25 kg/m2 46 69.2 ± 23.2 
B 25 – 30 kg/m2 25 59.7 ± 22.1 
C >30 kg/m2 15 43.8 ± 14.6 
0.001
Mean 25(OH)D levels were compared among levels of BMI with use of ANOVA. 
Tukey’s post-hoc analysis: A,C (p < 0.0005); B,C (p = 0.069); A,B (p = 0.184). 
 
Percent Body Fat 
 
 There was no significant difference in serum 25(OH)D levels (Table 8a) in the 
treatment group compared to the placebo group among tertiles of percent body fat.  There 
was a significant inverse correlation between baseline serum 25(OH)D levels and percent 
body fat (r = -0.405, p < 0.0005) and serum 25(OH)D levels were significantly lower in 
subjects in the highest tertile of body fat compared to those in the lower tertiles (Table 
8b). 
Table 8a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
treatment and placebo groups among tertiles of body fat in the 86 subjects who 
completed the study. 
Treatment Group Placebo Group Percent Body Fat 
Tertile  
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
<26% 19 69.8 ± 22.7 9 67.5 ± 22.4 NS 
26 – 33% 17 68.3 ± 25.4 12 71.1 ± 22.4 NS 
>33% 19 48.9 ± 18.9 10 45.8 ± 14.6 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 8b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of body 
fat in the 86 subjects who completed the study. 
 Percent Body Fat 
Tertile 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
A <26% 28 69.0 ± 22.2 
B 26 – 33% 29 69.4 ± 23.8 
C >33% 29 47.8 ± 17.3 
<0.0005 
Mean 25(OH)D levels were compared among tertiles of body fat with use of ANOVA. 
Significant differences (Tukey’s post-hoc analysis): A,C (p = 0.001); B,C (p = 0.001). 
 
Weight 
 There was no significant difference in baseline serum 25(OH)D levels between 
the treatment and placebo group among the tertiles of body weight (Table 9a).    Weight 
was inversely correlated with serum 25(OH)D levels (r = -0.302, p = 0.005).  However, 
serum 25(OH)D levels did not differ among the tertiles of body weight (Table 9b). 
Table 9a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
treatment and placebo groups among tertiles of body weight in the 86 subjects who 
completed the study. 
Treatment Group Placebo Group  
Baseline Body 
Weight Tertile 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
<62.5 kg 21 65.1 ± 22.0  8 69.3 ± 22.4 NS 
62.5 – 71 kg 16 62.5 ± 27.3 14 66.2 ± 22.2 NS 
>71 kg 18 58.2 ± 24.0 9 48.5 ± 19.9 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 9b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of body 
weight in the 86 subjects who completed the study. 
 
Baseline Body Weight Tertile 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
<62.5 kg  29 66.3 ± 21.8 
62.5 – 71 kg 30 64.2 ± 24.7 
>71 kg 27 55.0 ± 22.8 
0.170 
Mean 25(OH)D levels were compared among tertiles of weight with use of ANOVA. 
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 Skin Type  
 Skin types II and III made up 76% of the overall group (Figure 5).  There were no 
significant differences in the frequency of each skin type between the treatment and 
placebo groups.  Within each skin type there was no difference in serum 25(OH)D level 
between the treatment and placebo groups (Table 10a).  Skin type was not significantly 
correlated with serum 25(OH)D levels in February 2005 (r = 0.181, p = 0.095), nor was 
there a significant difference in serum 25(OH)D levels among skin types (Table 10b). 
 
5 Brown
4 Olive / L
Brown
3 Medium
2 Fair
1 Ext Fair
Skin Type1
1% 4
5%
23
27%
42
49%
16
18%
 
Figure 5.  Frequency of skin type at baseline (February 2005) in the 86 subjects who 
completed the study. 
  
Table 10a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among skin types in the 86 subjects who 
completed the study. 
Treatment Group Placebo Group  
Skin Type  
n 
Mean 25(OH)D ± 
SD (nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
I Extremely fair 2 28.8 ± 16.6 2 65.6 ± 43.0 NS
II Fair 13 60.7 ± 23.5 10 58.2 ± 22.2 NS
III Medium 29 62.6 ± 24.2 13 59.1 ± 23.8 NS
IV Olive or Light brown 10 70.8 ± 22.7 6 72.8 ± 16.0 NS
V Brown 1 46.3   - 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 10b.  Baseline (February 2005) serum 25(OH)D levels among skin types in the 
86 subjects who completed the study. 
 
Skin Type 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
I Extremely fair 4 47.2 ± 34.1 
II Fair 23 59.6 ± 22.5 
III Medium 42 61.5 ± 23.8 
IV Olive or Light brown 16 71.5 ± 19.9 
V Brown 1 46.3 
NS 
Mean 25(OH)D levels were compared among skin type with use of ANOVA. 
 
Tanning Bed Use 
 Seven (13%) subjects in the treatment group and four (13%) subjects in the 
placebo group used a tanning salon prior to having their blood drawn in February 2005.  
There was no significant difference in mean 25(OH)D levels between the treatment and 
placebo groups (Table 11a).  Although subjects who used a tanning salon had higher 
serum 25(OH)D levels than did those who did not use a tanning salon, independent 
samples t-tests revealed this difference was not significant (Table 11b). 
Table 11a.  Baseline (February 2005) serum 25(OH)D levels between the treatment 
and placebo groups among users and non-users of tanning beds during winter 2004-
2005 in the 86 subjects who completed the study.  
Treatment Group Placebo Group  
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
No tanning bed use – 
Winter 2004-2005 48 59.4 ± 22.6 27 61.5 ± 23.1 NS
Tanning bed use –  
Winter 2004-2005 7 80.2 ± 27.3 4 64.1 ± 21.6 NS
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 11b.  Baseline (February 2005) serum 25(OH)D levels among users and non-
users of tanning beds during winter 2004-2005 in the 86 subjects who completed the 
study. 
  
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
No tanning bed use –  
Winter 2004-2005 75 60.2 ± 22.7 
Tanning bed use –  
Winter 2004-2005 11 74.3 ± 25.6 
0.061 
Subject groups were compared with use of independent samples t-tests. 
 
Summer Sun Exposure 
 There were no significant differences in serum 25(OH)D levels between the 
treatment and placebo groups in any tertile of summer sun exposure (Table 12a).  
Summer sun exposure and serum 25(OH)D levels were positively correlated (r = 0.229,  
p = 0.034).  However, analysis of variance showed that the increase in serum 25(OH)D 
levels among tertiles of sun exposure was not significant (Table 12b).   
Table 12a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among tertiles of weekly sun exposure during 
summer 2004 in the 86 subjects who completed the study. 
Treatment Group Placebo Group  
Summer Sun 
Exposure 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
<11 h/wk 22 57.9 ± 22.6 7 58.75 ± 24.6 NS
11 – 20 h/wk 17 60.6 ± 19.8 12 63.9 ± 23.5 NS
>20 h/wk 16 69.5 ± 29.2 12 61.6 ± 22.4 NS
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 12b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of 
weekly sun exposure during summer 2004 in the 86 subjects who completed the 
study. 
 
Summer Sun Exposure 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
<11 h/wk 29 58.11 ± 22.7 
11 – 20 h/wk 29 62.0 ± 21.1 
>20 h/wk 28 66.1 ± 26.4 
NS 
Mean 25(OH)D levels were compared among tertiles of sun exposure with use of 
ANOVA. 
 
Dietary Vitamin D Intake  
 There was no significant difference in serum 25(OH)D levels between the 
treatment and placebo groups in any tertile of dietary vitamin D intake (Table 13a).  
There was no correlation between serum 25(OH)D and vitamin D intake, nor did serum 
25(OH)D levels differ significantly among tertiles of vitamin D intake (Table 13b). 
Table 13a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among tertiles of dietary vitamin D intake in the 
86 subjects who completed the study. 
Treatment Group Placebo Group  
Dietary Vitamin D 
Tertile 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
<73 IU/d 20 60.7 ± 28.0 8 56.3 ± 26.2 NS 
73 – 159 IU/d 17 65.7 ± 26.7 13 60.6 ± 22.9 NS 
>159 IU/d 18 60.3 ± 16.4 10 68.0 ± 20.0 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 13b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of 
dietary vitamin D intake in the 86 subjects who completed the study. 
 
Dietary Vitamin D Tertile 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
<73 IU/d 28 59.4 ± 27.1 
73 – 159 IU/d 30 63.5 ± 24.8 
>159 IU/d 28 63.0 ± 17.8 
NS 
Mean 25(OH)D levels were compared among tertiles of vitamin D intake with use of 
ANOVA. 
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 Dietary Calcium Intake  
 There was no significant difference in serum 25(OH)D levels between the 
treatment and placebo groups in any tertile of dietary calcium intake (Table 14a).  There 
was no correlation between serum 25(OH)D and calcium intake, nor did serum 25(OH)D 
levels differ significantly among tertiles of calcium intake (Table 14b). 
Table 14a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among tertiles of dietary calcium intake in the 86 
subjects who completed the study. 
Treatment Group Placebo Group  
Dietary Calcium 
Intake 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
<703 mg/d 20 63.3 ± 28.5 9 59.8 ± 28.4 NS 
703 – 983 mg/d 19 65.1 ± 23.8 11 57.1 ± 20.1 NS 
>983 mg/d 16 57.1 ± 18.0 11 68.3 ± 20.4 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 14b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of 
dietary calcium intake in the 86 subjects who completed the study. 
 
Dietary Calcium Intake 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
<703 mg/d 29 62.1 ± 28.0 
703 – 983 mg/d 30 62.2 ± 22.5 
>983 mg/d 27 61.7 ± 19.4 
NS 
Mean 25(OH)D levels were compared among tertiles of calcium intake with use of 
ANOVA. 
 
Alcohol Consumption 
 Alcohol consumption was positively associated with serum 25(OH)D levels (r = 
0.221, p = 0.040).  Among tertiles of alcohol consumption, serum 25(OH)D levels did not 
differ significantly between the treatment and placebo groups (Table 15a).  Analysis of 
variance revealed significant differences in serum 25(OH)D levels between the lowest 
and highest tertiles of alcohol consumption (Table 15b). 
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 Table 15a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among tertiles of alcohol consumption in the 86 
subjects who completed the study. 
Treatment Group Placebo Group  
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
0 drinks/wk 18 51.1 ± 20.0 12 58.1 ± 22.5 NS 
0.5 - 3 servings/wk 20 59.1 ± 18.5 11 65.4 ± 20.7 NS 
>3 servings/wk 17 77.3 ± 26.9 8 62.7 ± 27.2 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 15b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of 
alcohol consumption in the 86 subjects who completed the study. 
 
Alcohol Intake 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
0 drinks/wk 30 53.9 ± 20.9* 
0.5 - 3 servings/wk 31 61.3 ± 19.2 
>3 servings/wk 25 72.6 ± 27.3* 
0.011 
Mean 25(OH)D levels were compared among tertiles of alcohol consumption with use of 
ANOVA.   
*Tukey’s post-hoc analysis: p = 0.008 
 
Smoking 
 Ninety-three percent (51/55) of the treatment group and 97% (30/31) of the 
placebo group did not smoke cigarettes.  Four subjects (3 in the treatment group and 1 in 
the placebo group) smoked less than half a pack of cigarettes per day.  One subject in the 
treatment group smoked more than one pack of cigarettes per day.  Serum 25(OH)D 
levels were not significantly different between the placebo and treatment groups among 
smokers and non-smokers (Table 16a).  There was a trend toward an inverse relationship 
between smoking and serum 25(OH)D levels (r = -0.180, p = 0.097).  Serum 25(OH)D 
levels, however, were not significantly different between smokers and non-smokers 
(Table 16b). 
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 Table 16a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among smokers and non-smokers in the 86 
subjects who completed the study. 
Treatment Group Placebo Group  
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
Non-smokers 51 63.0 ± 24.3 30 62.9 ± 22.3 NS 
Smokers 4 50.0 ± 17.4 1 32.0 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
Table 16b.  Baseline (February 2005) serum 25(OH)D levels among smokers and 
non-smokers in the 86 subjects who completed the study. 
  
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
Non-smokers 81 63.0 ± 23.5 
Smokers 5 46.4 ± 17.1 
0.125 
Subject groups were compared with use of independent samples t-tests. 
 
Serum PTH 
 There were no significant differences in serum PTH levels between the treatment 
and placebo groups among tertiles of serum 25(OH)D levels (Table 17a).  There was no 
significant correlation between baseline serum PTH levels and serum 25(OH)D levels, 
nor were there any significant differences in serum PTH levels among tertiles of serum 
25(OH)D at baseline (Table 17b).   
Table 17a.  Comparison of baseline (February 2005) serum PTH levels between the 
treatment and placebo groups among tertiles of serum 25(OH)D levels in the 86 
subjects who completed the study. 
Treatment Group Placebo Group  
Baseline Serum 
25(OH)D Tertiles 
 
n 
Mean PTH ± SD 
(pg/mL) 
 
n 
Mean PTH ± SD 
(pg/mL) 
 
 
p 
Lowest tertile 
(<47 nmol/L) 
16 32.6 ± 7.2 12 33.5 ± 16.1 NS 
Middle tertile 
(47 – 72.4 nmol/L) 
20 27.6 10.2 9 32.0 ± 15.9 NS 
Highest tertile 
(≥72.5 nmol/L) 
19 29.5 ± 9.1 10 33.1 ± 12.0 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 17b.  Baseline (February 2005) serum PTH levels among tertiles of serum 
25(OH)D in the 86 subjects who completed the study. 
 Baseline Serum 25(OH)D Tertiles  
n 
Mean PTH ± SD 
(pg/mL) 
 
p 
A Lowest tertile (<47 nmol/L) 28 33.0 ± 11.6 
B Middle tertile (47 – 72.4 nmol/L) 29 29.0 ± 12.2 
C Highest tertile (≥72.5 nmol/L) 29 30.7 ± 10.1 
NS 
Mean PTH levels were compared among tertiles of baseline 25(OH)D levels with use of 
ANOVA. 
 
Menstrual Cycle 
 Serum 25(OH)D levels did not differ between treatment and placebo groups 
during any phase of the menstrual cycle (Table 18a), nor did serum 25(OH)D levels 
differ among menstrual cycle phases (Table 18b).  However, there was a positive 
correlation between day of menstrual cycle and serum 25(OH)D levels (r = 0.319, p = 
0.003). 
Table 18a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among three menstrual cycle phases in the 86 
subjects who completed the study. 
Treatment Group Placebo Group  
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
Days* 0 – 10 19 59.2 ± 22.2 7 73.7 ± 23.5 0.160
Days* 11 – 20 20 64.1 ± 23.6 12 64.5 ± 26.1 NS 
Days* 21 - 35 11 63.7 ± 21.7 9 50.8 ± 14.4 0.143
*Day of menstrual cycle on which blood was drawn for 25(OH)D analysis. 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 18b.  Baseline (February 2005) serum 25(OH)D levels among three menstrual 
cycle phases in the 86 subjects who completed the study. 
  
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
Days* 0 – 10 26 63.1 ± 23.0 
Days* 11 – 20 32 64.2 ± 24.2 
Days* 21 – 35 20 57.9 ± 19.5 
NS 
*Day of menstrual cycle on which blood was drawn for 25(OH)D analysis. 
Mean 25(OH)D levels were compared among menstrual cycle phase with use of 
ANOVA. 
 
Number of Days with a Cold   
 The number of days with a cold is being used as a rough estimate of subjects’ 
immune status.  Eighty-five out of 86 subjects completed this question on the 
questionnaire.  Serum 25(OH)D levels differed significantly between treatment and 
placebo groups in the highest tertile of the number of days with a cold, but were not 
significantly different in the lower two tertiles (Table 19a).  Serum 25(OH)D levels did 
not differ among tertiles of the number of cold days (Table 19b).  There was no 
correlation between the number of cold days and serum 25(OH)D levels. 
Table 19a.  Comparison of baseline (February 2005) serum 25(OH)D levels between 
the treatment and placebo groups among tertiles of number of days with a cold in 85 
of the 86 subjects who completed the study. 
Treatment Group Placebo Group  
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
 
p 
0 to 0.66 days 18 67.2 ± 23.9 10 58.5 ± 21.0 NS 
0.67 to 7 days 19 64.3 ± 28.7 11 54.8 ± 23.5 NS 
>7 days 17 53.7 ± 17.2 10 73.0 ± 21.0 0.015
Treatment and placebo groups were compared with use of independent samples t-tests. 
 
 
 
 
 
 
 88
 Table 19b.  Baseline (February 2005) serum 25(OH)D levels among tertiles of 
number of days with a cold in 85 of the 86 subjects who completed the study. 
  
n 
Mean 25(OH)D ± SD 
(nmol/L) 
 
p 
0 to 0.66 d 28 64.1 ± 22.9 
0.67 to 7 d 30 60.8 ± 26.9 
>7 d 27 60.8 ± 20.6 
NS 
Mean 25(OH)D levels were compared among tertiles of days wit a cold with use of 
ANOVA. 
 
Variables Affecting Baseline Serum 25(OH)D Levels 
 Linear and logistic regression analyses were performed to determine which 
factors influenced baseline serum 25(OH)D levels.  Both methods identified estrogen 
dose, percent body fat, and alcohol consumption to be significant predictors of baseline 
serum 25(OH)D levels.  In addition, logistic regression found the number of days with a 
cold during winter 2004-2005 to be significant. 
 The advantage of using logistic regression is that the dependent variable, serum 
25(OH)D level, can be categorized into optimal (≥75 nmol/L) and suboptimal (<75 
nmol/L) levels, and one can determine which parameters predict optimal serum 25(OH)D 
levels, which is especially useful to a clinician.  The logistic regression results are 
described below. 
 Logisitic regression analysis was used to predict the probability that the baseline 
serum 25(OH)D levels would be greater than 75 nmol/L.  A backward stepwise approach 
was used for this analysis.  In the backward stepwise model, all of the variables start in 
the model and, in a stepwise fashion, one variable is eliminated at each step.  Estrogen 
dose, percent body fat, number of days with a cold, and alcohol consumption were the 
predictors included in the final model.  
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  A test of the full model versus a model with constant only was statistically 
significant, X2 (df = 4) = 42.661, p < 0.0005.  Table 20a shows the logistic regression 
coefficient, Wald test, and odds ratio for estrogen dose, percent body fat, number of days 
with a cold, and alcohol consumption.  Table 20b shows the logistic regression 
coefficient and Wald test for the variables eliminated from the final model. 
 The model was able to correctly classify 86% of the subjects with serum 
25(OH)D levels less than 75 nmol/L and 72% of those with levels greater than 75 
nmol/L, with an overall success rate of 81% (Table 20c).  Nagelkerke R2 was 0.577 and   
-2 Log likelihood was 57.456.  Fifty-eight percent of the variation in baseline serum 
25(OH)D levels can be explained by the logistic regression model.   
 A Hosmer and Lemeshow Test was performed, X2 (df = 8) = 2.429, p < 0.965.  
Therefore we did not reject the null hypothesis that the observed and predicted values are 
the same and concluded that the model fits the data reasonably well.   
Table 20a.  Logistic regression predicting baseline serum 25(OH)D levels from 
estrogen dose, percent body fat, number of days with a cold, and alcohol 
consumption. 
Variable Beta S.E. Wald p Odds Ratio 
Estrogen dose 0.164 0.043 14.503 <0.0005 1.179 
Percent body fat -0.103 0.057 3.304 0.069 0.902 
Number of days with a cold -0.141 0.060 5.460 0.019 0.869 
Alcohol 0.240 0.109 4.866 0.027 1.272 
Constant -1.519 1.806 0.707 0.400 0.219 
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 Table 20b.  Variables eliminated from the backward stepwise logistic regression 
model predicting baseline serum 25(OH)D levels. 
Step Variable Eliminated Beta coefficient Wald Coefficient P Value
1 Smoking -59.815 0.000 0.999 
2 Years of oral contraceptive use -0.005 0.000 0.984 
3 Sun exposure summer 2004 -0.003 0.007 0.933 
4 Tanning bed use -0.107 0.010 0.920 
5 BMI -0.015 0.008 0.929 
6 Summer 25(OH)D increase  0.004 0.095 0.758 
7 Age 0.040 0.103 0.748 
8 Vitamin D from diet -0.001 0.406 0.524 
9 Calcium from diet -0.001 0.406 0.524 
10 Skin type 0.352 0.630 0.428 
11 Day of menstrual cycle 0.035 0.962 0.327 
 
Table 20c.  Classification table. 
Predicted  
<75 nmol/L ≥75 nmol/L 
<75 nmol/L 48 8 Observed 
≥75 nmol/L 7 18 
Sensitivity = 48/56 = 86% 
Specificity = 18/25 = 72% 
Positive Predictive Value = 48/55 = 87% 
Negative Predictive Value = 18/26 = 69% 
Total Correct = 66/81 = 81% 
 
September 2005 Serum 25(OH)D Levels and the Seasonal Increase in Levels 
 In September 2005, the mean serum 25(OH)D level was 103.0 ± 33.2 nmol/L.  
The mean seasonal summer increase was 41.0 ± 26.1 nmol/L.  Seventy-seven percent of 
subjects had optimal serum 25(OH)D levels (≥75 nmol/L); 22% had insufficient levels 
(50 – 74 nmol/L); and no subjects had deficient levels (<50 nmol/L) at the end of the 
summer.   
 There was no significant difference in September serum 25(OH)D levels or the 
seasonal increase in serum 25(OH)D levels between the treatment and placebo groups 
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 (Table 21a).  There was also no significant difference between treatment and placebo 
groups regarding September serum 25(OH)D levels and the seasonal change when these 
groups were further divided into hormonal contraceptive users (OCP+) and non-users 
(OCP-; Table 21a).  Hormonal contraceptive users had significantly higher September 
serum 25(OH)D levels in the treatment group (p = 0.025) and in the placebo group (p = 
0.007) compared with non-users.  The seasonal summer increase did not differ 
significantly between hormonal contraceptive users in the treatment group (p = 0.362) or 
in the placebo group (p = 0.090) (Table 21a), or in the overall group (Table 21b).  Nor 
did the seasonal change differ significantly among doses of estrogen (Table 21b).   
Table 21a.  Comparison of the September serum 25(OH)D levels and the seasonal 
summer increase in serum 25(OH)D levels between treatment and placebo groups in 
the 86 subjects who completed the study. 
Treatment Group Placebo Group  
n (nmol/L) n (nmol/L 
 
p 
Total 55 104.7 ± 33.1 31 100.2 ± 33.7 NS 
OCP-* 27 94.6 ± 25.0 10 77.2 ± 21.32 0.059 
September 
25(OH)D 
OCP+* 28 114.4 ± 37.3 21 111.1 ± 33.4 NS 
 
Total 55 42.6 ± 27.9 31 38.3 ± 22.7 NS 
OCP-* 27 46.1 ± 25.6 10 28.3 ± 24.7 0.065 
Seasonal summer 
increase 
in 25(OH)D OCP+* 28 39.2 ± 30.1 21 43.1 ± 20.6 NS 
*OCP- group includes individuals with ≤15 μg daily estrogen (contraceptive patch and 
ring users) 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 21b.  Seasonal increase in serum 25(OH)D levels among levels of estrogen 
dose in the 86 subjects who completed the study. 
 
Estrogen Dose 
 
n 
Summer Increase in Serum 25(OH)D 
(nmol/L) 
 
p 
Non-oral contraceptive users* 37 41.3 ± 26.3 
Oral contraceptive users 49 40.9 ± 26.3 
NS
    
Non-oral contraceptive users* 28 40.9 ± 25.5 
Low-exogenous estrogen (15 
μg/d) 
9 42.6 ± 30.1 
Medium exogenous estrogen 
(20-25 μg/d) 
15 48.8 ± 29.4 
High exogenous estrogen (>25 
μg/d) 
34 37.3 ± 24.4 
NS
*Non-oral contraceptive users include individuals with ≤15 μg daily estrogen 
(contraceptive patch and ring users). 
Subject groups were compared with use of independent samples t-tests. 
Mean 25(OH)D levels were compared among levels of estrogen dose with use of 
ANOVA. 
 
 Pearson correlations were performed between the magnitude of seasonal change 
in serum 25(OH)D levels and estrogen dose, percent body fat, baseline serum 25(OH)D 
levels, skin type, and summer sun exposure.  There was a significant inverse relationship 
between skin type and seasonal change (r = -0.282, p = 0.009).  Individuals with darker 
skin pigmentation experienced less seasonal increase in serum 25(OH)D levels than did 
those with lighter skin.  One-way analysis of variance with Tukey’s post-hoc analysis 
identified significant differences between September serum 25(OH)D levels in subjects 
with extremely fair skin and those with light brown skin (Table 22).  There were no 
significant correlations between the seasonal change in serum 25(OH)D levels and 
estrogen dose, percent body fat, baseline serum 25(OH)D levels, or summer sun 
exposure. 
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 Table 22.  Seasonal change in serum 25(OH)D levels among skin types in the 86 
subjects who completed the study. 
Skin Type n Summer Increase in Serum 25(OH)D (nmol/L) p 
I Extremely fair 4 73.9 ± 7.7* 
II Fair 23 42.5 ± 32.7 
III Medium 42 41.7 ± 21.6 
IV Olive / Light brown 16 30.7 ± 23.6* 
V Brown 1 15.3 
0.028
Mean 25(OH)D levels were compared among skin type with use of ANOVA. 
*Tukey’s post-hoc analysis: mean difference is significant (p = 0.015). 
 
 Logistic regression analysis was performed to determine which factors influenced 
the summer seasonal increase in serum 25(OH)D levels.  Logistic regression analysis was 
used to predict the probability that the summer increase in serum 25(OH)D levels would 
be at least 60 nmol/L.  A backward stepwise approach was used for this analysis.  Skin 
type was the only predictor included in the final model. 
 A test of the full model versus a model with constant only was statistically 
significant, X2 (df = 1) = 15.160, p < 0.0005.  Table 23a shows the logistic regression 
coefficient, Wald test, and odds ratio for skin type.  Table 23b shows the logistic 
regression coefficient and Wald test for the variables eliminated from the final model. 
 The model was able to correctly classify 100% of the subjects with a seasonal 
change less than 60 nmol/L and 20% of those with a change greater than 60 nmol/L, with 
an overall success rate of 95% (Table 23c).  Nagelkerke R2 was 0.244 and -2 Log 
likelihood was 78.124.  Twenty-four percent of the variation in the seasonal change in 
serum 25(OH)D levels was explained by the logistic regression model.   
 A Hosmer and Lemeshow Test was performed, X2 (df = 1) = 0.237, p < 0.627.  
Therefore we did not reject the null hypothesis that the observed and predicted values 
were the same and concluded that the model fits the data reasonably well.   
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 Table 23a.  Logistic regression predicting the seasonal increase in serum 25(OH)D 
levels from skin type. 
Variable Beta S.E. Wald p Odds Ratio 
Skin type -1.385 0.406 11.656 0.001 0.250 
Constant 2.465 1.048 5.529 0.019 11.761 
 
Table 23b.  Variables eliminated from the backward stepwise logistic regression 
model predicting the seasonal increase in serum 25(OH)D levels. 
Step Variable Eliminated Beta coefficient Wald Coefficient P Value
1 Body fat 0.001 0.001 0.977 
2 Sun exposure summer 2005 -0.005 0.032 0.859 
3 Baseline serum 25(OH)D 0.012 0.705 0.401 
4 Estrogen dose -0.011 0.287 0.592 
5 Sunscreen use 0.254 1.222 0.269 
 
Table 23c.  Classification table. 
Predicted  
<75 nmol/L ≥75 nmol/L 
<75 nmol/L 66 0 Observed 
≥75 nmol/L 16 4 
Sensitivity = 66/66 = 100% 
Specificity = 4/20 = 20% 
Positive Predictive Value = 66/82 = 80% 
Negative Predictive Value = 4/4 = 100% 
Total Correct = 70/74 = 95% 
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 One-Year Change  
 Body mass index, percent body fat, weight, vitamin D intake, and urinary 
calcium:creatinine ratio changed significantly between February 2005 and February 2006 
(Table 24a).  However, these changes were not significantly different between the 
placebo and treatment groups (Table 24b).   
Table 24a.  Comparison of parameters in February 2005 and February 2006 in the 
overall group (n=86).   
  
n 
February 2005 
Mean ± SD 
February 2006 
Mean ± SD 
 
p 
BMI  (kg/m2) 85 25.8 ± 5.0 26.5 ± 5.5 <0.0005
Total body fat (%) 85 30.0 ± 7.5 31.3 ± 7.7 <0.0005
Weight (kg)  85 69.7 ± 14.0 71.8 ± 15.1 <0.0005
Vitamin D from diet (IU/d) 83 137 ± 118 103 ± 96 0.008 
Summer sun exposure, 2004 
and 2005 (h/wk) 
86 16.3 ± 9.2 15.4 ± 9.3 NS 
Serum calcium (mg/dL) 86 9.7 ± 0.26 9.8 ± 0.34 NS 
Urine calcium:creatinine 86 0.141 ± 0.083 0.168 ± 0.113 0.046 
Number of cold days 85 6.47 ± 7.45 5.48 ± 6.19 NS 
Subject groups were compared with use of independent samples t-tests. 
 
Table 24b. Comparison of one-year change in parameters between treatment and 
placebo groups. 
Treatment Group Placebo Group  
n Mean ± SD n Mean ± SD 
 
p 
Change in BMI (kg/m2) 55 0.68 ± 1.23 30 0.96 ± 1.65 NS 
Change in body fat (%) 55 1.19 ± 2.20 30 1.47 ± 2.26 NS 
Change in weight (kg) 55 1.81 ± 3.49 30 2.5 ± 4.50 NS 
Change in vitamin D intake (IU/d) 53 -46.3 ± 116.3 30 -13.2 ± 111.7 0.211
Change in sun exposure (h/wk) 55 -0.296 ± 11.5 31 -2.05 ± 7.73 NS 
Change in serum calcium (mg/dL) 55 -0.012 ± 0.397 31 0.118 ± 0.398 0.150
Change in urine calcium:creatinine 55 0.010 ± 0.127 31 0.056 ± 0.111 0.095
Change in number of cold days 54 -0.893 ± 8.12 31 -1.17 ± 8.46 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Tolerance to Vitamin D Supplementation 
 Serum calcium and urinary calcium and creatinine levels were measured to 
monitor tolerance to the supplementation.  Mean serum calcium levels and the urinary 
calcium to creatinine ratios were not significantly different between the placebo group 
and the treatment group after five months of supplementation with 800 IU vitamin D3 
(Table 25a).  There was no significant difference in serum calcium levels or the calcium 
to creatinine ratio in the treatment group between February 2005 and February 2006 
(Table 25b).  In the placebo group, however, the urinary calcium to creatinine ratio 
increased significantly from February 2005 (0.13 ± 0.09) to February 2006 (0.18 ± 0.14); 
serum calcium levels did not change in the placebo group (data not shown).  The one-
year change in serum calcium and in the urine calcium to creatinine ratio was not 
significantly different between the treatment and placebo groups (Table 24b).  After the 
supplementation period, three subjects in the treatment group and four subjects in the 
placebo group had urinary calcium to creatinine ratios above 0.40, indicating 
hypercalciuria.  However, all seven subjects had serum calcium levels within normal 
limits. 
Table 25a.  Comparison of serum calcium levels and urinary calcium to creatinine 
ratios in treatment and placebo groups after five month supplementation period. 
 Treatment Group Placebo Group p 
Serum calcium (mg/dL) 55 9.7 ± 0.33 31 9.8 ± 0.37 NS 
Urinary calcium to creatinine ratio 55 0.16 ± 0.10 31 0.18 ± 0.14 NS 
Treatment and placebo groups were compared with use of independent samples t-tests. 
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 Table 25b.  Comparison of serum calcium and urinary calcium to creatinine ratios 
in the treatment group in February 2005 (before supplementation) and in February 
2006, after five months of supplementation. 
 February 2005 February 2006  
 n = 55 n = 55 p 
Serum calcium (mg/dL) 9.8 ± 0.27 9.7 ± 0.33 NS 
Urinary calcium to creatinine ratio 0.15 ± 0.08 0.16 ± 0.10 NS 
Subject groups were compared with use of independent samples t-tests. 
 
Response to Supplementation 
 
 As seen in Table 26, serum 25(OH)D levels increased by 35.3 ± 23.2 nmol/L in 
the treatment group between February 2005 and February 2006.  In the placebo group, 
serum 25(OH)D levels increased 10.9 ± 16.9 nmol/L.  The net treatment effect was a 24.4 
nmol/L increase in serum 25(OH)D levels. 
Table 26.  One-year change in serum 25(OH)D levels. 
  
 
 
n 
February 
2005 
25(OH)D 
(nmol/L) 
February 
2006 
25(OH)D 
(nmol/L) 
 
One-Year Change in Serum 
25(OH)D Levels 
(nmol/L) 
Treatment  55 62.1 ± 24.0† 97.4 ± 31.3*† 35.3 ± 23.2* 
Placebo 31 61.9 ± 22.6† 72.7 ± 27.8*† 10.9 ± 16.9* 
*Treatment and placebo groups compared using independent samples t-tests, p < 0.0005. 
†February 2005 and February 2006 serum 25(OH)D levels compared using paired 
samples t-tests, p < 0.0005. 
  
 The actual vitamin D3 content of the vitamin D capsules was measured by the 
manufacturer at the time they were made (February 2005, 869 IU), and by an independent 
laboratory at the beginning (September 2005, 956 IU) and end (April 2006, 832 IU) of 
the supplementation period.  The mean vitamin D3 content of the capsules was 885 IU 
(22 μg).  The net treatment effect of 24.4 nmol/L in those receiving 885 IU vitamin D3 
daily corresponds to an increase of 1.1 nmol/L for every μg of supplemental vitamin D3 
intake. 
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 Examination of Predictor Variables for Response to Supplementation in the 
Treatment Group 
Baseline Serum 25(OH)D Levels 
 There was no correlation between baseline (February 2005) serum 25(OH)D 
levels and the one-year change in serum 25(OH)D levels, nor was there any significant 
difference in the one-year change in serum 25(OH)D levels among categories of baseline 
serum 25(OH)D levels in the treatment group (Table 27a).  In the placebo group, there 
was no significant difference in the one-year change in serum 25(OH)D levels among 
categories of baseline serum 25(OH)D levels (Table 27b). 
Table 27a.  One-year change in serum 25(OH)D levels in the treatment group (n = 
55) among categories of baseline serum 25(OH)D levels. 
Baseline serum 25(OH)D level 
(nmol/L) 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<50 nmol/L 19 34.6 ± 22.0 
50 – 75 nmol/L 21 40.0 ± 22.7 
>75 nmol/L 15 29.6 ± 25.4 
NS 
Mean changes in 25(OH)D levels were compared among categories of baseline serum 
25(OH)D levels with use of ANOVA. 
 
Table 27b.  One-year change in serum 25(OH)D levels in the placebo group (n = 31) 
among categories of baseline serum 25(OH)D levels. 
Baseline serum 25(OH)D level 
(nmol/L) 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<50 nmol/L 14 14.0 ± 17.6 
50 – 75 nmol/L 7 5.8 ± 16.3 
>75 nmol/L 10 10.0 ± 16.9 
NS 
Mean changes in 25(OH)D levels were compared among categories of baseline serum 
25(OH)D levels with use of ANOVA. 
 
Hormonal Contraceptive Use  
 There was no correlation between exogenous estrogen dose and the one-year 
change in serum 25(OH)D levels in the treatment group.  Analysis of variance revealed 
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 no difference in one-year change in serum 25(OH)D levels among levels of exogenous 
estrogen dose in the treatment group, or in the placebo group (Table 28).   
Table 28.  One-year change in serum 25(OH)D levels in the treatment and placebo 
groups among levels of exogenous estrogen exposure. 
 Treatment Group Placebo Group 
  
 
n 
One-Year Change 
in Serum 25(OH)D 
(nmol/L) 
 
 
p 
 
 
n 
One-Year Change 
in Serum 25(OH)D 
(nmol/L) 
 
 
p 
Non-hormonal 
contraceptive users 21 31.3 ± 21.2 7 12.1 ± 7.6 
Hormonal 
contraceptive users 34 37.8 ± 24.4 
NS
24 10.5 ± 18.9 
NS
       
Non-hormonal 
contraceptive users 21 31.3 ± 21.2 7 12.1 ± 7.6 
Low exogenous 
estrogen (15 μg/d) 6 34.6 ± 19.3 3 4.8 ± 18.1 
Medium exogenous 
estrogen  
(20-25 μg/d) 
9 32.9 ± 23.8 6 18.2 ± 26.3 
High exogenous 
estrogen (>25 μg/d) 19 41.0 ± 26.6 
NS
15 8.6 ± 18.0 
NS
Hormonal contraceptive users and non-users were compared with use of independent 
samples t-tests. 
Mean changes in 25(OH)D levels were compared among levels of estrogen use with use 
of ANOVA. 
 
Mean Body Mass Index  
 There was no correlation between mean BMI and the one-year change in serum 
25(OH)D levels in the treatment group.  There was no significant difference in the one-
year change in serum 25(OH)D levels among BMI categories in the treatment group 
(Table 29), or in the placebo group (data not shown). 
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 Table 29.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among mean BMI categories. 
 
Mean BMI 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<25 kg/m2 26 37.7 ± 21.0 
25 – 30 kg/m2 20 34.3 ± 27.6 
>30 kg/m2 9 30.5 ± 20.1 
NS 
Mean changes in 25(OH)D levels were compared among levels of BMI with use of 
ANOVA. 
 
Mean Percent Body Fat  
 There was no correlation between mean percent body fat and the one-year change 
in serum 25(OH)D levels in the treatment group.  There was not a significant difference 
in the one-year change in serum 25(OH)D levels among tertiles of mean percent body fat 
in the treatment group (Table 30a), or in the placebo group (Table 30b). 
Table 30a.  One-year change in serum 25(OH)D levels in the treatment group 
among tertiles of mean body fat. 
 
Tertile of Mean Body Fat 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<26% 19 39.3 ± 26.8 
26 – 33% 18 32.9 ± 22.9 
>33% 18 33.4 ± 20.0 
NS 
Mean changes in 25(OH)D levels were compared among tertiles of body fat with use of 
ANOVA. 
 
Table 30b.  One-year change in serum 25(OH)D levels in the placebo group (n = 31) 
among tertiles of mean body fat. 
 
Tertile of Mean Body Fat 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<27% 10 9.3 ± 19.2 
27 – 34.9% 11 15.3 ± 17.2 
≥35% 10 7.6 ± 14.7 
NS 
Mean changes in 25(OH)D levels were compared among tertiles of body fat with use of 
ANOVA. 
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 Mean Body Weight  
 There was no correlation between mean weight and the one-year change in serum 
25(OH)D levels in the treatment group.  There was no significant difference in the one-
year change in serum 25(OH)D levels among tertiles of mean weight in the treatment 
group (Table 31), or in the placebo group (data not shown). 
Table 31.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among tertiles of mean body weight. 
 
Mean Body Weight Tertile 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<62 kg 18 36.0 ± 23.9 
62 – 74 kg 19 41.5 ± 21.1 
>74 kg 18 27.9 ± 23.8 
0.205
Mean changes in 25(OH)D levels were compared among tertiles of weight with use of 
ANOVA. 
 
Skin Type  
 There was no correlation between skin type and the one-year change in serum 
25(OH)D levels in the treatment group.  There was no significant difference in the one-
year change in serum 25(OH)D levels among skin type classifications in the treatment 
group (Table 32), or in the placebo group (data not shown). 
Table 32.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among skin types. 
Skin Type n One-Year Change in Serum 25(OH)D (nmol/L) p 
I Extremely fair 2 35.1 ± 17.9 
II Fair 13 36.8 ± 22.0 
III Medium 29 37.8 ± 25.8 
IV Olive or Light brown 10 26.4 ± 19.0 
V Brown 1 32.5 
NS
Mean changes in 25(OH)D levels were compared among skin type with use of ANOVA. 
 
 
 
 102
 Tanning Bed Use 
 As seen in Table 33, in the treatment group, subjects who only tanned during 
winter 2005-2006 had a significantly higher one-year change in serum 25(OH)D levels 
than did subjects who only tanned during winter 2004-2005.  In the placebo group, there 
was no significant difference in the one-year change in serum 25(OH)D levels according 
to tanning bed use (data not shown). 
Table 33.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among users and non-users of tanning beds.  
 
Tanning Bed Use 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
No tanning bed use  45 34.9 ± 22.0 
Tanning bed use both winters 3 39.2 ± 3.4 
Tanning bed use –  
winter 2004-2005 only 3 6.6 ± 19.0* 
Tanning bed use –  
winter 2005-2006 only 4 58.0 ± 28.9* 
0.031 
Mean changes in 25(OH)D levels were compared among levels of tanning bed use with 
use of ANOVA. 
*Tukey’s post-hoc analysis: p = 0.017 
 
Dietary Vitamin D Intake  
 There was no correlation between mean vitamin D intake and the one-year change 
in serum 25(OH)D levels in the treatment group.  There was no significant difference in 
the one-year change in serum 25(OH)D levels among tertiles of mean vitamin D intake in 
the treatment group (Table 34), or in the placebo group (data not shown). 
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 Table 34.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among tertiles of mean dietary vitamin D intake. 
Mean Vitamin D 
Intake 
 
n 
One-Year Change in Serum 25(OH)D 
(nmol/L) 
 
p 
<56 IU 18 33.6 ± 16.8 
56 – 125 IU 19 29.5 ± 24.8* 
>125 IU 18 42.9 ± 26.0* 
0.199 
Mean changes in 25(OH)D levels were compared among levels of vitamin D intake with 
use of ANOVA. 
*Tukey’s post-hoc analysis: p = 0.184 
 
Dietary Calcium Intake   
 There was no correlation between mean calcium intake and the one-year change 
in serum 25(OH)D levels in the treatment group.  There was no significant difference in 
the one-year change in serum 25(OH)D levels among tertiles of mean calcium intake in 
the treatment group (Table 35), or in the placebo group (data not shown). 
Table 35.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among tertiles of mean dietary calcium intake. 
Mean Calcium Intake n One-Year Change in Serum 25(OH)D (nmol/L) p 
<725 mg/d 18 31.7 ± 13.9  
726 to 981 mg/d 19 35.8 ± 29.6 
>981 mg/d 18 38.3 ± 23.7 
NS 
Mean changes in 25(OH)D levels were compared among levels of calcium intake with 
use of ANOVA. 
 
Alcohol Consumption 
 There was no significant difference in the one-year change in serum 25(OH)D 
levels among tertiles of alcohol consumption in the treatment group (Table 36), or in the 
placebo group (data not shown). 
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 Table 36.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among tertiles of alcohol consumption. 
 
Tertile of Alcohol Consumption 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
0 drinks/wk 18 40.2 ± 18.8 
≤3 servings/wk 20 31.7 ± 26.6 
>3 servings/wk 17 34.3 ± 23.7 
NS 
Mean change in 25(OH)D levels were compared among tertiles of alcohol consumption 
with use of ANOVA. 
 
Smoking  
 There was no significant difference in the one-year change in serum 25(OH)D 
levels between smokers and non-smokers in the treatment group (Table 37), or in the 
placebo group (data not shown). 
Table 37.  One-year change in serum 25(OH)D levels in the treatment group (n = 55) 
among smokers and non-smokers. 
 
Tobacco Use 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
Non-smokers 51 34.8 ± 22.8 
Smokers 4 41.0 ± 31.7 
NS 
Subject groups were compared with use of independent samples t-tests. 
 
Magnitude of Summer Increase in Serum 25(OH)D Levels 
 The seasonal summer increase in serum 25(OH)D levels was positively correlated 
with the one-year change in serum 25(OH)D levels in the treatment group (r = 0.402, p = 
0.002).  Analysis of variance revealed significant increases in the one-year change in 
serum 25(OH)D levels among tertiles of the summer increase in serum levels in the 
treatment group (Table 38a), but not in the placebo group (Table 38b). 
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Table 38a.  One-year change in serum 25(OH)D levels in the treatment group (n = 
55) among tertiles of magnitude of seasonal change. 
Magnitude of Seasonal 
Change 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<29 nmol/L 18 25.4 ± 21.0* 
29 – 52 nmol/L 19 36.3 ± 21.1 
>52 nmol/L 18 44.0 ± 24.7* 
0.051 
Mean changes in 25(OH)D levels were compared among tertiles of seasonal change with 
use of ANOVA. 
*Tukey’s post-hoc analysis: p = 0.041 
 
Table 38b.  One-year change in serum 25(OH)D levels in the placebo group (n = 31) 
among tertiles of magnitude of seasonal change. 
Magnitude of Seasonal 
Change 
 
n 
One-Year Change in Serum 
25(OH)D (nmol/L) 
 
p 
<27 nmol/L 10 4.0 ± 11.6 
27 – 42 nmol/L 11 16.0 ± 11.4 
>42 nmol/L 10 12.1 ± 16.9 
NS 
Mean changes in 25(OH)D levels were compared among tertiles of seasonal change with 
use of ANOVA. 
 
Serum PTH Concentration 
 There was no correlation between February 2006 serum PTH levels and the one-
year change in serum 25(OH)D levels.  As seen in Table 39, February 2006 PTH levels in 
the treatment group were significantly higher in subjects who started out in the lowest 
tertile of baseline serum 25(OH)D levels compared to those in the highest tertile.  
Furthermore, in the subjects who started out in the highest tertile of serum 25(OH)D 
levels, serum PTH levels were significantly lower in February 2006, after the 
supplementation period, than in February 2005.  In the placebo group, the February 2005 
and February 2006 PTH levels were not significantly different among tertiles of baseline 
serum 25(OH)D levels, nor was the one-year change in PTH significantly different 
among tertiles of baseline serum 25(OH)D levels (data not shown).
 Table 39.  February 2006 serum PTH levels and the one-year change in serum PTH levels in the treatment group (n = 55) 
among tertiles of baseline serum 25(OH)D levels from the overall group. 
 
Baseline 
serum 
25(OH)D 
tertiles 
(nmol/L) 
 
 
n 
February 2005 
Mean Serum 
25(OH)D Levels 
(nmol/L) 
February 2006 
Mean Serum 
25(OH)D Levels 
(nmol/L) 
February 2006 
mean serum 
PTH levels 
(pg/mL) 
 
 
p 
February 2005 
mean serum 
PTH levels 
(pg/mL) 
 
 
p 
One-year 
change in 
PTH levels 
p 
A Lowest tertile (< 47 nmol/L) 16 37.4 ± 6.9 71.7 ± 25.7 36.2 ± 10.4* 32.6 ± 7.2 0.183 
B 
Middle tertile 
(47 – 72.4 
nmol/L) 
20 58.9 ± 8.3 97.6 ± 25.7 30.4 ± 11.3 27.6 ± 10.2 0.346 
C Highest tertile (≥ 72.5 nmol/L) 19 88.8 ± 13.9 118.7 ± 25.1 23.5 ± 10.3* 
0.004
29.5 ± 9.1 
NS
0.038 
*Tukey’s post-hoc analysis: February 2006 PTH A,C (p = 0.003) 
 
 107
 Variables Affecting One-year Change in Serum 25(OH)D Levels 
 Linear and logistic regression techniques were used to determine which factors 
predict the one-year change in serum 25(OH)D levels.  Both methods identified the 
treatment group, magnitude of the seasonal summer increase in 25(OH)D levels, estrogen 
dose, and baseline serum 25(OH)D levels to be significant predictors of one-year change.  
The logistic regression results are described below (Table 40a). 
 Logisitic regression analysis was used to predict the probability that the one-year 
increase in serum 25(OH)D levels would be greater than 40 nmol/L.  A backward 
stepwise approach was used for this analysis.  In the backward stepwise model, all of the 
variables start in the model and, in a stepwise fashion, one variable is eliminated at each 
step.  Estrogen dose, summer increase in 25(OH)D levels, baseline 25(OH)D levels, and 
treatment group were the predictors included in the final model.  
 A test of the full model versus a model with constant only was statistically 
significant, X2 (df = 4) = 37.351, p < 0.0005.  Table 40a shows the logistic regression 
coefficient, Wald test, and odds ratio for estrogen dose, summer increase in 25(OH)D 
levels, baseline 25(OH)D levels, and treatment.  Table 40b shows the logistic regression 
coefficient and Wald test for the variables eliminated from the final model. 
 The model was able to correctly classify 91% of the subjects with a change in 
25(OH)D less than 40 nmol/L and 65% of those with a change in levels greater than 40 
nmol/L, with an overall success rate of 83% (Table 40c).  Nagelkerke R2 was 0.509 and -
2 Log likelihood was 65.847.  Fifty-one percent of the variation in one-year change can 
be explained by the logistic regression model.   
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  A Hosmer and Lemeshow Test was performed, X2 (df = 8) = 9.572, p < 0.296.  
Therefore we did not reject the null hypothesis that the observed and predicted values are 
the same and concluded that the model fits the data reasonably well.   
Table 40a.  Logistic regression predicting the one-year change in serum 25(OH)D 
levels from estrogen dose, summer serum 25(OH)D increase, baseline 25(OH)D 
levels, and treatment category. 
Variable Beta S.E. Wald p Odds Ratio 
Estrogen dose 0.073 0.028 6.581 0.010 1.075 
Summer increase 0.045 0.014 10.227 0.001 1.046 
Baseline 25(OH)D -0.028 0.015 3.346 0.067 0.973 
Treatment 3.338 0.928 12.948 <0.0005 28.170 
Constant -8.394 2.185 14.755 <0.0005 0.000 
 
Table 40b.  Variables eliminated from the backward stepwise logistic regression 
model predicting one-year change in serum 25(OH)D levels. 
Step Variable Eliminated Beta coefficient Wald Coefficient p 
1 Mean calcium intake 0.000 0.024 0.877 
2 Skin type -0.087 0.037 0.848 
3 Mean body fat -0.016 0.071 0.789 
4 Change in serum calcium 0.374 0.136 0.713 
5 Smoking 1.350 0.202 0.653 
6 Change in vitamin D intake 0.002 0.224 0.636 
7 Alcohol -0.093 0.431 0.511 
8 Change in calcium:creatinine 2.224 0.693 0.405 
9 Days with a cold in 2006 0.051 0.859 0.354 
10 Change in sun exposure 0.034 1.139 0.286 
11 Tanning bed use 2005-2006 1.450 2.374 0.123 
 
Table 40c.  Classification table. 
Predicted  
<40 nmol/L ≥40 nmol/L 
<40 nmol/L 52 5 Observed 
≥40 nmol/L 9 17 
Sensitivity = 52/57 = 91% 
Specificity = 17/26 = 65% 
Positive Predictive Value = 52/61 = 85% 
Negative Predictive Value = 17/22 = 77% 
Total Correct = 69/83 = 83% 
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 One-Year Change in Serum PTH Levels 
 Serum PTH followed a seasonal pattern, increasing during winter and decreasing 
during summer.  There were no significant differences in serum PTH levels between the 
treatment and placebo groups in February 2005, September 2005, or February 2006.  
Mean serum PTH levels did not change significantly from February 2005 to February 
2006 in the placebo group or in the group receiving 800 IU vitamin D3 (Table 41); 
however, they did change significantly in the treatment group who were in the highest 
tertile of baseline serum 25(OH)D levels (Table 39).  The one-year change in serum PTH 
levels was not significantly different among tertiles of one-year change in serum 
25(OH)D levels (Table 42). 
Table 41.  Change in serum PTH levels from February 2005 to February 2006. 
  
n 
February 2005 
PTH (pg/mL) 
September 2005  
PTH (pg/mL) 
February 
2006 
PTH (pg/mL) 
 
p 
Treatment group 55 29.7 ± 9.1 28.4 ± 14.5 29.7 ± 11.7 NS
Placebo group 31 32.9 ± 14.4 30.3 ± 17.4 32.3 ± 15.4 NS
Independent samples t-tests revealed no significant differences between treatment and 
placebo groups (p > 0.05). 
Independent samples t-tests revealed no significant differences between PTH levels in 
February 2005 and February 2006 (p > 0.05). 
 
Table 42.  One-year change in serum PTH levels in the whole group (n = 86) among 
tertiles of one-year change in serum 25(OH)D. 
Mean One-Year Change in Serum 
25(OH)D (nmol/L) 
 
n 
Mean One-Year Change in Serum 
PTH (pg/mL) 
 
p 
Overall (26.5 ± 24.1) 86 -0.22 ± 13.0 - 
 
Lowest tertile (<15 nmol/L) 28 3.0 ± 11.7 
Middle tertile (15 – 38.74 nmol/L) 29 -2.4 ± 13.7 
Highest tertile (≥38.75 nmol/L) 29 -1.1 ± 13.2 
NS
Mean change in PTH levels were compared among tertiles of change in 25(OH)D levels 
with use of ANOVA. 
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 Summary of Serum 25(OH)D Levels Over 12 Months 
 Serum 25(OH)D levels fluctuated seasonally in the placebo group and the winter 
decrease was attenuated in the treatment group (Figure 6). 
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Figure 6.  One-year fluctuation in serum 25(OH)D levels in the treatment and 
placebo groups. 
 
 Of the 55 subjects receiving daily 800 IU vitamin D3 supplementation, 80% had 
optimal serum 25(OH)D levels at the end of winter (Figure 7).  As seen in Table 42, 
subjects who achieved optimal serum 25(OH)D levels at the end of winter had 
significantly higher baseline serum 25(OH)D levels and lower percent body fat.  In 
addition, the subjects who used oral contraceptives appeared to be more likely to have 
optimal serum 25(OH)D levels (Table 43).  However, a Pearson Chi-Square revealed this 
difference was not significant. 
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 Table 43.  Characteristics of subjects in the treatment group who achieved optimal 
serum 25(OH)D levels (≥75 nmol/L) in February 2006. 
 February 2006 Serum 
25(OH)D <75 nmol/L 
(Suboptimal) 
February 2006 Serum 
25(OH)D ≥75 nmol/L 
(Optimal) 
 
 
p 
 (n = 11) (n = 44)  
Baseline 25(OH)D 
(nmol/L) 40.9 ± 16.4 67.4 ± 22.8 0.001
Percent Body Fat 35.4 ± 7.4 29.9 ± 7.1 0.028
Oral Contraceptive 
Use (%) 27 57 0.08 
Subject groups were compared with use of independent samples t-tests. 
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Figure 7.  Changes in the prevalence of vitamin D deficiency and insufficiency over 
one-year, and in response to 800 IU vitamin D3 supplementation. 
 
Summary of Association Between Serum 25(OH)D Levels  
and BMI or Body Composition 
There was a significant inverse correlation between serum 25(OH)D levels and BMI and 
percent body fat in February 2005, September 2005, and February 2006 (in both 
treatment and placebo groups).  However, there was no significant correlation between 
response to supplementation and BMI or body fat, nor was there a correlation between 
the seasonal increase in 25(OH)D levels during summer and BMI or body fat.  Percent 
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 body fat was a significant predictor of baseline serum 25(OH)D levels, but was not a 
significant predictor of the one-year change in serum 25(OH)D levels after treatment with 
800 IU vitamin D3. 
Summary of Association Between Serum 25(OH)D Levels  
and Hormonal Contraceptives 
There was a significant positive association between serum 25(OH)D levels and 
exogenous estrogen dose at all time points.  Hormonal contraceptive use was a strong 
predictor of both baseline serum 25(OH)D levels and of the one-year change in serum 
25(OH)D levels. 
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 Chapter 5 
DISCUSSION 
 The purpose of this research was to evaluate the serum 25(OH)D response to 
supplementation with 800 IU vitamin D3 during winter in premenopausal women living 
in Maine.  The goals were to achieve optimal serum 25(OH)D levels in the supplemented 
group at the end of winter, and to examine the effects of body composition and oral 
contraceptive use on baseline serum 25(OH)D levels and response to supplementation. 
 One hundred twelve women aged 19 to 35 years were recruited to participate in 
the study.  All subjects received placebo from March 2005 until September 2005, at 
which time they were randomized to receive either 800 IU vitamin D3, or matching 
placebo until March 2006.  Blood samples were collected from each subject for the 
analysis of serum 25(OH)D, parathyroid hormone, and calcium levels in March 2005, 
September 2005, and March 2006.  Every three months from March 2005 until March 
2006, the subjects picked up a new supply of supplements and completed a brief 
questionnaire about other factors that affect serum 25(OH)D levels, such as sun exposure, 
medical conditions, medications, and skin type.  In addition, they completed a three-day 
food record during the winter to assess dietary vitamin D intake.  Body fat was measured 
at the beginning and end of the study using a dual energy x-ray absorptiometry (DXA) 
scan. 
 There were high rates of vitamin D insufficiency and deficiency among the 
subjects in February 2005.  Serum 25(OH)D levels increased greatly over the summer 
and there were no cases of vitamin D deficiency at the end of summer.  Eighty percent of 
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 the treatment group had optimal serum 25(OH)D levels at the end of February 2006, after 
receiving 800 IU vitamin D3 daily during winter. 
Vitamin D Status in Maine 
 Vitamin D insufficiency is common in Maine.  At the end of winter, 29% of 
subjects in this study of white premenopausal women had optimal serum 25(OH)D levels 
(≥75 nmol/L).  In Maine, due to the tilt of the earth, there is insufficient ultraviolet-B 
radiation from November until March for cutaneous vitamin D synthesis5 resulting in 
high levels of vitamin D insufficiency at the end of winter.  The vitamin D synthesized 
during the summer, and the vitamin D consumed from the diet are not able to sustain 
optimal serum 25(OH)D levels through winter.  If vitamin D insufficiency is common in 
this group of active young women, it is likely indicative of vitamin D insufficiency in all 
age groups in Maine. 
 The rates of deficiency in the current study were similar to those seen in other 
studies in the United States.8,121  Analysis of NHANES III data found 40% of 
premenopausal women (20 to 39 years) had levels less than 50 nmol/L during winter in 
the southern US (latitude range 25o to 41oN; median 32oN).121  In the southern US, at 
latitudes below 35oN, there is sufficient sun for cutaneous synthesis of vitamin D year-
round,121 and, therefore, a lower prevalence of vitamin D deficiency would be expected at 
the end of the winter.  However, the higher prevalence of vitamin D deficiency seen in 
the NHANES III data is most likely due to the lower serum 25(OH)D levels present in 
the non-Hispanic Black and Mexican American women who made up 38% and 47% of 
the sample, respectively.121  In the 12 to 29 year old female age group in the south, 15% 
of non-Hispanic white females had serum 25(OH)D levels less than 50 nmol/L during 
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 winter compared to 70% of non-Hispanic black, and 41% of Mexican American 
females.121  Thirty-six percent of 18 to 29 year old healthy men and women in Boston 
(42oN) had serum 25(OH)D levels less than 50 nmol/L in March.8 
 Few other studies have examined optimal serum 25(OH)D levels at the end of 
summer.  In the current study, there was a large increase in serum 25(OH)D levels during 
the summer due to increased cutaneous synthesis of vitamin D.  Rates of vitamin D 
insufficiency were much lower at the end of the summer, and there was no occurrence of 
vitamin D deficiency (25(OH)D <50 nmol/L).  Other studies, on the other hand, showed 
higher rates of vitamin D deficiency during summer in the US than the current study.4,121  
NHANES III data showed that, in the northern US, 18% of 20 to 39 year old women had 
serum 25(OH)D levels less than 50 nmol/L, and only 70% of women in the north had 
serum 25(OH)D levels greater than 62.5 nmol/L during summer.121  The higher 
prevalence of vitamin D deficiency seen in the NHANES data is again most likely due to 
the lower levels of serum 25(OH)D seen in non-Hispanic blacks and Mexican Americans.  
People with dark skin experience a smaller seasonal summer increase in serum 25(OH)D 
levels than do people with light skin.129,141  In addition, the NHANES data includes all 
serum 25(OH)D levels measured during summer (between April and October) rather than 
at the end of the summer.  Therefore, it includes many serum levels that had not yet 
peaked, as well as some that had peaked and started to decrease due to declining sun 
exposure.  However, 17% of white adolescent girls in Maine had serum 25(OH)D levels 
below 50 nmol/L at the end of summer.4  Unlike the NHANES data, this higher incidence 
of deficiency cannot be explained by race or time of measurement, but may be due to the 
use of a different assay. 
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  In areas far from the equator, such as Maine, serum 25(OH)D levels increase 
during summer and decrease during winter when there is insufficient sunlight for 
cutaneous vitamin D synthesis.  Over time, the suboptimal serum 25(OH)D levels seen at 
the end of winter in many people, and even year-round in some people, may result in 
lower bone mineral densities, increased risk of osteoporosis and fractures, increased risk 
of autoimmune disease, increased risk of certain cancers, and decreased immune 
function.30  During winter, individuals living in Maine and other sun-deprived areas need 
supplemental vitamin D to maintain optimal serum 25(OH)D levels. 
Estrogen 
 Serum 25(OH)D levels are significantly higher in women who use hormonal 
contraceptives.139,152,153  In addition, although there was no correlation between 
exogenous estrogen dose and response to supplementation, logistic regression revealed 
that exogenous estrogen appeared to be one of the forces causing a better response to oral 
vitamin D supplementation in premenopausal women, independent of estrogen’s effects 
on baseline serum 25(OH)D levels.   
 The elevation in serum 25(OH)D levels due to oral contraceptive use in the 
current study was similar to that seen in other studies.139,152,153  At the end of winter, 
serum 25(OH)D levels were 20.3 nmol/L higher in hormonal contraceptive users.  Both 
Nesby-O’Dell and colleagues,139 and Harris and Dawson-Hughes153 saw similar 
differences of 24.8 nmol/L and 24.0 nmol/L, respectively, in white women at the end of 
winter.  Sowers and colleagues152 saw a 15.0 nmol/L difference in summertime serum 
25(OH)D levels between oral contraceptive users and non-users, which is similar to the 
21 nmol/L difference in the current study.   
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  The current study was the only study to look at the effect of the dose of estrogen 
on serum 25(OH)D levels.  Serum 25(OH)D levels increased as the estrogen dose within 
the contraceptives increased above 15 μg.  The lack of an effect at doses of 15 μg could 
be because 15 μg estradiol was too low to cause an increase in 25(OH)D levels, or it 
could be because the 15 μg contraceptives were not taken orally, but are in the form of a 
skin patch, or vaginal ring.   
 No other studies have examined the effect of estrogen on response to 
supplementation.  The two theories offering explanations for the increased levels of 
serum 25(OH)D levels in subjects receiving estrogen can also be used as possible 
explanations for the improved response to supplementation.  If estrogen increases 
hydroxylation activity in the liver, a higher percentage of vitamin D intake would be 
hydroxylated,154,155 increasing serum 25(OH)D levels more in women receiving 
exogenous estrogen.  On the other hand, if estrogen increases serum 25(OH)D levels by 
increasing vitamin D-binding protein concentration, then more DBP is present in 
circulation, and more 25(OH)D could be bound to DBP in women receiving estrogen, 
resulting in more serum 25(OH)D being measured.25  Similarly, increased DBP could 
result in more vitamin D3 being picked up in circulation and transported to the liver for 
hydroxylation, causing an increase in serum 25(OH)D levels. 
 It is not known whether there is a physiological benefit to the increased serum 
25(OH)D levels in oral contraceptive users, or if oral contraceptive use simply raises the 
measurable 25(OH)D.  PTH is the only measure available in this study to evaluate the 
functional effect of serum 25(OH)D levels, and there was no significant difference in 
mean PTH levels between oral contraceptive users and non-users at baseline (Table 17c) 
 118
 despite significantly higher serum 25(OH) levels.  However, other researchers suggest 
that oral contraceptives may impact PTH levels independently of vitamin D,234 so PTH is 
of limited use in examining the effect of oral contraceptive use on vitamin D status.  
Furthermore, due to the large amount of individual variation in serum PTH levels, a 
larger number of subjects would be needed to use PTH to evaluate the functional effect of 
serum 25(OH)D levels.  Further research is needed to determine whether oral 
contraceptive use provides a beneficial effect on vitamin D status.   
 Oral contraceptive use must be considered in any research involving 
premenopausal women and adolescents looking at a change in serum 25(OH)D levels, 
and all contraceptives do not affect vitamin D status equally. 
Body Composition 
 Increased body fat, BMI, and weight were associated with lower serum 25(OH)D 
levels in the current study.  However, as also reported by Arunabh,129 body fat percentage 
had the strongest correlation with serum 25(OH)D levels, indicating that it is adiposity, 
and not simply body mass, that affects serum 25(OH)D levels.  Therefore, body fat was 
the variable included in the regression analyses and was found to be a significant 
predictor of baseline serum 25(OH)D levels, while controlling for other variables known 
to affect serum 25(OH)D levels such as, season, vitamin D intake, exogenous estrogen, 
and age.  The change in serum 25(OH)D levels due to supplementation, however, was not 
affected by body fat content. 
 The impact on baseline serum 25(OH)D levels was greatest in those with the 
highest tertile of body fat (>33% body fat).  This difference in serum 25(OH)D levels 
based on body fat is consistent with the findings of Arunabh and colleagues,129 who 
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 found significantly lower serum 25(OH)D levels in the highest quartile (>44% body fat) 
compared with the lowest quartile (<31% body fat) of body fat in women, and with 
Nesby-O’Dell and colleagues139 who found significantly lower serum 25(OH)D levels in 
white women with BMI greater than 30 compared to those with normal BMI (18.5 to 
24.9).   
 As vitamin D is transported by DBP to the liver for hydroxylation, some is 
deposited in adipose tissue for storage along the way.146  Obese people have larger 
amounts of adipose tissue, and therefore pick up more vitamin D from circulation, 
resulting in lower serum 25(OH)D levels.146   
 The change in serum 25(OH)D levels due to supplementation was not affected by 
body fat content.  This lack of relationship is consistent with the findings of Wortsman 
and colleagues146 who found that obese individuals experienced an attenuated increase in 
vitamin D3 upon exposure to sunlight compared to non-obese peers, but the response to 
supplementation with oral vitamin D2 was not different between the two groups.  
Likewise, Brazilian nursing home residents responded similarly to a weekly dose of 7000 
IU vitamin D3 regardless of body fat category.200  In contrast, Barger-Lux and 
colleagues145 saw BMI, but not body weight, contribute significantly to the variance in 
25(OH)D response to supplementation with vitamin D3.  It is not clear why BMI 
influenced response to supplementation in the study by Barger-Lux and colleagues, but 
not in others.  Barger-Lux and colleagues145 used much larger doses of vitamin D3 (1000, 
10,000, 50,000 IU), so more of it may have been transferred from the chylomicrons to 
vitamin D-binding protein in circulation,31 some of which is then deposited in adipose 
tissue for storage.22-24  
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  Body composition affects baseline serum 25(OH)D levels and, therefore, 
indirectly affects response to supplementation.  Because obese women have lower 
baseline serum 25(OH)D levels than non-obese women, obese women require a higher 
dose of vitamin D3 to optimize their vitamin D status.  However, overweight and obese 
individuals do not need a higher dose of vitamin D3 to produce the same incremental 
serum 25(OH)D response to supplementation as normal weight individuals.   
Sun Exposure 
 Cutaneous synthesis of vitamin D following exposure to UVB radiation provides 
80% to 90% of the vitamin D input for people who spend time in sunlight.3  The increase 
in serum 25(OH)D levels provided by one MED (minimal erythemal dose) of sunlight 
(the amount that causes a slight pinkness to the skin) while wearing a bathing suit is 
equivalent to the consumption of 10,000 to 25,000 IU oral vitamin D2.115  However, the 
exact amount of vitamin D produced in response to sunlight varies by age and skin 
type.116  Comparatively, consumption of eight ounces of fortified milk provides only 
about 100 IU vitamin D, and three ounces of salmon provides 245 to 988 IU vitamin 
D3.235   
 Summer sun exposure, as measured in this study, was not a significant predictor 
of serum 25(OH)D levels, or of the summer increase in serum 25(OH)D levels.  Sun 
exposure not being predictive of serum 25(OH)D levels is not likely due to a lack of 
effect, but is more likely a result of the difficulty in estimating sun exposure.  Sun 
exposure and, therefore, cutaneous synthesis of vitamin D, vary on a daily basis 
depending on the weather and cloud cover, the type of clothing worn, the amount of 
sunscreen used and frequency of application of sunscreen, and the length of time spent 
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 outside, which makes cutaneous vitamin D synthesis a very difficult variable to quantify 
with validity.  To truly ascertain the impact of sun exposure on serum 25(OH)D levels, a 
valid and reliable measurement tool must be developed.  To further complicate matters, 
however, cutaneous vitamin D production is highly variable between individuals, with 
some individuals having low serum 25(OH)D levels despite abundant sun exposure.117   
Alcohol Consumption 
 The current study, like others169-171 showed higher levels of serum 25(OH)D 
levels with consumption of moderate amounts of alcohol, compared to no alcohol 
consumption.  The likely mechanism for alcohol’s effect on serum 25(OH)D levels is due 
to an increase in estrogen levels with alcohol consumption.167  It is not clear whether this 
increase in serum 25(OH)D levels due to estrogen provides any physiological benefit, or 
simply increases the amount of measurable 25(OH)D. 
Number of Days with a Cold 
 The number of days with a cold was used as a rough indicator of immune status.  
The subjects were simply asked how many times they had a cold in the previous three 
months, and the approximate number of days the cold lasted (see Lifestyle 
Questionnaires in Appendix B).  Surprisingly, this simple retrospective measure was a 
significant variable in the logistic regression looking at determinants of baseline serum 
25(OH)D levels.  Women with higher serum 25(OH)D levels may have improved 
immunity over women with lower 25(OH)D levels, which may be associated with fewer 
days with a cold.  Researchers believe 1,25(OH)2D stimulates the innate immune 
response.83-85  It is possible that raising serum 25(OH)D levels during winter provides 
more substrate for production of 1,25(OH)2D, which may protect against colds and the 
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 flu.90  Further research in this area would be beneficial, especially to children, the elderly, 
and the immunosuppressed during cold and flu season. 
Tanning Bed Use 
 Although serum 25(OH)D levels were much higher in the 11 subjects who used a 
tanning bed during winter than in subjects who did not tan, this difference was not 
significant due to the small number of tanners in this study.  At the end of winter in 
Boston, Tangpricha and colleagues142 saw serum 25(OH)D levels 90% higher in subjects 
who used tanning beds in the previous six months compared with adults who did not tan.  
Artificial UVB radiation promotes cutaneous vitamin D synthesis and may provide an 
alternative to oral supplementation for increasing serum 25(OH)D levels during winter.  
However, due to the increased risk of melanoma and squamous cell carcinoma in tanning 
bed users,236 artificial UVB radiation for tanning is not an acceptable public health 
approach to improving vitamin D status. 
Seasonal Increase in Serum 25(OH)D Levels 
 The 66% summer increase in serum 25(OH)D levels was much greater than that 
seen in other studies.4,6,215  Serum levels in adolescents living in the Bangor area (44oN) 
increased 14 nmol/L or 28% during the summer.4  In 24 to 70 year old women living in 
London (51oN), serum 25(OH)D levels were 36% higher in summer than in winter.215  In 
white 18 to 35 year old women living in Toronto (43oN), serum 25(OH)D levels 
measured in summer were 31% higher than in winter.6   
 There are many factors that affect cutaneous synthesis of vitamin D, and 
therefore, affect the seasonal summer increase in serum 25(OH)D levels.  London has a 
reputation for cloudiness and more air pollution than Maine, which could explain the 
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 lower seasonal increase in serum 25(OH)D levels seen in London.  In all of the studies, 
cloud cover and temperature could affect the amount of clothing worn, which affects 
vitamin D synthesis.  The blood samples in the current study were specifically drawn 
when serum 25(OH)D levels are at their lowest (end of February) and highest 
(September),122 whereas in the Toronto and London studies, blood samples were 
measured during winter and during summer, so not all levels had reached their nadir and 
peak.  It is also possible that the subjects in the current study exhibited more sun-seeking 
behavior than those in the other studies. 
 Skin type was the only variable determined to predict the seasonal change in 
serum 25(OH)D levels.  As expected, subjects with darker skin experienced a smaller rise 
in serum 25(OH)D levels than did subjects with lighter skin, which is consistent with the 
findings of other researchers.5,138  Melanin acts as a natural sunscreen, so individuals with 
darker skin require more ultraviolet exposure to effect the same increase in serum 
25(OH)D levels as individuals with lighter skin.138  Using artificial UVB radiation, 
Armas and colleagues116 found that together, skin type and the UVB dose explained 80% 
of the variation in the serum 25(OH)D response to UVB radiation.  Age, gender, BMI, 
body surface area, and baseline 25(OH)D levels did not significantly contribute to the 
variation in serum 25(OH)D response.   
 The seasonal summer 2005 increase in serum 25(OH)D levels was unexpectedly a 
significant predictor of the one-year change (February 2005 to February 2006) in serum 
25(OH)D levels.  Since serum 25(OH)D levels increase every summer, and individual 
sun exposure behavior is presumed to be consistent from year to year, the affect on 
February serum 25(OH)D levels was expected to be similar from year to year, and, 
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 therefore, was not expected to affect the overall one-year change in serum 25(OH)D 
levels.  Indeed, in a three-year study by Sullivan and colleagues,4 the summer serum 
25(OH)D levels increased to approximately the same levels every September and 
decreased to approximately the same levels every March.  The difference found in the 
current study suggests greater cutaneous synthesis in summer 2005 than in summer 2004, 
resulting in higher serum 25(OH)D values in February 2006. The one-year increase in 
serum 25(OH)D levels in the placebo group also suggests a bigger influence of summer 
on February levels during the second February.  Analysis of climatological data from the 
National Oceanic and Atmospheric Administration revealed that summer 2004 was 
cooler than summer 2005,237,238 so the subjects may have spent less time outside, or may 
have worn more clothing while outside in 2004 than in summer 2005, both of which 
would decrease vitamin D production.  Temperatures in summer 2004 (May through 
August) were 6.4oF below normal compared to 1.1oF below normal in summer 
2005.237,238  During May through August 2004, Bangor had 236 cooling degree days237 
compared to 405 cooling degree days during the same period in summer 2005.238  One 
cooling degree day is accumulated for each whole degree that the daily mean temperature 
is above 65oF.237 
 Researchers cannot assume that the summer increase in serum 25(OH)D levels 
will have a consistent impact on serum 25(OH)D levels the following February from year 
to year.  Therefore, it is important to control for this change with a placebo group when 
looking at the one-year change in serum 25(OH)D levels. 
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 Baseline Serum 25(OH)D Levels 
 Although there was no correlation between baseline serum 25(OH)D levels and 
response to supplementation, logistic regression analysis identified baseline serum 
25(OH)D levels as having an independent effect on response to supplementation.  
Subjects with lower baseline serum 25(OH)D levels had a stronger serum 25(OH)D 
response to supplementation, which is consistent with other research studies.197-200   
The hydroxylation of vitamin D3 to 25(OH)D is likely a saturable process,145 causing a 
weaker response to supplementation in individuals with higher baseline serum 25(OH)D 
levels. 
 Rather than adjusting vitamin D supplementation dosages depending on baseline 
serum 25(OH)D, a single dose could be used for everyone since people with lower 
baseline serum 25(OH)D levels have a greater response to supplementation, and people 
with higher baseline levels have a weaker response.  Because vitamin D toxicity has only 
occurred after exceptionally high intakes of vitamin D, one dose can be used safely for 
everyone. 
Magnitude of Response to Supplementation 
 On average, serum 25(OH)D levels increased 1.1 nmol/L for every microgram of 
supplemental vitamin D3 input, which is within the range (0.59 to 2.1 nmol/L) found by 
other researchers.145,198,209,210,219  In fact, Barger-Lux and colleagues145 estimated that in a 
70 kg person (the mean weight of subjects in the current study), serum 25(OH)D levels 
would increase by 22 nmol/L on 800 IU supplemental vitamin D3 daily, which would be 
a 1.1 nmol/L increase for each mcg of input. 
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  The current study confirms the findings of other researchers that serum 25(OH)D 
levels increase approximately 1.0 nmol/L for every microgram of oral vitamin D3 input.  
However, these numbers (0.7, 1.0, 1,1, and so on) are just average responses to one 
microgram of vitamin D3.  Some individuals may have a stronger or lesser response 
depending on baseline vitamin D status, and estrogen use. 
Adequacy of Dose 
 Eighty percent of the premenopausal women receiving 800 IU vitamin D3 daily 
achieved optimal vitamin D status at the end of the second winter, compared to 29% of 
the subjects at baseline.  The women for whom 800 IU was inadequate had lower mean 
baseline serum 25(OH)D levels, had a higher mean body fat content, and were less likely 
to be taking oral contraceptives; 73% of women with suboptimal serum 25(OH)D levels 
after supplementation were not on oral contraceptives.  Thirty percent of the women 
receiving 800 IU vitamin D3 daily who were not using oral contraceptives had suboptimal 
serum 25(OH)D levels after five months of supplementation.   
 An adequate dose of vitamin D3 would increase serum 25(OH)D levels 
sufficiently to suppress PTH secretion during winter.  Other researchers have seen a 
suppression of PTH secretion with serum 25(OH)D levels of at least 75 nmol/L.13  As 
seen in Table 39, in the treatment group, the one-year change (decrease) in serum PTH 
levels was significant in the highest tertile of baseline serum 25(OH)D levels.  The 
February 2006 serum PTH levels were also significantly lower in those with the highest 
baseline serum 25(OH)D levels compared to those in the lowest serum 25(OH)D tertile.  
It appears that 800 IU vitamin D3 increased serum 25(OH)D levels in the highest tertile 
of baseline serum 25(OH)D levels enough to result in significant suppression of PTH. 
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  The women in the treatment group were consuming approximately 1000 IU 
vitamin D daily from supplementation and diet.  The current Adequate Intake (200 IU) 
set for this age group by the Food and Nutrition Board21 is only one-fifth of the amount 
consumed in this study.  An AI is set when the Board feels there is not enough evidence 
available to establish a Recommended Daily Allowance (RDA).  By definition, the RDA 
is the average daily intake required to meet the needs of 97% to 98% of healthy 
individuals in a specific age and gender group.21   
 In the current study, 97.5% of subjects had baseline serum 25(OH)D levels 
greater than 28.0 nmol/L.  Therefore, in order to ensure that 97% to 98% of subjects have 
optimal serum 25(OH)D levels of at least 75 nmol/L, the individuals with baseline serum 
25(OH)D levels as low as 28.0 nmol/L would need to be optimized.  Evidence suggests a 
linear relationship between vitamin D3 intake and the increase in serum 25(OH)D 
levels.209  Therefore, based on the 1.1 nmol/L increase in serum 25(OH)D levels per 
microgram of vitamin D3 input seen in the current study, approximately 1700 IU vitamin 
D3 would be required daily to optimize the vitamin D status of 97.5% of the population.  
Doing the same calculation, but using a 0.7 nmol/L increase per microgram as 
determined by Heaney and colleagues,209 2700 IU would be required for 97.5% of the 
population to achieve serum 25(OH)D levels above 75 nmol/L.  Similarly, using 
NHANES III data and a 0.7 nmol/L increase per microgram of vitamin D3 input, 
Heaney134 determined that approximately 2600 IU vitamin D3 would be needed to meet 
the needs of 97.5% of a population of 60 to 79 year old white women.  There are many 
factors that affect baseline serum 25(OH)D levels and response to oral supplementation, 
therefore 0.7 and 1.1 nmol/L per microgram of vitamin D3 intake are just estimates.  
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 Nevertheless, many studies145,198,209,210,219 have found values in the same range and 
Heaney believes these estimations are very close to the amount needed.134 
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 Chapter 6 
CONCLUSIONS 
 Researchers speculate that approximately 800 to 1000 IU vitamin D3 is required 
to achieve optimal serum 25(OH)D levels of at least 75 nmol/L in the absence of 
sunlight.1  However, further research is needed to determine how much vitamin D3 is 
required to optimize serum 25(OH)D levels for different age groups. 
 The purpose of this study was to measure the serum 25(OH)D response to daily 
supplementation with 800 IU vitamin D3 during winter in premenopausal women living 
in Maine, and to examine the effects of body composition and hormonal contraceptive 
use on baseline serum 25(OH)D levels and on the response to supplementation.  From the 
sample of white premenopausal women in the current study, many conclusions can be 
extrapolated into the entire population.   
 There is a high rate of vitamin D insufficiency in the northeastern United States 
and serum 25(OH)D levels fluctuate seasonally.  In February 2005, less than one-third of 
young women in Maine had optimal serum 25(OH)D levels (≥75 nmol/L).  Serum 
25(OH)D concentrations increased 66% during the summer, and 77% of young women 
had optimal levels at the end of the summer.  For 80% of this relatively homogeneous 
sample, 800 IU supplemental vitamin D3 daily was sufficient to achieve serum 25(OH)D 
levels of at least 75 nmol/L at the end of winter.   
 Exogenous estrogen from hormonal contraceptive use increases serum 25(OH)D 
levels, and, in the current study, also increased the serum 25(OH)D response to 
supplementation.  Further research is needed to determine whether or not these higher 
serum 25(OH)D levels are merely a result of an increase in the amount of 25(OH)D that 
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 is measured or actually represent a functional improvement in vitamin D status.  Percent 
body fat, on the other hand, is negatively associated with serum 25(OH)D levels.  
Women with higher percent body fat, have lower serum 25(OH)D levels.  Body fat did 
not, however, affect serum 25(OH)D response to supplementation in the current study.  
Women who started with lower serum 25(OH)D levels had a greater increase in serum 
25(OH)D levels during supplementation than women who started with higher serum 
25(OH)D levels. 
 Because of the large variation in vitamin D requirements due to factors such as 
body composition, oral contraceptive use, and initial serum 25(OH)D levels, as well as 
the many factors affecting vitamin D synthesis, including skin color, sun exposure, and 
geographic location, it is very difficult to develop a strategy to optimize vitamin D status 
for everyone.  For the health of the nation, the Food and Nutrition Board must review the 
abundant research that has been conducted since the current Adequate Intake for vitamin 
D was established in 1997 and revise their recommendations.2  Ideally, everyone should 
have their serum 25(OH)D levels measured at the end of winter to determine 
supplementation needs.  However, screening everyone for vitamin D deficiency would be 
expensive.  Therefore, people who do not receive adequate sunlight, which includes 
everyone who resides at latitudes above 35oN, may need 800 IU vitamin D3 or more daily 
during winter.  Given the low risk of toxicity, vitamin D supplementation 
recommendations should be high enough to optimize serum 25(OH)D levels in the 
population regardless of body composition, baseline serum 25(OH)D levels, or skin 
color.   
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  In the current study, 800 IU vitamin D3 was only adequate to optimize vitamin D 
status in 80% of this sample of white, young adult women.  Therefore, supplementation 
with 800 IU vitamin D3 is not likely to optimize vitamin D status in the population as a 
whole.  Further research is needed to determine the dose of vitamin D3 required to 
optimize vitamin D status in the US population as a whole. 
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 VITAMIN D CONTENT OF FOODS 
 
Table A1.  Vitamin D content of fish. 
Food 
International Units (IU)  
Per Serving  
(mean ± SEM when available) 
Cod liver oil, 1 Tablespoon 1,360a 
Salmon, wild-caught, 3½ ounces 988 ± 524b 
Salmon, farm raised, raw, 3½ ounces 240 ± 108b 
Salmon, farm raised, baked, 3½ ounces 240b 
Salmon, farm raised, fried in vegetable oil, 3½ ounces 123b 
Blue fish, 3½ ounces 280 ± 68b 
Cod, 3½ ounces 104 ± 24b 
Trout, farm raised, 3½ ounces 388 ± 212b 
Tuna, Ahi-yt, 3½ ounces 404 ± 440b 
Mackerel, cooked, 3½ ounces 24b – 345a 
Tuna fish, canned in oil, 3 ounces 200a 
Sardines, canned in oil, drained, 1¾ ounces 250a 
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 Table A2.  Vitamin D content of foods fortified with vitamin D. 
Food International Units (IU)  
Per Serving  
MILK  
Milk, nonfat, reduced fat, and whole fat, vitamin D 
fortified, 1 cup 
100a 
Soy Milk Silk® regular, lowfat and fat free, 8 oz 120c 
Soy Milk, 8th Continent®, regular, lowfat, and fat free, 
8 oz 
100c 
  
YOGURT  
Colombo® Classic® and Light Yogurt, 6 oz 0c 
Colombo® Lowfat Yogurt, 8 oz 100c 
Dannon® Light & Fit®, 6 oz 60 – 80c 
Dannon® Activia®, 4 oz 0c 
Dannon®, Fruit on the Bottom and Fruit Blends, 6 oz 0c 
Dannon®, Danimals®, 4 oz 60c 
Stonyfield Farm®, Organic Whole Milk and Lowfat, 
and All Natural Fat Free, 6 oz 
0c 
Stonyfield Farm®, 2-a-Day Yogurt, 6 oz 80 
Yoplait® Original Fruit Flavors, Custard Style, and 
Light Flavors, 6 oz 
80c 
Yoplait® Trix® Yogurt, 4 oz 40c 
Yoplait® Whips®, Fruit Flavors 4 oz 40c 
Yoplait® Go-Gurt®, 2.25 oz tube 24c 
  
CEREAL  
General Mills: Cheerios®, Chex®, Wheaties®, Total®, 
Trix®, Lucky Charms®, Kix®, 1 oz 
40c 
Kellogg’s Special K®, Frosted Mini Wheats®, 1 oz 0c 
Kellogg’s Rice Krispies®, All Bran®, Corn Flakes®, 
Froot Loops®, Corn Pops®, Frosted Flakes®, Smart 
Start®, 1 oz 
40c 
Quaker Cap’n Crunch®, Life®, Oatmeal Squares®, 1 oz 0c 
Post Honey Bunches of Oats®, Golden Crisp®, Grape 
Nuts®, 1 oz 
40c 
Post Shredded Wheat®, 1 oz 0c 
Kashi Heart to Heart®, Go Lean®, Go Lean Crunch®, 1 
oz 
0c 
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 Food International Units (IU)  
Per Serving  
(mean ± SEM when available) 
MARGARINE  
Margarine, fortified, 1 tablespoon 60a 
Land O’Lakes®, 1 Tbsp 0c 
Fleischman’s® Original (stick), 1 Tbsp 60c 
Fleischman’s® made with olive oil, 1 Tbsp 0c 
Promise® Regular, Light, 1 Tbsp 60c 
Smart Balance®, 1 Tbsp 60c 
Smart Balance®, Light, 1 Tbsp 0c 
Shedd’s Spread® Country Crock® with calcium and 
vitamins, 1 Tbsp 
60c 
  
ORANGE JUICE  
Orange Juice, fortified, 8 oz 
(such as, Tropicana Pure Premium® Healthy Kids, 
Tropicana Pure Premium® Calcium + Vitamin D, 
Minute Maid Kids+®, Minute Maid® Calcium and 
Vitamin D) 
100c 
Orange Juice, not fortified with vitamin D, 8 oz 0c 
  
OTHER  
Egg yolk, 1 whole 20a 
Liver, beef, cooked, 3½ ounces 15a 
Cheese, Swiss, 1 ounce 12a 
aOffice of Dietary Supplements, Dietary Supplement Fact Sheet: Vitamin D [Internet].  
Bethesda (MD): National Institutes of Health; [modified 2007 Aug 30, cited 2007 Sep 
17].  Available from: http://ods.od.nih.gov/factsheets/vitamind.asp#h2. 
bLu Z, Chen TC, Zhang A, Persons KS, Kohn N, Berkowitz R, Martinello S, Holick MF.  
An evaluation of the vitamin D3 content in fish: is the vitamin D content adequate to 
satisfy the dietary requirement for vitamin D?  J Steroid Biochem Molec Biol  
2007;103:642-4. 
cAccording to package label 2007 Sep 18 
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 Date of Visit:  Subject Number:  
Health History Screening Form 
(January 2005) 
 
We are asking these health history questions because certain conditions and 
medications affect vitamin D metabolism.  A positive response may or may 
not disqualify you from participation in the study.  Please answer as 
accurately as possible. 
 
 
Date of Birth      
 
 
Do you have, or have you ever had: 
 
Diabetes   Y N Celiac Disease / Sprue Y N 
Cystic Fibrosis  Y N Gluten Intolerance  Y N 
Crohn’s Disease  Y N Liver Disease  Y N 
Ulcerative Colitis  Y N Kidney Disease  Y N 
Chronic Diarrhea  Y N Pacemaker   Y N 
Whipple’s Disease  Y N   
 
Do you have any other medical conditions?  If so, please explain:   
             
 
 
What is your current height ?   Weight?   
 
Please do not write 
in this box. 
 
BMI = _________ 
 
 
 
Are you pregnant?  Yes No Maybe 
 
 
 
Are you planning to become pregnant in the next 12 months?  Yes   No 
 
 
Do you have a regular menstrual cycle (occurring every 23-35 days)?  If not, 
how often do you menstruate? 
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 Health History Screening Questionnaire, continued 
(January 2005) 
 
Are you currently taking: 
 Steroids, including inhalers (i.e. prednisone)  
 Anti-seizure medication (i.e. phenytoin, valproic acid, and others) 
 Thyroid medication (i.e. synthroid) 
 Cholesterol-lowering medication (i.e. Questran, Colestid) 
 Depo-Provera 
Mineral Oil 
 
Do you take any vitamins or minerals?  If so, which ones, how much, and 
how often? 
 
 
 
 
 
What other medications or herbal supplements do you take, and how often? 
 
 
 
 
 
 
Will you be able to be available on a weekday between 8:00 am and 5:00 pm 
to have your blood drawn in March 2005, September 2005, and March 2006, 
and to have your body composition measured in March 2005 and 2006?
 Y N 
 
 
 
 
 
Due to the nature of this study, we ask that all participants refrain from 
taking supplemental multivitamins, calcium, or vitamin D other than those 
on an approved list.  You must also have no plans to travel south of Southern 
California, Southern Texas, Louisiana, New Mexico, Georgia, Alabama, or 
Florida over winter 2004/2005 and 2005/2006.  (Spring Break will be okay) 
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 Lifestyle Questionnaire – Sun Exposure 
(March 2005) 
 
Please help us estimate the amount of time you typically spent outdoors last 
summer between the hours of 10 :00 am and 3 :00 pm between the beginning of 
May and the end of August 2004. 
Work Day : On a typical workday last summer, how much time did you spend 
outdoors between the hours of 10 am and 3 pm ? 
On average, how many days per week did you work last summer ? 
Day Off : On a typical day off last summer, how much time did you spend 
outdoors between the hours of 10 am and 3 pm ? 
On average, how many days off per week did you have last summer ? 
Vacation Time : While you were on vacation last summer, how many hours per 
day did you spend outdoors between the hours of 10 am and 3 pm ? 
How many days were you on vacation last summer ? 
 
When you were outside, did you wear sunscreen on your face ?   
 Never     Rarely     Sometimes     Often     Always 
When you were outside did you wear sunscreen on the rest of your body ? 
 Never     Rarely     Sometimes     Often     Always 
To which part(s) of your body did you typically apply sunscreen?   
 □ Arms □ Back and Shoulders 
 □ Hands □ Legs  □ All Bare Skin 
What number SPF sunscreen did you typically wear?       
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 Lifestyle Questionnaire, continued 
(March 2005) 
 
Did you use a tanning bed in the past 5 months?  If so, how many times?    
 
Have you traveled to a southern climate since October?  If so, where and for what 
dates?  
 
Are you allergic to any of the following ingredients that are in the vitamin D or 
placebo capsules?  Placebo: Gelatin, maltrin, magnesium stearate.  Vitamin D3: 
gelatin and synthetic vitamin D3.  Yes No 
 
When was the first day of your last period?        
 
Are you pregnant?  Yes No Maybe 
 
Do you use a birth control pill, patch, shot, or ring?  If so, which brand? 
 
If yes, have you been on this birth control for at least 4 months?   Y N 
 
Please list any new medications that you took during the past 2 months: 
 
Did you take any vitamins, minerals, or herbal supplements during the past 2 
months?  If so, which ones, how much, and how often did you take them?   
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 Lifestyle Questionnaire, continued 
(March 2005) 
 
Do you have any chronic medical condition?  If so, please explain. 
 
 
How many times did you have a cold or the flu in the past 3 months?   
How many days did it usually last? 
 
 
Do you smoke? Y N If yes, how many packs/day?     
 
 
Which of the following best describes how often you take an antacid such as Tums 
or Rolaids? 
 At least once a day  At least once a week Never 
 At least once a month Less than once a month 
 
Which antacid do you take? 
 
 
Which of the following best describes how often you eat fat-free snacks that 
contain the fat substitute, olestra (i.e. WOW Chips)?  
At least once a day  At least once a week Never 
At least once a month Less than once a month 
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 Contact Information 
 
Do you have a new address or phone number since we last saw you?  If so, please 
provide below:           
            
            
             
 
 
 
Your next visit for the Vitamin D Study is in June.  You will need to pick up a 
new supply of capsules and return the unused ones.  Please provide your summer 
address and phone number so that we can get in contact with you.   
 
June Address:           
 
June Phone Number:          
 
 
If you are not going to be near Orono this summer, are you planning to be on 
campus or in the Bangor area anytime during June?  If so, when could we 
connect? 
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 Lifestyle Questionnaire 
(June 2005) 
 
Please let us know if your contact information will change this fall. 
 
 
Over the past 3 months: 
 
Did you experience any side effects that you think are related to the capsules given 
to you in this study?  If yes, please describe  
 
 
 
Approximately how many capsules did you forget to take during the past 3 
months?  
 
 
 
Did you use a tanning bed?  If so, how many times?  
 
 
Have you traveled to a southern climate since March?  If so, where and for what 
dates?  
 
 
Are you pregnant?   Yes No Maybe 
 
 
Do you use a birth control pill, patch, shot, or ring?  If so, has your prescription 
changed in the past 3 months (what brand do you use now)?  What month did this 
change occur? 
 
 
 
 
Have you quit using a birth control pill, patch, shot, or ring in the past 3 months?  
If so, what month did you stop taking it? 
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 Lifestyle Questionnaire, continued 
(June 2005) 
 
Please list any new medications that you took during the past 3 months: 
 
 
 
Did you take any vitamins, minerals, or herbal supplements during the past 3 
months?  If so, which ones, how much, and how often did you take them?  (Not 
including the capsule for this study) 
 
 
How often do you take an antacid such as Tums or Rolaids? 
 At least once a day  At least once a week Never 
 At least once a month Less than once a month 
 
Which antacid did you typically take?  
 
 
Do you smoke? Y N If yes, how many packs/day?    
  
 
 
Were you diagnosed with any chronic medical condition in the past 3 months? 
 
 
 
How many times did you have a cold or the flu in the past 3 months?   
How many days did it usually last? 
 
 
 
Which of the following best describes how often you eat snacks that contain the 
fat substitute Olestra (i.e. WOW Chips or Light Chips)?  
At least once a day  At least once a week Never 
At least once a month Less than once a month 
 
 
 
How do you remember to take your daily capsule?  I would like to compile these 
responses (without names attached) to give the other participants some 
suggestions. 
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The Vitamin D Study 
Lifestyle Questionnaire 
(September 2005) 
 
Please change the above address label to reflect your current address.  This is the 
address to which your October check will be sent. 
 
Do you receive a paycheck from the University of Maine?  Y N 
(When I submit the information for your check, payroll needs to know this.) 
 
Please help us estimate the amount of time you typically spent outdoors between 
the hours of 10:00 am and 3:00 pm between the beginning of May and the end of 
August 2005. 
 
Work Day:  If you worked or went to school, on a typical work or school day, 
how much time did you spend outdoors between the hours of 10 am and 3 pm? 
 
 
On average, how many days per week did you work or go to school? 
 
 
Day Off:  On a typical day off, how much time did you spend outdoors between 
the hours of 10 am and 3 pm? 
 
 
On average, how many days off did you have per week?   
 
 
Vacation Time:  If you went on vacation, while you were on vacation, how many 
hours per day did you spend outdoors between the hours of 10 am and 3 pm? 
 
 
How many days were you on vacation?   
 
 
Over the past 3 months: 
 
When you were outside, did you wear sunscreen on your face?   
Never      Rarely      Sometimes      Often      Always 
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 Lifestyle Questionnaire, continued 
 
hen you were outside, did you wear sunscreen on the rest of your body?   
 
o which part(s) of your body did you typically apply sunscreen?   
e Skin 
hat number SPF sunscreen did you typically wear?      
(September 2005) 
W
Never      Rarely      Sometimes      Often      Always 
 
T
 □ Arms □ Back and Shoulders 
 □ Hands □ Legs  □ All Bar
 
 
W  
id you use a tanning bed?  If so, how many times?      
 
 
D  
hen was the first day of your last period?       
 
 
W  
re you pregnant?  Yes No Maybe 
id you experience any side effects from the capsules given to you in this study? 
 yes, please describe:          
 
 
A
 
 
D
 
If  
pproximately how many capsules did you forget to take in the past 3 months?  
o you use a birth control pill, patch, shot, or ring?  If so, has your prescription 
s 
ave you quit using a birth control pill, patch, shot, or ring in the past 3 months?  
 
 
A
 
 
 
D
changed in the past 3 months (what brand do you use now)?  What month did thi
change occur? 
 
 
 
 
H
If so, what month did you stop taking it? 
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 Lifestyle Questionnaire, continued 
 
lease list any medications that you took over the past 3 months: 
id you take any vitamins, minerals, or herbal supplements over the past 3 
lease 
ow often do you take an antacid such as Tums or Rolaids? 
 th 
hich antacid do you typically take?        
(September 2005) 
P
 
 
 
 
D
months?  If so, which ones, how much, and how often did you take them?  P
include brand names if possible.  (Do not include the capsule for this study) 
 
 
 
H
 At least once a day  At least once a week 
 At least once a month Less than once a mon
 
W  
o you smoke? Y N If yes, how many packs/day?    
 
 
 
D  
ere you diagnosed with any chronic medical condition in the past 3 months? 
ow many times did you have a cold or the flu in the past 3 months?   
ow often do you eat fat-free snacks that contain the fat substitute, olestra (i.e. 
eas once a week Never 
 h 
 
 
W
 
 
 
H
How many days did it usually last? 
 
 
 
H
WOW Chips or Light Potato Chips)?  
 At least once a day  At l t 
 At least once a month Less than once a mont
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 Skin Type Questionnaire 
(September 2005) 
 
Skin color affects the amount of vitamin D your skin is able to make. Skin type is 
often categorized by the Fitzpatrick skin type scale which ranges from very fair 
(skin type I) to very dark (skin type VI).  This classification is based on a person’s 
complexion and response to sun exposure.  Please check the description which 
best fits your skin type: 
 
□ Skin Type I: Persons with this skin type have blond or red hair and very 
fair skin or ivory white skin.  They often have freckles and blue eyes.  They 
easily burn, never tan, and are extremely sensitive to sunlight.   
 
□ Skin Type II:  Persons with this skin type usually have blue or hazel eyes, 
and red or blonde hair.  Their skin color is white or fair and they may have 
freckles.  They typically burn easily and tan slightly or slowly. 
 
□ Skin Type III:  Persons with this skin type have fair skin and are blond or 
brunette.  Their skin is white to slightly beige or olive.  They tan slowly and 
moderately, gradually turning to a light brown color.  They sometimes 
burn. 
 
□ Skin Type IV:  Persons with this skin type usually have beige, light brown, 
or olive-colored skin, dark eyes, and dark hair.  They tan easily and 
moderately, and rarely burn. 
 
□ Skin Type V:  Persons with this skin type are similar to those with skin 
type IV, but they never burn.  They tan profusely to a deep brown or black 
color. 
 
□ Skin Type VI:  Persons with this skin type have dark eyes and hair and 
dark brown or black skin.  They never burn. 
 
 
 
To further help us understand the ability of your skin to make vitamin D, how 
would you describe (the largest portion of) your ethnicity? 
□ White     □ Asian 
□ Black or African American □ Indian or Alaska Native 
□ Hispanic or Latino  □ Native Hawaiian or Other Pacific Islander 
□ Some other race 
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The Vitamin D Study 
Lifestyle Questionnaire 
(December 2005) 
 
Phone Number: 
 
If you are a student, in what semester did you start (year and month) at UM 
or UCB?  
 
Over the past 3 months: 
 
Did you experience any side effects from the capsules given to you in this 
study? 
 
If yes, please describe:  
 
Approximately how many capsules did you forget to take in the past 3 
months?  
 
 
Are you pregnant?  Yes No Maybe 
 
Do you use a birth control pill, patch, shot, or ring? (circle one) Yes     No   
 
If so, as your prescription changed in the past 3 months? (circle one) Yes No   
 
In what month did this change occur?  
 
Which brand do you use now? 
 
Have you quit using a birth control pill, patch, shot, or ring in the past 3 
months?  If so, what month did you stop taking it? 
 
How often do you take an antacid such as Tums or Rolaids? 
 At least once a day  At least once a week  Never 
 At least once a month Less than once a month 
 
Which antacid do you typically take? 
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 Lifestyle Questionnaire, continued 
(December 2005) 
 
Please list any medications that you took during the past 3 months: 
 
 
 
 
Did you take any vitamins, minerals, or herbal supplements during the past 3 
months?  If so, which ones, how much, and how often did you take them?  
(Not including the capsule for this study) 
 
  
 
Did you use a tanning bed in the past 3 months?  If so, how many times?  
 
 
Did you travel to a southern climate in the past 3 months?  If so, where, and 
for what dates?  
 
 
Did you ski in the past 3 months?  If so, how many hours do you spend 
skiing each week during the day (don’t count night skiing)? 
 
 
Do you smoke? Y N If yes, how many packs/day?     
 
 
Have you been diagnosed with any chronic medical condition in the past 3 
months? 
 
 
How many times did you have a cold or the flu in the past 3 months?   
How many days did it usually last? 
 
 
How often do you eat fat-free snacks that contain the fat substitute, olestra 
(i.e. WOW Chips)?  
 At least once a day  At least once a week Never 
 At least once a month Less than once a month 
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The Vitamin D Study 
Lifestyle Questionnaire 
(March 2006) 
 
Please change the above address label to reflect your current address.   
 
Are you currently a UM student (I need to know this for billing purposes)?    Y    N 
 
Over the past 3 months: 
 
Did you experience any side effects from the capsules given to you in this study?  Y      N 
 
If yes, please describe           
 
 
Approximately how many capsules did you forget to take in the past 3 months?   
             
 
 
Did you use a tanning bed in the past three months?       
If so, where and how many times?          
 
 
Did you travel to a southern climate in the past three months?  If so, where, and for what 
dates?  
 
 
Did you ski?  If so, how many hours do you spend skiing each week during the day 
(don’t count night skiing)? 
 
 
Please list any medications that you took over the past 3 months: 
 
 
 
 
Did you take any vitamins, minerals, or herbal supplements over the past 3 months?  If 
so, which ones, how much, and how often did you take them?  (Not including the capsule 
for this study) 
 
When was the first day of your last period?         
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 Do you use a birth control pill, patch, shot, or ring?    Y N 
If so, has your prescription changed in the past 3 months (what brand do you use now)?   
What month did this change occur? 
 
 
Have you quit using a birth control pill, patch, shot, or ring in the past 3 months?  If so, 
what month did you stop taking it? 
 
 
If you have ever used a birth control pill: 
Approximately how many years did you /have you used it? 
 
 
Which years did you use a birth control pill? 
 
 
Do you smoke? Y N If yes, how many packs/day?      
 
 
On average, how many days a week do you consume alcohol? 
 
 
Using the serving information below, on average, how many servings of alcohol do you 
drink in a week?   
  
1 serving of alcohol: 
1 can or bottle (12 oz) or ½ of a “big red” or Solo cup of beer / 1 bottle (12 oz) of wine coolers / 5 oz wine / 1 shot of liquor (1 ½ oz) 
/ 1 Dixie cup of jello shots 
 
 
Have you been diagnosed with any chronic medical condition in the past 3 months? 
 
 
How many times did you have a cold or the flu in the past 3 months?   
How many days did it usually last? 
 
 
How often do you eat fat-free snacks that contain the fat substitute, olestra (i.e. WOW 
Chips)? At least once a day  At least once a week  Never 
  At least once a month Less than once a month 
 
 
How often do you take an antacid such as Tums or Rolaids? 
 At least once a day  At least once a week  Never 
 At least once a month  Less than once a month 
 
What brand of antacid do you most often use?        
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November 16, 2004 
 
Dear Student: 
 
Did you know that almost half of the women living in Maine have low levels of vitamin 
D in their blood, putting them at increased risk of developing weak bones or other health 
problems?  These low levels occur because the sun is not strong enough in winter in 
Maine for the skin to make vitamin D.  However, researchers are not sure how much 
extra vitamin D women need during winter.   
 
We plan to do a study to find out how much vitamin D is needed to maintain normal 
blood levels in winter in Maine.  We are looking for women between the ages of 19 and 
35 to participate in “The Vitamin D Study”, a 12-month supplementation study.  For a 
relatively small effort on your part, you can help make a difference in vitamin D research. 
 
What the study involves: 
? Three blood tests (March 2005, September 2005, and March 2006) 
? Filling out short questionnaires every 3 months 
? Taking a vitamin D or placebo capsule daily (A placebo is a capsule that 
looks like the vitamin D capsule, but contains an inactive, harmless 
substance instead) 
? Body composition measurement at the beginning and end of the study 
 
We are looking for women to sign up for the study this fall.  The first testing will take 
place in March 2005.  Compensation will be $200 for completion of the study. 
 
Please consider participating in our study and encourage your friends to do the same.  If 
you are interested in participating or would like more information, please call 581-1622. 
 
Thank you, 
 
 
 
 
Monica Nelson, MPH, RD    Susan Sullivan, DSc, RD 
Graduate Student      Director Didactic Program 
Food Science and Human Nutrition   Food Science and Human Nutrition 
University of Maine     University of Maine 
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 DO YOU GET ENOUGH SUN? 
 
Skin makes vitamin D when it is exposed to sunlight.  
During winter in Maine, the sun is not strong enough for skin 
to make vitamin D.  Researchers at the University of Maine are 
looking for women between the ages of 19 and 35 to 
participate in a 12-month study to find out how much extra 
vitamin D young women need to keep blood levels high 
enough during winter in Maine. 
 
What the study involves: 
o Blood tests every 6 months (3 tests - less than two 
tablespoons of blood will be drawn each time.) 
o Filling out short questionnaires every 3 months 
o Taking a vitamin D capsule or a sugar pill daily 
o Body composition measurement in Bangor in March 
2005 & 2006 
We are looking for women to sign up for the study this fall.  
The first testing will take place in March 2005.  Compensation 
will be $200 for completion of the study. 
 
For more information, please call Susan Sullivan, D.Sc., R.D. 
of the Department of Food Science and Human Nutrition at the 
University of Maine or Monica Nelson, graduate student, at 
581-1622. 
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 PATIENT INFORMATION AND INFORMED CONSENT STATEMENT 
 
TITLE: Serum 25-Hydroxyvitamin D Response to Customized Doses of      
Vitamin D3 in Premenopausal Women 
 
DATE: June 1, 2005 
 
 
You have been asked to take part in a research study being conducted by Dr. 
Susan Sullivan, faculty member, and Monica Nelson, graduate student, in the 
Department of Food Science and Human Nutrition at the University of Maine.  
Funding for this study is being provided by the United States Department of 
Agriculture (USDA).    
 
You have initially qualified to take part in this study because you are a 19-35 year 
old healthy woman.  You cannot have any serious medical conditions such as 
diabetes, celiac disease or Crohn’s disease or take any prescription medications 
such as steroids that affect vitamin D and calcium metabolism.  If you are 
pregnant or become pregnant, you will not be allowed to continue in this research 
study.  Your body mass index (BMI) must be between 18.5 and 40 to participate.  
BMI is the product of 705 times your weight in pounds divided by your height in 
inches, squared (BMI = lbs/inches2 x 705).  These conditions and medications 
will be discussed with you in detail prior to your enrolling in the study.  In addition, 
you must agree to avoid taking most vitamin, mineral, and herbal supplements, 
other than those on an approved list.  You must avoid tanning booths during the 
study period, and you must try to avoid traveling south of 35o north latitude 
(southern California, southern Texas, New Mexico, Louisiana, Alabama, Georgia, 
and Florida) from October through February (see attached map).   
 
 
WHY IS THIS STUDY BEING DONE? 
 
Vitamin D is important for building and maintaining healthy bones.  Vitamin D 
may also reduce a person’s risk for some cancers, immune disorders, high blood 
pressure and type I diabetes.  In Maine, it is common to have low blood levels of 
vitamin D because there is not enough sunlight in the winter for the skin to make 
vitamin D.  Exposure to strong sunlight during winter can ruin the results of this 
study, therefore you must try to avoid traveling south from October through 
February.  If southern travel becomes necessary please wear sunscreen 
(minimum SPF 8) and avoid the sunlight as much as possible. 
 
The main purpose of this study is to help identify how much extra vitamin D 
young women in Maine need to keep blood levels normal during winter.  This 
study will also look at how body fatness affects vitamin D levels in the blood.  
There will be about 120 women in this study. 
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 WHAT IS INVOLVED IN THE STUDY? 
 
In this study you will either be in the treatment group where you will receive a 
vitamin D capsule containing 800 International Units (IU) of vitamin D, or in the 
control group where you will receive a placebo (we call it a sugar pill even though 
it does not contain any sugar).  The sugar pill looks exactly like the vitamin D 
capsule, but does not contain any vitamin D.  A computer will randomly decide if 
you will be in the treatment or control group.  You will not be told which group you 
are in.  You will have a 2 in 3 chance of receiving vitamin D and a 1 in 3 chance 
of receiving a sugar pill. 
 
If you meet the requirements for the study and agree to take part in it, you will 
need to take one vitamin D capsule or sugar pill every day.  Taking the capsules 
every day is very important for this study to be successful.  If you forget to take a 
capsule one day, you can take two pills the following day. 
 
You will need to report to Cutler Health Center at the University of Maine three 
times over the next 12 months for testing (March 2005, September 2005, and 
March 2006).  You will also report to the research office at the University of 
Maine to pick up a new supply of capsules every three months.  In March 2005 
and March 2006 you will visit the Maine Center for Osteoporosis Research and 
Education (MECORE) in Bangor for body composition measurement. 
 
In January 2005 there will be an informational meeting at the University of Maine.  
The estimated time for this meeting is 1-2 hours.  During this time you will: 
• Be given time to ask questions about the study 
• Be asked to read and sign this informed consent 
• Be asked questions about your health and medications to make sure you 
qualify for the study.  You will be asked questions such as: 
o Do you have, or have you ever had diabetes, celiac disease, cystic 
fibrosis, gluten intolerance, Crohn’s disease, ulcerative colitis… 
 
The first visit to Cutler Health Center will be in March 2005.   The estimated time 
for this visit is 30-45 minutes.  During this time you will: 
• Have your weight and height measured 
• Have less than 2 tablespoons of blood drawn 
• Provide a urine sample 
 
Blood will be drawn to measure calcium, parathyroid hormone, and vitamin D.  
Urine will be collected to measure calcium. 
 
After the first blood draw, if your blood vitamin D is very low (<22.5 nmol/L) or 
high (>175 nmol/L), you will not be allowed to continue in the study, and you will 
be advised to speak with your doctor for evaluation at your own expense. 
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 If you meet the requirements and want to be in the study, the computer will 
choose which one of the treatments you will receive (vitamin D or sugar pill).  
During the 12 months of the study, you will be on sugar pill for six of the months 
and either vitamin D or sugar pill for the other six months.  Neither you nor the 
researchers will know whether you are taking vitamin D or the sugar pill.  No one 
at the clinic will be able to tell you which pill you are taking.  This information will 
be available at Cutler Health Center in case of emergency. 
 
You will return to Cutler Health Center for two more visits over the next 12 
months.  These visits will be in September 2005, and March 2006.  At each of 
these visits, the testing will be the same as described above.  The estimated time 
for each of these visits is 30 minutes. 
 
Starting in March 2005 you will visit the research office at the University of Maine 
every three months to return any unused capsules and receive a new supply.  
You will be asked to stop taking all other multivitamins, vitamin D, or calcium 
supplements during the study.  You will be given a list of vitamins such as vitamin 
C and folate that you will be allowed to take.  The estimated time for this visit is 
15 minutes.  At this time you will be asked brief questions about your health, 
such as: 
• Did you take any vitamins, minerals, or herbal supplements over the past 
3 months?  If so, which ones, how much, and how often did you take 
them? 
 
Between January and March 2005 and 2006 you will be asked to keep a three-
day record of what you eat and drink.  The day after you finish this record, the 
researcher will call you to find out what you ate and drank.  This information will 
be used to estimate how much vitamin D, calcium, phosphorus, protein, and 
calories you ate.  The estimated time for this phone call is 30 minutes.  In 
addition, during your visits to the research office, you will be asked some 
questions about the foods that you typically eat and drink. 
 
In March 2005 and 2006 you will visit the Maine Center for Osteoporosis 
Research and Education (MECORE) in Bangor to have your body fat and bone 
density measured by dual energy x-ray absorptiometry (DXA).  The DXA scanner 
is similar to an x-ray.  During the exam you will lie on a padded table and the arm 
of the machine will pass over your body.  You will not be enclosed in any way 
during this exam. 
 
The estimated time for this MECORE visit is ½ hour.  During this time you will: 
• Have your weight and height measured 
• Take a urine pregnancy test before your body fat is measured because an 
embryo should not be exposed to the small amount of radiation used to 
measure body fat. 
• Have a total body DXA scan to measure your body fat and bone density 
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 POSSIBLE BENEFITS OF THE STUDY: 
 
This study is being done to find out more about vitamin D needs during winter.  It 
may not provide any direct benefit to you.  If you would like, at the end of the 
study, you and your doctor will be given your body fat and vitamin D results along 
with information on how to optimize vitamin D levels and body composition.  
Based on this information, decisions can be made to help decrease your future 
risk of osteoporosis and other health concerns.   
 
If you complete all of the requirements you will be compensated a total of $200 
for your mileage, time, and effort.  You will be paid in April 2005 ($25), October 
2005 ($50), and March 2006 ($125).  If you choose to discontinue the study 
before March 2006, you may keep any money you have received. 
 
 
POSSIBLE RISKS OR DISCOMFORTS OF THE STUDY: 
 
You will have blood drawn three times during the study.  When you have blood 
drawn you may have some pain, bleeding, or a black and blue spot at the site of 
the blood draw.  The total blood volume drawn will be less than two tablespoons. 
 
During the bone density scan (DXA) you will be exposed to less radiation than 
you would get during a chest x-ray or a long flight in an airplane.  The radiation 
may be harmful to an embryo, therefore you will be withdrawn from the study if 
you become pregnant.   
 
There are no known side effects of 800 IU of vitamin D which is in the safe dose 
range set by the Food and Nutrition Board.  In comparison, a light-skinned 
person wearing a swimsuit in the summer will absorb about 20,000 IU of vitamin 
D in the amount of time it takes her skin to get lightly pink.  If you have any 
concerns about this vitamin D supplementation, please contact the researchers 
at 581-1622. 
 
 
CONFIDENTIALITY: 
 
The results of all testing and questionnaires will be recorded on special forms.  
These forms will have no name on them, but will use a code number to protect 
your privacy.  All records will be kept for no more than five years following 
completion of the study.  Your name will not be used in any publication 
describing this research.  Medical information from the study will be made 
available to your physician upon your request after you have signed a written 
release. 
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 VOLUNTARY PARTICIPATION: 
 
Taking part in this study is voluntary.  You can choose not to answer any 
questions on the forms.  You are free to leave the study at any time.  If you fail to 
meet the requirements of the study, the researchers can remove you from the 
study at any time.  There will be no charge to you or to your insurance company 
for tests or services that are required by this study.  You will receive 
compensation for your time, travel and general inconvenience.  St. Joseph 
Hospital and the University of Maine do not provide financial payment for any 
injury resulting from this study. 
 
 
ADDITIONAL INFORMATION: 
 
To become a part of this study, you must sign this consent.  By signing this 
consent, you are confirming the following: 
 
1) You have had time to consider if you want to take part in this study.  You have 
read or had read to you this consent and had it explained to you in language you 
are able to understand.  
  
2) You have had a chance to ask questions, and you have received answers that 
fully satisfy your questions.   
 
3) You understand the information in this consent form.  You willingly agree to 
take part in this study.   
 
4) You understand the study has been reviewed and approved by an ethical 
research review committee to protect your legal rights.   
 
5) You have been given a copy of this informed consent.   
 
6) If you have any further questions about this study, you may contact Susan 
Sullivan at (207) 581-3130 or Monica Nelson at (207) 581-1622.  If you have any 
questions about your rights as a research subject you may contact Gayle 
Anderson, Assistant to the University of Maine’s Protection of Human Subjects 
Review Board, at (207) 581-1498. 
 
 
        
Subject Signature / Date     
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 CALCULATION FOR DETERMINING SUN EXPOSURE 
 
Example: 
Work days – 6 days per week; 1 hour sun per day 
Days off – 1 day per week; 3 hours sun per day 
Vacation days – 2 weeks; 5 hours sun per day 
Table F1.  Calculation used for determining sun exposure. 
 
Step Instructions Example 
1 Multiply days worked per week x 16 weeks = Work 
Days 
6x16=96 work days 
2 Multiply days off per week x 16 weeks = Days Off. 1x16=16 days off 
3 Determine how many days of vacation would have 
been days worked versus days off based on typical 
week from Steps 1 and 2. 
2 weeks vacation = would 
have been 12 work days, 2 
days off 
4 Subtract vacation days from Work Days or Days Off 
as appropriate 
96 - 12 = 84 days worked; 
16 - 2 = 14 days off 
5 Multiply new Work Days (from Step 4) by number 
of hours in sun per work day = Total Work Sun  
84 days worked x 1 hour 
sun = 84 hours work sun 
6 Multiply new Days Off (from Step 4) by number of 
hours in sun per day off = Total Day-Off Sun  
14 days off x 3 hours sun = 
42 hours day-off sun 
7 Multiply vacation days x hours of sun per vacation 
day = Total Vacation Sun 
14 vacation days x 5 hours 
sun = 70 hours vacation 
sun 
8 Add up Total Work Sun + Total Day-Off Sun + 
Total Vacation Sun = Total Sun 
84 + 42 + 70 = 196 hours 
sun 
9 Divide Total Sun by 16 to determine number of 
hours of sun per week. 
196 / 16 = 12.25 hours sun 
/ week 
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